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The protein ADAM-9 (A disintegrin and metalloprotease-9) belongs to the family of the ADAM 
proteases, which are type I transmembrane proteins and are unique among transmembrane 
proteins as they exhibit protease as well as adhesive functions. The ADAM proteases are 
involved in ectodomain shedding of membrane-bound molecules as well as in cell-cell and 
cell-matrix interactions.  
 
In human melanoma ADAM-9 is located at the tumor-stroma border in the stromal cells, but 
also in the melanoma cells. The aim of this work was to find out the function of ADAM-9, 
produced by the melanoma cells, for the development and invasion of melanoma. 
 
In vitro experiments, in which high invasive melanoma cells with stable down-regulation of 
ADAM-9 mediated via shRNA were used, showed that silencing of ADAM-9 slightly 
increased melanoma cell proliferation and remarkably reduced basement membrane 
penetration in an in vivo like invasion system. The reduced invasion through the basement 
membrane might be due to decreased adhesion to the basement membrane, as the ADAM-9 
down-regulated cells exhibited significantly reduced adhesion towards type IV collagen and 
matrigel. Additionally it was found that the laminin β3-chain, which is a component of the 
basement membrane protein laminin 332, was cleaved by ADAM-9 in the N-terminal region.  
This work further confirmed that extracellular IL-1α down-regulates ADAM-9 expression in 
melanoma cells, which is mediated via a JNK dependent pathway and showed that in 
melanoma cells intracellularly active IL-1α controls constitutive expression levels of ADAM-9 
via the involvement of ERK. Despite the activity of IL-1α as regulator of ADAM-9 expression, 
also indirubins, which are anti-cancer drugs, were identified as molecules down-regulating 
ADAM-9 expression in high invasive melanoma cells, but not in fibroblasts.  
 
To analyze if ADAM-9 also influences melanoma development and invasion in vivo, 
HGF/CDKR24C/R24C animals, which spontaneously develop melanomas as well as upon DMBA 
treatment, were crossbred with ADAM-9-/- mice. This strategy enabled to investigate 
melanoma development and progression in the absence of ADAM-9 in stromal as well as in 
the tumor cells. The created Adam-9mutated/ko (Adam-9-/-//Hgf/Cdk4R24C/R24C) animals developed 
more tumors compared to control (Adam-9+/+//Hgf/Cdk4R24C/R24C) mice at week four after 
DMBA treatment, whereas from week six onwards the Adam-9mutated/ko animals exhibited a 
reduced tumor number. This finding it most likely attributed to a differential proliferation of the 
tumor cells at both analyzed time-points.  
Interestingly lung metastases formation was significantly reduced in the Adam-9mutated/ko mice. 
This might be attributed to an impaired extravasation generated by a decreased adhesion of 
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ADAM-9 deficient melanoma cells to endothelial cells, because it could be shown that 
ADAM-9 down-regulated melanoma cells exhibited a significantly reduced adhesion towards 
endothelial cells. Additionally the intravasation might also be reduced indicated by 
immunohistochemical stainings for laminin β3-chain. This staining was confined to the 
basement membrane zone and appeared continuous in the tumors obtained from the Adam-
9mutated/ko animals, whereas in the control animals the basement membrane appeared 
destructed and discontinuous. This indicates that in the absence of ADAM-9 break down of 
the basement membrane by the melanoma cells might be reduced resulting in decreased 
intravasation.  
 
To summarize the in vitro and in vivo data, melanoma-derived ADAM-9 is involved in 
basement penetration and melanoma metastases formation in the lungs. The obtained data 
suggest that ADAM-9 can contribute to lung metastases formation by facilitating basement 
membrane penetration and mediating adhesion of melanoma cells to endothelial cells. 
 !!!!!!!!!!!!!!!!!!





Das Protein ADAM-9 (A disintegrin and metalloprotease-9) ist ein Mitglied der Familie der 
ADAM Proteasen, welche zur Klasse der Typ I Transmembranproteine gehören und als 
einzige Transmembranproteine eine Funktion als Protease sowie als Adhäsionsmolekül 
ausüben. ADAM Proteasen sind beteiligt an der Prozessierung von membrangebundenen 
Proteinen (ectodomain shedding) sowie an Zell-Zell und Zell-Matrix Interaktionen.  
 
In histologischen Färbungen von humanen Melanomen ist ADAM-9 an der Stroma-Tumor 
Grenze, sowohl in stromalen Zellen als auch in Melanomzellen, nachgewiesen worden. Das 
Ziel dieser Arbeit war es die Beteiligung von ADAM-9, das in Melanomzellen produziert wird, 
an der Melanomentstehung und -invasion herauszufinden.  
 
In in vitro Experimenten mit hoch invasiven Melanomzellen, in welchen die ADAM-9 
Expression mittels shRNA stabil herunterreguliert wurde, zeigte sich dass die 
Herunterregulation von ADAM-9 die Proliferation von Melanomzellen leicht erhöht und die 
Invasion der Zellen durch die Basalmembran stark verringert. Ein Grund für die reduzierte 
Basalmembraninvasion könnte eine verringerte Adhäsion der ADAM-9 herrunterregulierten 
Melanomzellen auf der Basalmembran sein, da diese Zellen eine signifikant reduzierte 
Adhäsion gegenüber Typ IV Kollagen sowie Matrigel aufwiesen. Außerdem wurde gezeigt, 
dass die Laminin β3-Kette, welche ein Bestandteil des Basalmembranproteins Laminin 332 
ist, von ADAM-9 in ihrem N-terminal Ende proteolytisch geschnitten werden kann. 
Des Weiteren konnte durch diese Arbeit bestätigt werden, dass extrazelluläres IL-1α die 
Expression von ADAM-9 in Melanomzellen, unter der Beteiligung von JNK, 
herrunterregulieren kann und dass in Melanomzellen interzellulär aktives IL-1α die 
konstitutive Expression von ADAM-9 durch einen ERK abhängigen Signalweg kontrolliert. 
Außer der Aktivität von IL-1α als Regulator der ADAM-9 Expression, konnten zudem 
Indirubine, welche in der Krebstherapie eingesetzt werden, als Moleküle identifiziert werden, 
welche die ADAM-9 Expression in hoch invasiven Melanomzellen, aber nicht in Fibroblasten 
reduzieren.  
 
Um die Beteiligung von ADAM-9 an der Melanomentstehung und -invasion in der in vivo 
Situation zu analysieren, wurden HGF/CDKR24C/R24C Mäuse, welche sowohl spontan als auch  
nach DMBA Behandlung Melanome entwickeln, mit ADAM-9-/- Mäusen gekreuzt. Diese 
Strategie ermöglichte es die Melanomentstehung und -progression in einer Situation, in der 
sowohl die Stroma-, als auch die Tumorzellen kein ADAM-9 exprimieren, zu untersuchen. 
Die generierten Adam-9-/-//Hgf/Cdk4R24C/R24C Tiere wiesen vier Wochen nach der DMBA 
Behandlung zunächst mehr Tumore im Vergleich zu Adam-9+/+//Hgf/Cdk4R24C/R24C 
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Kontrolltieren auf ab Woche sechs hingegen entwickelten die Adam-9-/-//Hgf/Cdk4R24C/R24C 
Tiere weniger Tumore. Dieses Ergebnis könnte auf eine unterschiedliche Proliferation der 
Tumorzellen zu beiden untersuchten Zeitpunkten zurückzuführen sein. 
Interessanterweise entwickelten die Adam-9-/-//Hgf/Cdk4R24C/R24C Mäuse signifikant weniger 
Lungenmetastasen als die Adam-9+/+//Hgf/Cdk4R24C/R24C Tiere. Dieser Effekt könnte auf eine 
gestörte Extravasation zurückzuführen sein, da gezeigt werden konnte, dass die Adhäsion 
von Melanomzellen, in denen ADAM-9 herrunterreguliert wurde, gegenüber Endothelzellen 
signifikant reduziert ist. Zusätzlich könnte auch die Intravasation reduziert sein, da in 
immunhistochemischen Färbungen der Tumore gegen die Laminin β3-Kette, die Färbung in 
den Adam-9-/-//Hgf/Cdk4R24C/R24C Tieren eine intakte und kontinuierliche Basalmembran 
zeigte. In den Adam-9+/+//Hgf/Cdk4R24C/R24C Tieren hingegen war die Basalmembran 
degradiert und diskontinuierlich. Dieses Ergebnis weist darauf hin, dass in ADAM-9 
defizienten Tieren die Degradierung der Basalmembran durch die Melanomzellen vermindert 
sein könnte, was zu einer reduzierten Intravasation führt. 
 
Zusammenfassend haben die in vitro und in vivo Daten gezeigt, dass von Melanomzellen 
produziertes ADAM-9 an der Basalmembraninvasion und der Entstehung von 
Lungenmetastasen beteiligt ist. Die erhaltenen Ergebnisse lassen vermuten, dass ADAM-9 
in der Überwindung der Basalmembran durch Melanomzellen eine Rolle spielt und in der 
Lage ist Adhäsion zwischen Melanom- und Endothelzellen zu vermitteln. 
  



















1.1 Human melanoma 
 
1.1.1 Melanoma origin  
Melanoma is a highly malignant tumor arising from the malignant transformation of 
melanocytes (de Vries et al., 2003). Melanocytes are derived from highly migratory 
embryonic cells called neural crest cells (Uong and Zon, 2010). These cells differentiate into 
melanocyte precursor cells, the melanoblasts, and subsequently, under the influence of 
melanocyte-stimulating hormone, are converted into pigment producing melanocytes (Herlyn 
et al., 2000). In healthy human epidermis melanocytes are scattered among keratinocytes at 
the epidermal-dermal border, forming structural and functional contacts with keratinocytes, 
which control melanocyte proliferation, differentiation and expression of surface molecules 
(Mc Gary et al., 2002). The localization of melanocytes in the skin differs between human 
and mice, being present in hair follicles and the basal layer of the interfollicular epidermis in 
humans and in the hair follicles and dermis, but not in the epidermis in the mouse (Herlyn et 
al., 2000). In Figure 1 the development of melanoma is illustrated. 
Figure 1: Development of melanoma. Melanoma evolves from normal melanocytes located in the 
basal layer of the epidermis. The melanocytes can either develop directly into melanoma cells or fist 
transform into nevi cells, which can also give rise to melanoma cells. In the radial growth phase (RGP) 
melanoma first grows in horizontal direction without substantial penetration of the underlying dermis. 
With entering the vertical growth phase (VGP) the transformed cells invade into the dermis and finally 
enter the circulation where they are transported to distant organs with the potential to form metastases 
(Gaggioli and Sahai, 2007). The right panel shows some examples of the macroscopic appearance of 
melanoma with typical morphologic characteristics like unequal borders, brown-black color, 
asymmetry and elevation. 
 
In human skin, increased proliferation of melanocytes in the epidermis marks their benign 
transformation into melanocytic nevi. These nevi can show some cellular aberrations, but are 
not invasive. Although some melanomas can develop from pre-existing nevi, most 
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melanomas evolve de novo from melanocytes without the presence of a premelanocytic 
nevus lesion (Haass and Herlyn, 2005). Initially melanoma grows in horizontal direction 
within in epidermis without crossing the basement membrane (BM), this phase is called the 
radial growth phase. In later stages the tumor cells degrade the BM and enter the dermis, 
which is defined as vertical growth phase. Invasion through the dermis is followed by 
invasion into the circulation via the bloodstream or the lymphatic vessels and leads to 
metastatic spread to distant organs (Gaggioli and Sahai, 2007).  
 
1.1.2 Etiology of melanoma 
Risk factors for melanoma comprise light skin phenotype, high number of nevi, chronic sun 
exposure, particularly in childhood and a familial history of melanoma (Tucker et al., 2003; 
Benjamin et al., 2007). The influence of exposure to UV irradiation as a cause for melanoma 
is discussed controversially, because melanomas lack typical UV signature mutations, as 
induction of thymidin dimers in DNA by UV-B radiation (Fu et al., 2003; Holmes et al., 2007). 
Moreover melanoma can also arise in completely sun-protected areas. On the other hand UV 
treatment in animal models suggests a connection between melanoma and UV exposure. 
Thus for example irradiation of hepatocyte growth factor/scatter factor (HGF/SF) transgenic 
mice with UVB, but not UVA light, induces melanoma formation (De Fabo et al., 2004).  
The recent advances in sequencing technology allowed performing genome-wide screening 
studies using melanoma cell lines and tissues, identifying several chromosomal aberrations, 
like alterations in gene copy number or loss of heterozygosity, in melanoma. These studies 
discovered several hot spots, which are frequently mutated in melanoma including the 
CDKN2A locus, BRAF, NRAS or MITF, suggesting that the onset of melanoma is caused by 
the sequential accumulation of inherited and/or acquired mutations (Curtin et al., 2005; Stark 
and Hayward, 2007). 
As already mentioned several genes are frequently mutated in melanoma, including the 
CDKN2A locus encoding the two tumor suppressor genes p16Ink4a and p14ARF. Germline 
mutations in this locus were observed in 25-50% of familial and somatic mutations in about 
40% of sporadic melanomas (Tsai and Tsao, 2004; Hocker et al., 2007). The protein p16Ink4a 
inhibits CDK4, which no longer phosphorylates the retinoblastoma protein thereby blocking 
transition from G1- to S-phase of the cell cycle. On the contrary, abrogation of the inhibitory 
activity of p16Ink4a results in constantly active CDK4 and increased cell survival and 
proliferation (Hocker et al., 2007). Activating mutations in CDK4 have also been described in 
familial melanoma and lead to enhanced cell proliferation and survival (Zuo et al., 1996). The 
other protein encoded by the CDKN2A locus, p14ARF functions as tumor suppressor by 
inhibiting the action of MDM2 thereby promoting the activity of p53. Mutations in p14ARF lead 
to increased levels of MDM2, subsequent inhibition of p53 and loss of cell cycle control 
(Lowe and Sheer, 2003). Mutations in melanoma are also often found in the RAS pathway, 
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particular in NRAS as well as in downstream targets of NRAS in the MAPK pathway, like 
BRAF. Thus in up to 90% of melanomas activating mutations in one of the two key MAPK 
genes, BRAF or NRAS are present (Hocker et al., 2007). Genome-based oncogene 
scanning studies showed that the most common mutation in BRAF is an amino acid 
substitution in exon 15 in codon 600 from valine to glutamic acid (BRAFV600E ) (Davies et al., 
2002). Interestingly, selective inhibition of this mutated BRAF in clinical trials led to complete 
or partial tumor regression in the majority of the patients (Flaherty et al., 2010), however 
follow up studies showed that one third of the patients developed squamous cell carcinomas 
(Sosman et al., 2012). In 50-60% of melanomas mutations are found in molecules of the 
PI3K/AKT pathway, e.g. in PTEN and AKT (Chudnovsky et al., 2004; Hocker et al., 2007), 
resulting in increased cell survival and proliferation (Wu et al., 2003). Mainly these two 
networks, the MAPK and the PI3K/AKT pathway, regulate melanoma proliferation, survival 
and invasion. Mutations in one of the most prominent tumor suppressor genes TP53 
encoding for the p53 protein were only found in 10% of melanomas, suggesting that this 
pathway is not one of the major networks responsible for melanoma development 
(Chudnovsky et al., 2004; Tsai and Tsao, 2004; Hocker et al., 2007).  
 
1.1.3 Melanoma development, growth and metastasis 
Under physiological conditions melanocyte growth and behaviour is controlled by growth 
factors released from keratinocytes as well as by direct cell-cell interactions or interactions 
with the underlying matrix (Haass et al., 2005). It has been shown for example in vitro that 
the intercellular adhesion molecule E-cadherin is the main mediator of human melanocyte 
adhesion to keratinocytes (Tang et al., 1994) and loss of expression of E-cadherin, leads to 
melanoma cell escape from keratinocyte-mediated control during melanoma progression 
(Kuphal and Bosserhoff, 2011). Moreover, while expression of E-cadherin is lost, melanoma 
cells acquire expression of other receptors, e.g. N-cadherin, which mediate homotypic 
interaction of melanoma cells and heterotypic interaction of melanoma cells with other N-
cadherin expressing cells in the stroma, like fibroblasts and endothelial cells (McGary et al., 
2002; Alonso et al., 2007). Another up-regulated receptor found in melanoma cells is the 
melanoma cell adhesion molecule (MCAM), which mediates cell interactions with the 
extracellular matrix or other adhesion molecules on endothelial cells (e.g. platelet endothelial 
cell adhesion molecule-1 (PECAM-1) (McGary et al., 2002).  
Other cellular receptors, which are altered during the transformation of a melanocyte into a 
melanoma cell, are integrin receptors, which are known to mediate prominently cell-matrix 
interactions. Melanocytes were shown to express α3β1, α6β1 and αvβ1 integrins, but in 
melanoma cells increased expression of the fibronectin binding integrins αvβ3 and α5β1 was 
detected (Haass et al., 2005). Likely, these receptor are necessary for cells to better adhere 
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and migrate though the underlying tissue or they can bind proteolytic enzymes, e.g. MMP-2, 
localizing them to the cell surface as shown for the αvβ3 integrin (Brooks et al., 1996).  
As soon as the tumor cells have lost contact to their surrounding cells, they interact with and 
degrade the BM in order to invade the underlying tissue. It was shown that membrane-type 
matrix metalloproteases (MT-MMPs) expressed by cancer cells are mainly responsible for 
the breakdown of the BM in an ex vivo invasion system. This was true for all three members 
of this family, MMP-14, MMP-15 and MMP-16 (Hotary et al., 2006). However, in vitro, other 
MMPs, like MMP-2 or MMP-9, are also able to degrade type IV collagen, one of the main 
components of the BM, but these molecules were not able to promote cell penetration of the 
BM in an ex vivo like invasion system in which different cancer cells including melanoma 
were used (Hotary et al., 2006).   
These proteolytic enzymes may also play a role in the invasion through the dermal tissue, 
not only by mediating cellular migration, but also necessary to modify the extracellular matrix 
and release factors to create more favourable environment for melanoma progression 
(Zigrino et al., 2005). Expression of a number of MMPs, including MMP-1, -2, -9, -13 and 
MMP-14 has been detected in melanoma (Hofmann et al., 2000). High expression of MMP-1 
and MMP-3 correlated with shorter patient survival in agreement with the known function of 
MMP-1 to degrade type I and type IV collagens (Durko et al., 1997; Nikkola et al., 2002). 
Similarly MMP-9 seems to be involved in metastases formation (Itoh et al., 1999). In vitro 
studies with melanoma cells have further shown that expression of MMP-2 and MMP-14 in 
melanoma cells modulates melanoma cell adhesion, spreading and migration in the 
extracellular matrix (Nakahara et al., 1997; Iida et al., 2004). Stromal expression of MMP-13 
seems instead to be required for the induction of peritumoral angiogenesis in melanoma 
(Zigrino et al., 2009). Other enzymes have also been implicated in mediating melanoma 
invasion, one example of these are cathepsins, lysosomal proteases. Inhibition of cathepsin 
K reduced invasion of melanoma cells through matrigel (Quintanilla-Dieck et al., 2008). The 
activity of cathepsins B and L were detected in high invasive melanoma cells in vitro (Klose 
et al., 2006a) and contact of high invasive melanoma cell lines with type I collagen induced 
the release of cathepsin B in the extracellular environment (Klose et al., 2006b). More 
recently, also ADAM proteases have been implicated in melanoma progression. Stromal 
expression of ADAM-15 contributes to melanoma metastases formation (Schönefuß et al., 
2012), whereas stromal expression of ADAM-8 decreased melanoma growth (Guaiquil et al., 
2010). Interestingly, also expression of ADAM-9 by the host is required to counteract murine 
melanoma growth in vivo (Abety et al., 2012).  
During the invasive process, tumor cells not only degrade the extracellular matrix, but also 
influence the surrounding cells. Via the secretion of growth factors and cytokines or cell-cell 
interactions, tumor cells can alter the activities of fibroblasts and inflammatory cells with 
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respect to migration, proliferation and release of additional growth factors and proteases 
(Zigrino et al., 2005). Tumor cells that left the primary tumor, once migrated into the dermal 
compartment can form metastases using three principal routes: The cells can either 
disseminate via the lymphatic vessels (lymphogenous), the blood vessels (haematogenous) 
or via migration along visceral cavities (cavitary). The most common routes are the 
lymphogenous, mainly found in carcinomas, and the hematogenous, predominately occurring 
in sarcomas (Bacac and Stamenkovic, 2008). In Figure 2 the principal steps of melanoma 
invasion and metastases formation are summarized. 
 
Figure 2: Principal steps of melanoma invasion and metastases formation. Upon transformation from 
normal cells into an invasive cancer, cells first loose adherens junctions and detach from the 
surrounding cells. Subsequentely they degrade the basement membrane and invade into the 
underlying tissue, penetrate the circulation and are transported to distant organs. Upon attachment to 
the vessel wall, cells extravasate and adapt to the new microenvironment, where they proliferate and 
form a metastasis. Some cancer cells have also the ability to be dormant in the invaded tissue for a 
long period of time before they begin to proliferate  (modified according to: Bacac and Stamenkovic, 
2008).     
 
In melanoma the most frequently metastasized organs are the skin, lymph nodes, 
subcutaneous tissues, lung, liver, central nervous system and the bone (Leiter et al., 2004). 
Attraction of tumor cells to these organs is thought to occur by the interaction of chemokines 
with their receptors located on tumor cells. It was for example shown that melanoma cells 
express the chemokine receptors CXCR4, CCR7 and CCR10 (Leiter et al., 2004) and the 
release of the respective ligands CXCL12, CCL21 and CCL27 in the lung, lymphatic system 
or the skin, respectively contributes to the spreading of metastatic tumor cells to these 
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specific organs (Kakinuma and Hwang, 2006). After the cells have been transported to the 
target organs, the circulating tumor cells are retained in the target organs mechanically due 
to size restrictions in small capillaries and/or interact with endothelial cells and transmigrate 
into the tissue (Chambers et al., 2002; McGary et al., 2002).  
 
1.2 Mouse models to study melanoma 
Since the past 50 years different in vivo models for the investigation of the complex biological 
processes involved in melanoma have been established. One of the earliest models relied on 
the grafting of murine B16 melanoma cells into mice (Fidler and Nicolson, 1976). While this 
may represent a syngeneic system when using C57BL6 mice, xenogeneic models are also 
available and in these cells from a different species are injected (human cells into a mouse), 
requiring the use of immunodeficient mice to prevent cell rejection by the immune system 
(Becker et al., 2010). Since syngeneic models are often used to study melanoma 
immunology, xenogeneic models are employed to determine the behaviour of melanoma 
cells with respect to their invasiveness, metastatic potential or the role of melanoma stem 
cells. In contrast to transplantation models, genetically modified animals are largely used to 
analyze melanomagenesis (Becker et al., 2010). Currently several genetic models are 
available, in which mutations lead to spontaneous melanoma development after a period of 
latency and/or after physical or chemical treatment of the animals with UV light or 
carcinogens, e.g. 7,12-dimethylbenzanthracene (DMBA) (Larue and Beermann, 2007). One 
of these models is the hepatocyte growth factor overexpressing / cyclin dependent kinase 4 
knock-in mutant (HGF/CDK4) mouse model. The HGF/CDK4 mice carry a mutation in the 
CDK4 gene (Cdk4R24C), which was knocked into the germline. This mutation creates an 
altered binding pocket for p16Ink4a, the most important inhibitor for CDK4, and renders the 
CDK4 protein insensitive to inhibition by p16Ink4a resulting in a constitutively active CDK4 and 
impaired control of the G1 phase of the cell cycle (Tormo et al., 2006). The Cdk4R24C 
mutation, which functions as a dominant negative oncogene was also observed in some 
cases of sporadic and hereditary melanomas in humans (Zuo et al., 1996). It was shown that 
melanoma cells, but not normal melanocytes, express HGF and c-met, leading to constitutive 
autocrine activation of the MAPK and PI3K pathway (Li et al., 2001). In human melanoma 
specimen c-met expression correlated with melanoma growth and metastatic spread (Cruz et 
al., 2003) and the HGF was shown to stimulate the proliferation of melanocytes (Hirobe et 
al., 2004). In the HGF/CDK4 mouse model, different from wild-type mice, but similar to the 
human situation, melanocytes are not only located in the hair follicels and the dermis, but 
also in the basal layer of the epidermis and the dermo-epidermal junction. These mice 
develop melanomas spontaneously after about eight-to-ten month after birth and tumor 
formation can also by promoted by treatment with DMBA. The spontaneous as well as 
induced tumors recapitulate the histopathology of human melanoma and metastasize to the 
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lymph nodes and lungs (Tormo et al., 2006; Landsberg et al., 2010). Moreover melanoma 
formation can also be induced in these animals by neonatal UVB treatment, which closely 
mimics the human situation (Gaffal et al., 2011).  
For the sake of completeness it should be mentioned that several other transgenic models 
exist, which develop melanomas after carcinogen treatment as well as spontaneously. These 
mice carry different mutated genes under the control of melanocyte specific promoters. For 
example one widely used model is the transgenic overexpression of mutated NRAS or HRAS 
genes under the control of a melanocyte specific tyrosinase promoter (Walker and Hayward; 
2002; Larue and Beermann, 2007). 
 
1.3 ADAM proteases 
1.3.1 Structure 
The protein family of the ADAMs are multidomain type I transmembrane glycoproteins, which 
belong to the adamalysin family of proteins a subgroup of the metzincin zinc 
metalloproteases (Wolfsberg et al., 1995). To date 40 ADAMs have been identified in various 
species from human (23 ADAMs) and mice (33) to Xenopus laevis (6) and Drosophila 
melanogaster (2) (Blobel, 2005).  
ADAMs exhibit a conserved domain structure containing a pro- and a metalloprotease 
domain, a disintegrin-like and a cysteine-rich domain. Additionally most ADAMs also contain 
an EGF-like domain and a short cytoplasmic tail (Edwards et al., 2008). Only 13 of the known 
23 human ADAMs are suggested to be proteolytically active (Edwards et al., 2008) as they 
contain an HExxHxxGxxH….M motif with three histidine residues binding the zinc ion in the 
metalloprotease domain and an invariant methionin turn in the active site (Murphy, 2008). 
The inactive state of the ADAMs is maintained by the interaction of a cysteine residue 
located in the prodomain with the zinc ion in the catalytic site of the metalloprotease domain 
(Edwards et al., 2008). Enzyme activation is achieved by removal of the prodomain mediated 
via proprotein-convertases such as furin or by autocatalytic processing, by which the 
prodomain is cleaved off in the Golgi network (Blobel, 2005). This process is called the 
“cysteine switch mechanism”. Furthermore, the released prodomain functions as a 
chaperone mediating correct protein folding (Edwards et al., 2008). Once activated the 
metalloprotease domain exhibits proteolytic activity towards extracellular matrix proteins 
(Mochizuki and Okada, 2007) and acts as sheddase for many cell surface bound molecules 
activating and liberating them from the cell membrane. This leads to the induction of signals 
in auto- and paracrine manner (Blobel, 2005; Mochizuki and Okada, 2007). The disintegrin 
and the cysteine-rich domains can mediate cell-cell and cell-matrix interactions, via binding 
to integrins or heparansulfate proteoglycans, e.g syndecans (Edwards et al., 2008). The 
cytoplasmic domain of the individual ADAMs is highly variable, but the majority contains 
signalling motifs, such as phosphorylation sites for serine-threonine or tyrosine kinases and 
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proline rich regions, which bind Src-homolgy-3 (SH-3) domain containing proteins important 
for signal transduction (Edwards et al., 2008). In Figure 3 the structure of the ADAMs in 
inactive and active state is illustrated.  
 
Figure 3: Structure of ADAMs and ectodomain shedding. The general structure of the ADAM 
proteases with the C-terminal cytoplasmic tail, the transmembrane domain, the cysteine-rich, the 
disintegrin, the metalloprotease and the prodomain is shown. The metalloprotease domain contains a 
zinc ion in the catalytic site, which binds to a cysteine residue located in the prodomain keeping the 
protein in a latent state. In the trans-Golgi network the prodomain is removed leading to the activation 
of the protein (modified according to: http://en.wikipedia.org/wiki/File:Ectodomain_shedding_en.svg). 
 
1.3.2 Regulation  
The ADAM proteases can be regulated on transcriptional as well as on posttranscriptional 
level. The interaction of the cytoplasmic tail with intracellular proteins might be important for 
the localization and activation of the ADAMs (Edwards et al., 2008). Thus for example 
phosphorylation of the cytoplasmic tail of ADAM-17 by extracellular signal related kinase 
(ERK) induces translation of ADAM-17 to the cell surface (Soond et al., 2005). Other 
posttranscriptional control points for ADAM activity include regulation on the level of the 
zymogen activation and by interaction with tissue inhibitors of metalloproteinases (TIMPs) 
(Mochizuki and Okada, 2007). In contrast to the MMPs, ADAMs are only selectively inhibited 
by TIMPs, thus for example ADAM-17 is exclusively inhibited by TIMP-3 and ADAM-10 can 
be inhibited by TIMP-1 and -3, but not TIMP-2 and -4 (Amour et al., 1998; Amour et al., 
2000). Other ADAMs, like ADAM-8 and -9, are not sensitive to inhibition by TIMPs (Amour et 
al., 2002). Apart form the posttranscriptional regulation, ADAMs can also be regulated on 
gene expression level. It was shown that the estrogen receptor can bind to the ADAM-9 
promotor region, thereby acting as a transcription factor (Cong and Jia, 2009). ADAM-17 
expression was induced by the transcription factor Sp1 in glioma cells (Szalad et al., 2009) 
and TGF-β can induce ADAM-12 expression by degradation of the transcriptional repressor 
SnoN (Solomon et al., 2010).  
 
  Introduction 
13 
 
1.3.3 ADAM function in physiology and pathology 
Due to their multidomain structure, physiologically ADAMs are involved in various cellular 
processes such as cell proliferation, adhesion, migration and signalling (Rocks et al., 2008). 
The first ADAMs, which have been described were ADAMs 1 and 2 and were identified in the 
testis as molecules mediating the fusion of sperm and egg (Wolfsberg et al., 1995). Beside 
their function in fertilization, ADAMs contribute to proliferation, angio-, neuro and 
myogenesis, by their ability to mediate cellular interactions leading for instance to cell fusion 
or by shedding of surface molecules, which can induce para- and autocrine signalling 
(Edwards et al., 2008). ADAM-17 was described as the major sheddase for pro tumor 
necrosis factor-α (TNF-α) (Black et al., 1997), inducing paracrine TNF-α signalling, which for 
instance is crucial for adult myogenesis (Liu et al., 2010). ADAM-9 and ADAM-17 can shed 
heparin binding-hepatocyte growth factor (HB-EGF), which can induce proliferation and was 
for example shown to be important for heart development (Jackson et al., 2003). The 
mechanism, by which ADAM mediated activation of the EGF receptor is achieved, is called 
“triple membrane-passing signalling” (Blobel, 2005). This includes the activation of a 
membrane bound ADAM by ligand binding to a G-protein-coupled-receptor (GPCR), inducing 
intracellular signalling molecules, which phosphorylate the cytoplasmic domain of ADAMs, 
leading to their activation and subsequent shedding of ligands for the EGFR (Blobel, 2005). 
Another process, in which ADAM mediated shedding of surface molecules, plays an 
important role is called “regulated intramembrane proteolysis” (RIP). This process is defined 
as a sequential proteolytic cascade, which includes an initial shedding of the ectodomain of a 
transmembrane protein by an ADAM and a second cleavage in the membrane itself by 
another enzyme, generating an intracellular fragment, which can induce other intracellular 
events (Edwards et al., 2008; Murphy, 2008). The classical examples for RIP are the 
processing of amyloid-precursor-protein (APP) and Notch signalling (Edwards et al., 2008). It 
was shown that ADAM-10 and -17 cleave the extracellular domain of Notch, when it is bound 
to ligands like Delta or Jagged, followed by subsequent intramembrane processing of Notch 
by γ-secretase activity. This process is particularly important in neurogenesis (Bray, 2006). 
Similarly APP is processed by α-secretase activity of ADAM-9, -10 and -17, followed by 
sequential cleavages by β- and γ-secretases (Edwards et al., 2008). Also the adhesive 
functions of the ADAMs contribute to biological processes, like the involvement of ADAM-8 in 
neuron-glia interactions or the binding of ADAM-12 to integrins, which leads to cell 
differentiation during muscle development (Schlomann et al., 2000; Lafuste et al., 2005).   
In various studies it has been shown that members of the ADAM family of proteases play a 
role in cancer. ADAMs can promote tumor cell adhesion and migration, shown for example 
for ADAM-12 (Iba et al., 1999). In addition, ADAMs exhibit enzymatic activity towards 
extracellular matrix proteins as shown for the cleavage of type IV collagen by ADAM-10 and 
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ADAM-15, whereas ADAM-12 can degrade in addition also fibronectin (Mochizuki and 
Okada, 2007). Even though the relevance of these activities for the in vivo situation has not 
been clarified, one can envision that all these activities may contribute to migration through 
tissues. Furthermore, ADAMs can shed as well as bind to cell adhesion molecules, which 
mediate tumor cell interactions with the vasculature, like selectins and VCAM-1 (Murphy, 
2008). ADAM proteases are also involved in the inflammatory reaction, which accompanies 
cancer progression. Hence ADAM-9 and -17 are able to shed ligands of the activating natural 
killer cell receptor, NKG2D, like major histocompatibility complex chain 1 related proteins, 
MICA and MICB, from the tumor cell surface, leading to escape from NKG2D-mediated 
tumor immunosurveillance (Waldhauer et al., 2008; Kogha et al., 2009).  
 
1.4 Current knowledge on ADAM-9 function in physiology and pathology 
ADAM-9 was first identified in 1996 in breast carcinoma (Weskamp et al., 1996). The protein 
is produced as a 110kDa glycosylated proprotein, which is activated in the Golgi apparatus 
by furin activity to the 85kDa mature form that is found on the cell surface after prodomain 
removal (Roghani et al., 1999). As some other members of the ADAM family, in addition to 
its membrane bound form, ADAM-9 exists also as soluble form derived either from a deletion 
in the EGF-like domain creating an early stop codon or from alternative splicing (Hotoda et 
al., 2002; Mazzocca et al., 2005). The protein is ubiquitously expressed, however ADAM-9 
deficient mice show no obvious phenotype and develop normally (Weskamp et al., 2002). In 
adult animals at 20 month after birth, retinal degeneration appeared (Parry et al., 2009). In 
vitro proteolytic activity of ADAM-9 was shown towards various proteins like EGF (epidermal 
growth factor), FGFR2iiib (fibroblast growth factor receptor2 iiib), a murine variant of the 
human FGFR2, type XVII collagen or EphB4 (ephrin type-B receptor 4)  (Peduto, 2009). The 
shedding of FGFR2iiib for example has been shown to be relevant for the regulation of 
growth factor signalling during pathological events such as prostate cancer development 
(Peduto et al., 2005). In vivo, shedding of type XVII collagen by ADAM-9 modulated 
keratinocyte migration during skin repair (Mauch et al., 2010). ADAM-9 is also able to 
degrade extracellular matrix proteins such as fibronectin, gelatin and laminin 111 in vitro  
(Schlöndorff and Blobel, 1999; Schwettmann et al., 2001). Due to the presence of the 
disintegrin domain ADAM-9 provides also adhesive functions. The adhesive activity of 
ADAM-9 to integrin receptors has been shown by several in vitro studies, showing a cell–
type specificity. Thus for example binding to α2β1 integrins was observed in activated 
stellate cells, but to the α3β1 integrin in keratinocytes and fibroblasts (Mazzocca et al., 2005; 
Zigrino et al., 2007; Zigrino et al., 2011). Furthermore in vitro studies showed that membrane 
bound ADAM-9 suppresses, whereas the soluble from promoted breast cancer cell migration 
(Fry et al., 2010). 
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In vitro studies revealed that among several environmental factors, IL-1α and fibrillar type I 
collagen regulate the expression of ADAM-9 in melanoma cells (Zigrino et al., 2005). 
Additional studies have also identified reactive oxygen species as regulators of ADAM-9 
expression in prostate cancer cells (Sung et al., 2006) and in myeloma cells (Fischer et al., 
2004). Recently several studies showed that ADAM-9 expression in hepatocellular 
carcinoma and pancreatic cancer cells is also regulated by microRNAs (Zhou et al., 2011; 
Kim et al., 2011; Hamada et al., 2011).  
Several authors detected increased expression of ADAM-9 in different cancers including 
breast, intestinal, renal and prostate cancer (Lendeckel et al., 2005; Sung et al., 2006; 
Fritzsche et al., 2008) suggesting a role for ADAM-9 in cancerous processes. In prostate 
cancer ADAM-9 expression was associated with shorter relapse-free survival of patients 
(Fritzsche et al., 2008) and in agreement with these results in animals lacking expression of 
ADAM-9, development of aggressive prostate tumors was reduced (Peduto et al., 2005). 
Various melanoma cell lines also express ADAM-9 and in vivo it is expressed in primary 
human melanomas in both, the peripheral parts of the tumor and in stroma cells adjacent to 
the tumor border, whereas little if any expression was detected in metastases (Zigrino et al., 
2005). In vivo, the role of ADAM-9 in melanoma development is controversial being 
described as both a tumor suppressor and promoter in mouse studies (Guaiquil et al., 2009; 
Abety et al., 2012). Microarray analysis of human melanoma revealed an association of 
ADAM-9 expression with melanoma progression (Alonso et al., 2007). Thus the functional 
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1.5 Aims of the thesis 
ADAM-9 is expressed in human melanoma cell lines and in tumor cells located at the tumor- 
stroma border (Zigrino et al., 2005). Stromal expression of ADAM-9 influences melanoma 
growth in vivo (Abety et al., 2012), however the function of ADAM-9 expression in the 
melanoma cells remains unclear. The overall aim of this thesis is to elucidate the role of 
ADAM-9 produced by melanoma cells for tumor growth, invasion and metastases formation. 
To first study the function of ADAM-9 expression in melanoma cells for these processes in 
vitro, ADAM-9 expression in melanoma cells will be stably down-regulated using shRNA. 
This strategy allows to perform long-term experiments in vitro and to investigate proliferation 
and invasiveness of melanoma cells in an in vivo like system. According to the known 
function of ADAM-9 as an adhesive and proteolytic molecule, besides key processes for 
melanoma progression, like proliferation and invasion, further investigations are aimed to 
address melanoma cell adhesion, migration and matrix proteolysis, cellular processes also 
contributing to melanoma progression.  
To answer the question what is the function of melanoma-cell derived ADAM-9 for 
melanomagenesis and progression in vivo, ADAM-9-/- mice are planned to crossbred with 
HGF/CDK4 double mutant transgenic mice, which develop spontaneous melanomas and 
closely resemble human tumors (Tormo et al., 2006). These animals can be treated with 
DMBA to induce tumor growth and to monitor melanoma development and metastases 
formation in the absence of ADAM-9. These analyses will clarify if ADAM-9 participates in 
any of these processes and further investigations will help to unreveal underlying cellular and 
molecular mechanisms by which ADAM-9 contributes to melanoma formation and 
progression. On the one hand it is important to understand the function of melanoma-derived 
ADAM-9 in all processes involved in melanoma formation, but it is equally important to 
understand how this protein is regulated in these processes. The cytokine IL-1α, which is 
expressed in high amounts intracellularly and as well as secreted protein by melanoma cells 
(Löffek et al., 2005; Apte et al., 2006), was indicated as one key regulatory factor of ADAM-9 
expression in melanoma cell lines (Zigrino et al., 2005). Thus we hypothesized that there 
exists a threshold of this cytokine above which ADAM-9 is down-regulated and vice versa in 
these cells. To prove this hypothesis and to understand the molecular events leading to the 
regulation of the expression and activity of ADAM-9 in melanoma cells the intracellular 
pathways mediating regulation of ADAM-9 by either exogenous as well as intracellular IL-α 
will also be analyzed. For this purpose the effect of exogenously added IL-1α will be 
investigated using a pharmacological approach by inhibiting downstream mediators of the IL-
1α signalling pathway (JNK, NFκB). To investigate the intracellular pools, high invasive 
melanoma cells, in which IL-1α expression was stably down-regulated, will be used. 
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2. Material and Methods 
2.1 Material 
2.1.1 Chemicals 
All chemicals were purchased in analytical grade from Roth (Karlsruhe, Germany), Sigma 
Aldrich (München, Germany), Merck (Darmstadt, Germany), GIBCO (Karlsruhe, Germany) 
and Perbio (Lausanne, Switzerland). 
Tissue-Tek® (Polyvinyl alcohol < 11%, carbowax< 5%, nonreactive ingredients 85% was 
purchased from Sakura, Zoeterwoude, Netherlands. RNA inhibitors, Oligod(T)16 primers 
primers and MuLV reverse transcriptase were used from Applied Biosciences (Foster City, 
CA, USA); dNTPs were purchased from Roche (Mannheim, Germany).  
Molecular weight markers for proteins, PageRulerTMPlusPrestained Protein ladder and 
PageRulerTMUnstained Protein ladder were from Fermentas (St. Leon-Roth, Germany). DNA 
marker, 100bp DNA ladder were from NEB (Frankfurt/Main, Germany). The indirubin 
derivates SL-22, SL-85 and KD-65 were synthesized in the Department for Organic 
Chemistry at the University of Rostock and were a kind gift of Prof. Manfred Kunz. 
2.1.2 Recombinant and purified proteins 
Human recombinant or purified proteins used are summarized in Table 1. 
Table 1: Human recombinant and purified proteins. 
Human protein Source Application 
rec. ADAM-9 R&D Systems enzymatic assay 
rec. collagen I BD Biosciences enzymatic assay 
rec. collagen IV BD Biosciences adhesion, enzymatic assay, migration 
rec. fibronectin R&D Systems migration,  enzymatic assay 
laminin 332, isolated from 
foreskin kerationcytes Immundiagnostik 
adhesion, enzymatic 
assay, migration 
rec. laminin β3-chain 
Prof. M. Koch, Institute for Experimental Dental 
Medicine and Oral Muscoskeletal Biology, 
Cologne 
enzymatic assay 
rec. laminin 511 BioLamina enzymatic assay 
matrigel BD Biosciences adhesion, migration 
 
2.1.3 Cell culture material 
Plastic ware for cell culture was purchased from Greiner (Nürtingen, Germany), TPP 
(Trasadingen, Switzerland) and BD Biosciences (Heidelberg, Germany). Cell culture medium 
was purchased from PAA (RPMI, Cölbe, Germany) and GIBCO (DMEM, Karlsruhe, 
Germany). Antibiotics (Penicillin/Streptomycin) and L-Glutamine were from Biochrom (Berlin, 
Germany), FCS and non-essential amino acids from PAA (Cölbe, Germany). 
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2.1.4 Consumable materials 
CL-XPosureTMX-Ray exposure films  Thermo Fischer Scientific 
Cryomolds (standard, intermediate)  Sakura 
Embedding cassettes    KABE Labortechnik 
Eppendorf tubes (1.5 ml, 2 ml)  Eppendorf 
PCR tubes (0.5 ml)    peQlabBiotechnologie 
Microscopic slides    Menzel 
Microscopic coverslips, ø 12 mm  Assistent® 
Nitrocellulose membrane   AmershamBioscience 
Syringes and needles   BD Biosciences 
Whatman paper    VWR 
 
2.1.5 Buffers and solutions 
Anode Buffer I Tris 0.3M, 20% methanol 
Anode Buffer II Tris 25mM, 20% methanol 
Cathode Buffer    6-Aminohexan acid 40mM, 20% methanol 
DEPC-treated H2O    H2O, 0.1% DEPC 
DNA extraction buffer     50mM Tris base, pH 8.0, 100mM EDTA, 100mM    
 NaCl, 1%SDS 
FACS buffer  PBS, 1% BSA, 2mM EDTA 
Laemmli reducing loading  60mM Tris-HCl pH 6.8, 2% SDS, 0.1% 
bromphenolblue buffer 25% glycerol, 14.4mM 2-mercaptoethanol 
 
PBS   137mM NaCl, 2.7mM KCl, 8.4mM Na2HPO4,     
 1.4mM KH2HPO4, pH 7.4 
PBST   0.5% Tween/PBS 
Ponceau Red solution 0.1% Ponceau S (w/v) in 5% acetic acid (v/v) 
Running Buffer (PAGE) 250mM Tris base, 0.2M glycin, 1%SDS, pH 8.3 
RIPA Buffer 150mM NaCl, 0.5% sodium deoxycholate, 2% 
 SDS, 1%NP40, 50mM Tris pH 7.4 
Substrate buffer 25mM Tris, 2.5µM ZnCl2, 0.005% Brij-35, pH 9.0 
TBE 90mM Tris, 20mM Na2EDTA, 90mM boric acid pH 8.0                     
 
2.1.6 Devices 
Agarose gel electrophoresis Easy-Cast Electrophoresis System Model 2B, 
      Owl Scientific Model 40-0911, 
 peQlabBiotechnologie  
Cell counter     CASY® device model TT 
 
Cell incubators HERAcell 150i CO2-incubator, 
 Thermo Fisher Scientific  
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Centrifuges     Eppendorf Centrifuge 5415 R, Eppendorf  
     Centrifuge 5415 C, HeraeusSepatechMegafuge
     1.0 
Cool plate     Thermo Shandon   
Cryostat Microm HM 650 
ELISA MicroPlate Reader  1420 Multilabel Counter, VICTOR3TM,  
 Perkin Elmer    
Flow cytometer FACSCalibur flow cytometer, BD Biosciences 
Microscopes     Leica DM 4000 B, Nikon Eclipse TS100, Nikon 
      Eclipse E800, Olympus IX81 
Microtome Thermo Shandon Finesse microtome 
pH-meter     WTW inolab pH level 1 
Photometer      Eppendorf Bio Photometer, Eppendorf  
Real-time PCR 7300 Real-time PCR System, Step One Plus 
Real-time PCR System, Applied Biosystem  
Shaker     KS 250 basic, KIKA Labortechnik  
Sterile hoods Lamin Air 2448, Heraeus Instruments 
 Safa 2020, Thermo Fischer Scientific 
Thermocycler T3 Thermocycler, Biometra 
Thermomixer     EppendorfThermomixer 5437, TS 100  
      Thermoshaker 
Water bath     GFL, Julabu SW-20C    
Western Blot equipment   Mighty Small II SE 250, Hoefer Scientific  
      Instruments 
X-Ray film development  Curix 60 developing machine, AGFA 
            
   
2.1.7 Software 
Adobe Photoshop 7.0  
BD CellQuest Pro, BD Biosciences 
CellR® Imaging Software, Olympus 
Diskus 4.50, Hilgers 
Graph Pad Prism 4.03 
Image J 1.41(http://rsb.info.nih.gov./ij) 
NIS-Elements AR 2.30, NIS-Elements 














2.2.1 Cell culture 
2.2.1.1 Melanoma cell lines 
The human melanoma cell lines Skmel23, Skmel28, WM164/4, IF6, BLM, MeWo, VMM5, 
WM75/6, A375, Ma-Mel-86a and Ma-Mel-119 were used. In Table 2 the invasive capacities 
of the different cell lines including references are shown. All cell lines were cultured in RPMI 
1640 medium containing 10% FCS, 1% non-essential amino acids, 2% L-Glutamine, 
Penicillin/Streptomycin (100U/ml) (normal growth medium). Additionally, the murine 
melanoma cell line B16-F1 (Fiedler and Nicolson, 1976), which was stably transfected with 
GFP was used (Zigrino et al., 2009). These cells were cultured in DMEM medium 
supplemented with 10% FCS, Penicillin/Streptomycin (100 U/ml) and 800µg/ml G-418 (PAA, 
Cölbe, Germany). All cells were cultured at 37°C and 5% CO2 in humidified atmosphere. 
Cells were passaged at a ratio of 1:5 twice per week. Confluent cells were detached by 
incubation in Trypsin/EDTA (1% Trypsin/ 2.5% EDTA) and seeded in normal growth medium. 
 
Table 2: Information about the used human melanoma cell lines. 
Cell line Invasive capacity           in vivo Origin References 
A375 high Primary melanoma 
Giard, et al., 1973 
Kozlowski et al., 1984 
Luca et al., 1995 
BLM high Lung metastasis 
Lockshin et al.,1985 
Van Muijen et al.,1991 
IF6 low Lymph node metastasis Van Muijen et al., 1991 
Ma-Mel-86a not tested Lymph node metastasis 
Ugurel et al., 2007                                              
Schwinn et al., 2003 
Ma-Mel-119 not tested Skin metastasis Ugurel et al., 2007                    
MeWo high Lymph node metastasis 
Carey et al., 1976 
Ishikawa et al., 1988a 
Ishikawa et al., 1988b 
Welch et al., 1991 
Skmel23 low Primary melanoma Carey et al., 1976 
Skmel28 low Primary melanoma 
Carey et al., 1976 
Luca et al., 1995 
VMM5 high  (in collagen I matrix) 
Metastatic 
melanoma Benbow et al., 2002 
WM164/4 low Melanoma metastasis Herlyn, D. et al., 1990 
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2.2.1.2 Endothelial cell lines 
The mouse endothelial cell line sEND-1, which was originally isolated from middle T 
oncogene of polyoma virus induced hemangiomas (Williams et al., 1988), was cultured in 
DMEM medium supplemented with 10% FCS and Penicillin/Streptomycin (100U/ml) and sub- 
cultivated in a ratio of 1:5 two times per week by incubation in Trypsin/EDTA (1% Trypsin/ 
2.5% EDTA) and reseeding in normal growth medium. 
2.2.1.3 Isolation and culture of primary human dermal fibroblasts 
Primary dermal human fibroblasts were isolated from human skin obtained during surgeries 
in the Clinic for Dermatology and Venerology, University of Cologne. All samples were taken 
with the patients consent and approved by the local ethic committee (Ethikantrag: 08-144). 
Directly after the preparation by the surgeon the skin was freed from fat tissue and cut in ~ 5 
x 5mm small pieces. These pieces were adhered to the bottom of a culture flaks and 
incubated for 2h at 37°C and 5% CO2 in a humidified atmosphere. Cell culture medium 
(DMEM medium supplemented with 10% FCS and Penicillin/Streptomycin, 100U/ml) was 
introduced and the skin pieces cultured for two-three weeks until cells migrated out of the 
tissue. The fibroblasts were further cultured in DMEM medium supplemented with 10% FCS 
and Penicillin/Streptomycin (100U/ml) and used for experiments in passages two-six.  
2.2.1.4 Stimulation of BLM melanoma cells and fibroblasts 
For stimulation experiments melanoma cells were seeded in a density of 85,000 cells/cm² in 
RPMI 1640 medium containing 10% FCS, 1% non-essential amino acids, 2% L-Glutamine, 
Penicillin/Streptomycin (100U/ml). Human dermal fibroblasts (passages two-six) were 
seeded with a density of 60,000/cm² in DMEM medium containing 10% FCS and 
Penicillin/Streptomycin (100U/ml). All cells were grown as monolayer for 24h and washed 
twice with PBS before stimulation. The cells were stimulated with 10µM of indirubins (chapter 
2.1.1) or 10U/ml recombinant human IL-1α (tebu-bio, Offenbach, Germany) in medium 
containing 1% FCS. As a control, cells were also treated with 0.001% DMSO, the solvent for 
the indirubins.  
For pharmacological inhibition studies 10µM of the NFκB inhibitor SN50 (Biomol GmbH, 
Hamburg, Germany) and 18µM of the JNK inhibitor SP600125 (Biomol GmbH, Hamburg, 
Germany) were used. The melanoma cells were incubated for 24h with 10U/ml IL-1α alone 
or in combination with one of the inhibitors. Cells incubated with 0.0002% DMSO, the solvent 
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2.2.1.5 Generation of IL-1α  or ADAM-9 silenced stable melanoma cell clones 
BLM or B16-F1 melanoma cells were stably transfected with shRNA plasmids targeted to IL-
1α or ADAM-9 by using Lipofectamine® (Invitrogen, Karlsruhe, Germany) or nucleofection 
using the Nuleofector® Technology and the Nucleofector® Kit V (both Lonza AG, Cologne, 
Germany), respectively, according to the manufactures instructions. When shRNAs targeted 
to IL-1α or ADAM-9 were applied, five different shRNA plasmids provided by SA Biosciences 
(Frederick, USA) were used for the transfection: one control plasmid containing a scrambled 
artificial sequence, which does not match any human gene, and four additional plasmids 
each expressing a different shRNA sequence targeted to different areas of the IL-1α or 
ADAM-9 transcript under the control of the U1 promoter. The targeting vector is shown in 





For transfection of B16-F1 cells one control plasmid containing a scrambled artificial 
sequence, which does not match any mouse gene and a pool of five plasmids expressing 
different shRNA sequences targeted to ADAM-9 were used. The manufacturer (Santa Cruz, 
Heidelberg, Gemnay) does not provide the different shRNA sequences. The shRNAs were 
under the control of a H1 promoter. Two days post transfection BLM melanoma cells were 
selected using 600µg/ml G-418 (PAA, Cölbe, Germany) and B16-F1 cells using 400ng/ml 
puromycin (PAA, Cölbe, Germany), added to the normal growth medium (selection medium). 
After 14 days in culture under selection pressure, single colonies were isolated with cloning 
rings and further cultured in selection medium, until enough cells were available for analysis 
of IL-1α or ADAM-9 expression on mRNA and protein level. The IL-1α clones have been 
generated within the frame of the diploma thesis of Mrs. Birgit Seyfarth and clones used 















Table 3: Sequences of the four different shRNAs 
targeted to human ADAM-9 or IL-1α and the scram-
bled control sequence.!
Figure 4: pGeneClipTM Neomycin 
vector carrying the shRNA sequen-
ces. !
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2.2.1.6 Cell area and volume determination 
For measurement of cell area, 35,000 cells/cm² were plated on 100mm plastic petri dishes 
and grown for 24h to about 60% confluence in selection medium. Images (200x 
magnification) of the cells were captured with a Nikon Eclipse TS100 microscope connected 
to a Nikon DS-Fi1 camera. The cell area of 50 single grown cells of each clone was 
measured with the ImageJ program (http://rsb.info.nih.gov./ij). 
To quantify the cellular volume of ADAM-9 down-regulated or control cells 35,000 cells/cm² 
were seeded on 100mm plastic petri dishes in selection medium and cultured for three days 
until the cells were confluent. The cells were detached with Trypsin/EDTA (1% Trypsin/2.5% 
EDTA) and centrifuged at 100g for 5min at room temperature (RT). After centrifugation the 
cell pellet was resuspended in 10ml selection medium and 100µl of the cell suspension was 
diluted in 10ml isotonic NaCl solution. In this suspension cellular volume was determined 
using the CASY® device model TT (Schärfe System, Reutlingen, Germany). For each 
sample cell volume was determined in triplicate.  
For aquaporin inhibition studies, the cells were detached (1% Trypsin/2.5% EDTA) and 
centrifuged at 100g for 5min at RT. Afterwards the cells were resuspended in selection 
medium supplemented with 0.15mM mercuric chloride (HgCl2; Sigma Aldrich, München, 
Germany) and incubated at RT for 1h. Subsequently cell volume was determined as 
described above.  
2.2.1.7 Proliferation Assay 
To measure cell proliferation, 40,000 cells/cm2 were seeded in 96 multiwell plates and grown 
for 24 and 48h. Cellular proliferation was measured using a BrdU (Bromodeoxyuridine) 
Proliferation Kit (Roche, Penzberg, Germany) according to the manufacturer’s instructions. 
Briefly, cells were labeled with BrdU (10µM final concentration/well) for 2h at 37°C. After 
labeling, medium was removed and cells dried at RT for about 1h before being stored at 4°C 
until further processing. 
DNA was denatured by addition of 200µl of “FixDenat” solution to each well and incubation 
for 30min at RT. After removing the solution, 100µl of anti-BrdU-POD antibody working 
solution was added for 1.5h at RT. Plates were washed three times with PBS and incubated 
with substrate solution for 10min. The reaction was stopped using 25µl of 1M H2SO4 and 
fluorescence was analyzed at 450 nm using Victor3TM 1420 Multilabel counter. Cells in which 
only BrdU labelling step was omitted were used as control. For each clone BrdU labelling 
procedure was performed in triplicate. 
 
 2.2.1.8 Soft agar colony formation assay 
For colony formation soft agar assay, 6-well culture dishes were covered with a 0.5% base 
  Material and Methods 
24 
 
medium. This layer was covered by a 0.2% top agar layer containing 5000 ADAM-9 down-
regulated or scramble transfected control cells and 50% selection medium. The agar layers 
were covered by 500µl medium, which was exchanged twice per week. The cells were 
allowed to grow for 21 days before formed colonies were fixed and stained with 0.005% 
crystal violet dissolved in methanol for 1h. For every clone the experiment was performed in 
triplicate and for each culture dish the number of formed colonies was counted in 8 randomly 
chosen microscopic fields (100 x magnification). 
2.2.1.9 Dead de-epidermized skin assay 
For dead deepidermized skin (DDS) invasion assay healthy human skin was obtained from 
plastic surgery. The assay was performed as previously described (Dennhöfer et al., 2003), 
with the modification that melanoma cells were seeded in addition to the dermal side also on 
the basement membrane (BM) side. Briefly fat tissue was dissected and the remaining skin 
was repeatedly frozen and thaw at -80°C and in a 37°C water bath. This procedure led to 
death of all cells located in the tissue. Subsequently the epidermis was detached from the 
dermis by thermolysis (10min, 56°C in PBS) and stripped off mechanically retaining the BM. 
In the next step 1cm diameter punch biopsies were taken from the skin tissue and incubated 
for 10min in medium before they were placed on a stainless steel support in a 6-well culture 
plate with either the BM side or the fat free dermal side upside. The assembly of the skin 
composites and the location of melanoma cell seeding is schematically shown in Figure 5. 
On top of the skin composites 100,000 ADAM-9 or IL-1α silenced or control cells were 
seeded in 10µl medium either on the BM side or the fat free dermal side. Medium was filled 
below the stainless steel support and comparable to the in vivo situation, the cells were 
cultured at the air/liquid interphase for 21 days. The medium was exchanged every two-three 
days. For further analysis, the composites were embedded in Tissue-Tek® or fixed for 12h in 
Roti®-Histofix 4% (Roth, Karlsruhe, Germany) at 4°C. Paraffin sections of the cultures were 
stained with haematoxylin and eosin (H&E) and the invasion depth of cells, which penetrated 
the tissue was microscopically measured under bright field illumination (Leica DM 4000 B; 
Leica, Wetzlar, Germany). Images were captured with a computerized imaging system (JVC, 
KY-F75U camera; Dikus 4.50, Hilgers, Königswinter, Germany).  
The presence of the BM in the cultures was confirmed by immunohistochemical staining of 
BM components laminin α3-chain and collagen IV (see 2.2.2.3). 
 
 




Figure 5: Assembly of DDS composite and locations for melanoma cell seeding. BM: basement 
membrane 
2.2.1.10 Cell migration assay 
Cell migration assays were performed in 24-well tissue culture plates. The culture plates 
were coated with the following human proteins by overnight adsorption at 4°C: 10µg/ml 
recombinant fibronectin or recombinant collagen IV, 5µg/ml laminin-332 and matrigel. The 
next day the matrix was washed twice with PBS to remove excess proteins. For the 
experiment mitotic activity of the cells was arrested by treatment with mitomycin-C (1.6 
µg/ml; Sigma Aldrich, München, Germany) for 2h before seeding. The cells were seeded in 
metal cloning rings in the middle of a well and incubated for 1h at 37°C, allowing them to 
attach and spread. After removing the cloning rings carefully and washing the cells twice with 
PBS, new serum-free medium was introduced. The plates were placed under a microscope 
(Olympus IX81) in a chamber providing a humidified atmosphere at 37°C. Pictures of two 
distinct positions from each cell circle were taken every hour over a period of 24h. Areas 
covered by cells at different time points were measured with the ImageJ program.  
2.2.1.11 Adhesion Assay 
96-multiwell tissue culture plates were coated with the following human proteins by overnight 
adsorption at 4°C: 10µg/ml recombinant collagen IV, 10µg/ml recombinant collagen I, 5µg/ml 
human laminin-332, matrigel. Coating with 100% FCS or 1% heat inactivated BSA were used 
as positive and negative controls, respectively. After saturation of the wells with 1% heat 
inactivated BSA (fraction V, Sigma Aldrich, München, Germany) for 1h at 37°C, plates were 
washed with PBS and 40,000 ADAM-9 down-regulated or control cells were seeded in 100µl 
medium containing 0.5% BSA supplemented with insulin-transferrin-sodium selenite (ITS, 
Sigma Aldrich, München, Germany). The cells were allowed to adhere to the different 
proteins for 1h at 37°C. Subsequently, non adherent cells were washed away by two washes 
with PBS and remaining cells were fixed with 4% paraformaldehyde (PFA) for 10min at RT. 
After staining the cells for 15min with 0.5% crystal violet, retained stain was released using 
0.1M sodium citrate and measured by color reading at 595nm with an ELISA reader (1420 
Multilabel Counter VICTOR3TM, Perkin Elmer, Rodgau, Germany). A blank value 
corresponding to uncoated wells was subtracted after the measurement.  
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2.2.1.12 Cell-cell adhesion assay 
For cell-cell adhesion assays, B16-F1 melanoma cells, which were stably transfected with a 
scrambled shRNA or with shRNA targeted to ADAM-9 (chapter 2.2.1.5) were labeled by 
incubation of subconfluent cell layers with 10µM of Cell TrackerTM Green BODIPY                    
(8-choromethyl-4-4difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s-indacene; Invitrogen, 
Darmstadt, Germany) diluted in serum-free medium for 30min. The BODIPY can pass freely 
through the cell membrane and is intracellularly transformed into a cell-impermeable 
fluorescent dye-thioehter by a glutathione-s-transferase mediated reaction. After labeling, the 
cells were washed twice with PBS, incubated for 45min in serum-free medium and 
subsequently detached using 0.5% EDTA. 
For the assay 70,000 sEND-1 murine endothelial cells per well were seeded in 96 multiwell 
tissue culture plates in normal growth medium and allowed to attach and form a confluent 
monolayer for 6h. Subsequently the cells were washed three times with PBS and activated 
with 50ng/ml human recombinant TNF-α (MiltenyiBiotec, Bergisch-Gladbach, Germany) 
diluted in serum-free medium (Sikorski et al., 1993; McAteer et al., 2008). After 18h the cells 
were washed with PBS three times and 40,000 labeled B16-F1 cells were plated in 100µl 
serum-free medium on top of the endothelial cells. To ensure that equal cell numbers were 
used, the fluorescence of suspended cells was measured directly before plating the 
melanoma cells. After 1h incubation time at 37°C, non-attached cells were carefully removed 
by two washes in PBS and cells lysed with 2% SDS diluted in PBS. The extent of adhesion 
was measured by fluorescence reading (absorption 485nm/emission 535nm) with an ELISA 
reader (1420 Multilabel Counter VICTOR3TM, Perkin Elmer, Rodgau, Germany). A blank 
value corresponding to wells containing only 2% SDS was subtracted from the 
measurement. Alternatively, after removing non-adherent cells, cultures were fixed with 4% 
PFA for 10min at RT and attached cells were visualized and images recorded using an 
Olympus IX81 microscope.  
For analysis of adhesion molecules induced by TNF-α stimulation of sEND-1 cells, the cells 
were seeded and stimulated as indicated above 18h prior to processing them for RNA 
extraction.  
2.2.1.13 Fluorescence activated cell sorting (FACS) 
For FACS analysis 40,000 cells per cm2 were plated in serum-free medium on plastic tissue 
culture plates or plates coated with 10µg/ml human recombinant collagen IV (BD 
Biosciences, Heidelberg, Germany) by overnight adsorption at 4°C. After 2h adhesion, cells 
were detached using 0.1% Trypsin at 37°C, collected in serum-free medium, centrifuged for 
5min and resuspended in FACS buffer. For staining 100,000 cells were incubated with the 
first antibodies in ~100µl FACS buffer for 1h on ice. Subsequently the cells were washed with 
1ml FACS buffer and incubated with corresponding fluorescently labelled secondary 
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antibodies (1:500; Invitrogen, Darmstadt, Germany) for 30min on ice. Cells were washed with 
1ml FACS buffer and 7-AAD (7-Amino-Actinomycin; 1:20; eBioscience Inc., San Diego, CA, 
USA) was added 10min before the analysis to detect dead cells. Samples were analyzed 
with the flow cytometer with the appropriate laser and software. Used primary antibodies and 
the corresponding secondary antibodies are listed in Table 4. Each staining was performed 
in triplicate and included a negative control where first antibody was replaced by isotype 
specific antibodies.  
 
Table 4: Primary and secondary antibodies used for FACS analysis. 
Antigen Source Clone Host,      Type                 Dilution Secondary antibody 
human integrin α1 Chemicon FB12 mouse,   monoclonal 1:1000 
Alexa Fluor 488  
goat anti mouse IgG 1:500 
human integrin α2 Chemicon P1E6 mouse,   monoclonal 1:1000 
Alexa Fluor 488  
goat anti mouse IgG 1:500 
human integrin α3 Chemicon ASC-1 mouse,   monoclonal 1:1000 
Alexa Fluor 488  
goat anti mouse IgG 1:500 






12G10 mouse,   monoclonal 1:1000 
Alexa Fluor 488  
goat anti mouse IgG 1:500 
unspecific BD Biosciences / purified mouse IgG1 1:1000 
Alexa Fluor 488  
goat anti mouse IgG 1:500 
 
2.2.2 Protein analysis 
2.2.2.1 Preparation of cell lysates 
 
“Crude” membrane preparation: 
For crude membrane preparations, subconfluent cell monolayers were washed with PBS, 
collected by scraping and washed twice with PBS for 5min at 200g at 4°C. The cell pellet 
was suspended in 1ml Ca-free PBS supplemented with protease inhibitors (Sigma Aldrich, 
München, Germany) and subjected to three cycles of freezing/thawing using a dry ice/EtOH 
bath and a 37°C water bath. Lysates were further homogenized by shearing 20 times 
through a 20G needle and centrifuged for 5 min at 400g at 4°C. Collected supernatants were 
centrifuged at 1500g at 4°C for 30min to pellet cell membranes, which were resuspended in 
PBS containing protease inhibitors.  
Preparation of whole cell lysates: 
Subconfluent cell monolayers were directly lysed in RIPA buffer containing general protease 
inhibitors (Sigma Aldrich, München, Germany). To study phosphorylated proteins, the RIPA 
buffer was supplemented additionally with 1mM sodium vanadate, to inhibit phosphatase 
activity. Lysates were incubated over night under rotation at 4°C followed by centrifugation in 
a precooled centrifuge (5min, 1500g) and the supernatants transferred to new tubes.  
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The protein concentration was determined using a commercial protein assay (BCATM Protein 
assay, Pierce, Bonn, Germany) according to the manufacturer’s instructions. A freshly 
prepared gradient of BSA served as standard curve. Lysates were stored at -20°C until use.  
2.2.2.2 SDS-PAGE and immunoblotting 
Proteins were electrophoretically separated on 10 or 12% polyacrylamide gels containing 
SDS (SDS-PAGE) and transferred onto a Hybond-C SuperTM nitrocellulose membrane 
(Amersham, Freiburg, Germany) by semi-dry-blotting system (Sigma-Aldrich, München, 
Germany). Ponceau Red staining of the membranes was used to assess transfer efficiency. 
Blocking was performed in 5% milk PBS-Tween (0.5% Tween) at RT for 1h. To analyze 
phosphorylated proteins the blocking buffer also contained 5mM sodium fluoride, to inhibit 
phosphatase activity. Incubation with the primary antibodies (for information see Table 5) 
was conducted in blocking buffer over night at 4°C. The next day, after extensive washes, 
blots were incubated in HRP-coupled secondary antibodies (1:2000 in 5% milk powder in 
PBS-Tween; Dako, Glostrup, Denmark) at RT for 1h, followed by detection with the ECL 
system (ECL®, Amersham, Freiburg, Germany) and membranes exposed to X-ray films 
(Thermo Fisher, Karlsruhe, Germany). Specific signals were quantified using the Image J 
program.  
Table 5: Primary and secondary antibodies used for immunoblot analysis. 
Antigen Source Host,        Type Dilution Secondary antibody 
human ADAM-9 
ectodomain R&D Systems 
goat, 
polyclonal 1:500 
polyclonal HRP-coupled          
anti goat IgG 1:2000 
mouse ADAM-9 
ectodomain R&D Systems 
goat, 
polyclonal 1:500 
polyclonal HRP-coupled             
anti goat IgG 1:2000 
human β-actin Sigma Aldrich rabbit,  polyclonal 1:2000 
polyclonal HRP-coupled             
anti rabbit IgG 1:2000 
human ERK1/2 Santa Cruz rabbit,  polyclonal 1:500 
polyclonal HRP-coupled             
anti rabbit IgG 1:2000 
human JNK1/2/3 Santa Cruz rabbit,  polyclonal 1:500 
polyclonal HRP-coupled             
anti rabbit IgG 1:2000 
human laminin β3 chain Prof. M. Koch, Cologne 
rabbit,  
polyclonal 1:200 
polyclonal HRP-coupled            
anti rabbit IgG 1:2000   
human pERK Santa Cruz mouse,  polyclonal 1:500 
polyclonal HRP-coupled          
anti mouse IgG 1:2000 
human pJNK Santa Cruz mouse,    monoclonal 1:500 
polyclonal HRP-coupled          
anti mouse IgG 1:2000 
2.2.2.3 Immunohistochemistry 
Immunohistochemical stainings were performed on cryo or paraffin sections (7µm). 
Cryosections were fixed with ice-cold acetone for 10min at RT and allowed to air-dry or, 
alternatively, fixed using Roti®-Histofix 4% (Roth, Karlsruhe, Germany) for 10min at RT. 
Paraffin sections were deparaffinized in xylene (20 min) followed by a graded alcohol series 
(1min each): 100 % 2-Propanol, 96% EtOH, 75% EtOH, aqua bidest.  
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To detect collagen type IV, deparaffinized sections were pre-treated for 5min at 37°C with 
pepsin (DCS, Hamburg, Germany), for antigen retrieval. Prior to incubation with primary 
antibodies, unspecific binding sites were blocked by incubation with 10% normal goat serum 
for 1h. After washing, sections were incubated at 4°C over night with the first antibodies in 
PBS. For anti-CD31, anti-LVYE-1 and anti laminin α3-chain staining, antibodies were diluted 
in PBS containing 1% BSA. Bound first antibodies were visualized by incubation with 
corresponding fluorescently labelled secondary antibodies (1:800; Invitrogen, Darmstadt, 
Germany). Cell nuclei were visualized with fluorescent dye DAPI (4,6-diamidino-2-
phenylindol; Sigma Aldrich, München, Germany) or with propidiumiodid (Sigma Aldrich, 
München, Germany). In Table 6 the used primary antibodies and the corresponding 
secondary antibodies are shown. Negative controls were performed by omission of the 
primary antibodies. Images were captured with a Nikon Eclipse E800 microscope and a 
Nikon Digital Camera DXM 1200 connected to a computer equipped with an imaging 
program (NIS-Elements AR 2.30, NIS-Elements, Melville, NY, USA).  
 
Table 6: Information about antibodies used for immunohistochemistry. 
Antigen Source Host,                 Type Dilution Secondary antibody 
mouse ADAM-9 ectodomain R&D Systems rat, monoclonal 1:50 
Alexa Fluor 488  
goat anti rat IgG 1:800 
mouse CD3ε Acris rabbit,  polyclonal 1:200 
Alexa Fluor 488  
goat anti rabbit IgG 1:800 
mouse CD4 Abcam rat, monoclonal 1:200 
Alexa Fluor 488  
goat anti rat IgG 1:800 
mouse CD8 Abcam rat, monoclonal 1:200 
Alexa Fluor 488  
goat anti rat IgG 1:800 
mouse CD31  
(platelet endothelial cell 
adhesion molecule-1) 
BD Biosciences rat, monoclonal 1:1000 
Alexa Fluor 488  
goat anti rat IgG 1:800 
mouse CD45 Serotec rat, monoclonal 1:200 
Alexa Fluor 488  
goat anti rat IgG 1:800 
mouse CD68 Serotec rat, monoclonal 1:60 
Alexa Fluor 488  
goat anti rat IgG 1:800 
mouse cleaved caspase-3 Cell Signalling rabbit, polyclonal 1:200 
Alexa Fluor 594  
goat anti rabbit IgG 1:800 
human collagen IV Biogenex mouse,     monoclonal 
ready to 
use 
Alexa Fluor 488  
goat anti mouse IgG 1:800 
human collagen IV Progen rabbit,  polyclonal 1:100 
Alexa Fluor 488  
goat anti rabbit IgG 1:800 
mouse CXCR4 R&D Systems rat, monoclonal 1:50 
Alexa Fluor 488  
goat anti rat IgG 1:800 
mouse cytokeratin 14 Covance rabbit, polyclonal 1:1000 
Alexa Fluor 594  
goat anti rabbit IgG 1:800 
mouse Ki67 Dako rat, monoclonal 1:100 
Alexa Fluor 488  
goat anti rat IgG 1:800 




mouse,      
monoclonal 1:10 
Alexa Fluor 488  
goat anti mouse IgG 1:800 
human laminin β3-chain Prof. M. Koch,  Cologne 
rabbit, 
polyclonal 1:200 
Alexa Fluor 488  
goat anti rabbit IgG 1:800 
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mouse loricrin Covance rabbit, polyclonal 1:2000 
Alexa Fluor 594  
goat anti rabbit IgG 1:800 




Alexa Fluor 488  
goat anti rat IgG 1:800 
mouse LYVE-1  
(lymphatic vessel endothelial 
hyaluronan receptor-1) 
Abcam rabbit, polyclonal 1:800 
Alexa Fluor 594  
goat anti rabbit IgG 1:800 







Alexa Fluor 488  
goat anti rabbit IgG 1:800 
 
2.2.2.4 Immunocytochemistry 
For cellular staining of aquaporin-3, α-tubulin and integrin receptor subunits cells were fixed 
with 4% PFA for 5min and permeabilized by incubation with 0.1% Tween in PBS. Unspecific 
binding sits were blocked with 10% BSA in PBS (for aquaporin-3 and α-tubulin) or with 10% 
normal goat serum diluted in 0.05% PBST (for anti integrin antibodies) for 1h at RT. 
Incubation with primary antibodies diluted in PBS (for aquaporin-3 and α-tubulin) or 0.05% 
PBST (for anti-integrin antibodies) was carried out over night at 4°C. Bound primary 
antibodies were detected by incubation with fluorescently labelled secondary antibodies 
(1:800; Invitrogen, Darmstadt, Germany). Information about the primary and secondary 
antibodies used are supplied in Table 7. For staining of the actin cytoskeleton cells were 
incubated with fluorescently labelled phalloidin (1:200 in PBS; Sigma Aldrich) for 30min at 
RT. Cell nuclei were visualized with DAPI (Sigma Aldrich, München, Germany). Images were 
captured with a Nikon Eclipse E800 microscope and a Nikon Digital Camera DXM 1200 
connected to a computer equipped with an imaging program (NIS-Elements AR 2.30, NIS-
Elements, Melville, NY, USA).  
 
Table 7: Information about antibodies used for immunocytochemistry. 
Antigen Company Host,       Type Dilution Secondary antibody 
human aquaporin-3 Santa Cruz goat, polyclonal 1:100 
Alexa Fluor 594  
donkey anti goat IgG 1:800 
human integrin α1 Chemicon rabbit, polyclonal 1:500 
Alexa Fluor 488  
goat anti rabbit IgG 1:800 
human integrin α2 Chemicon rabbit, polyclonal 1:500 
Alexa Fluor 488  
goat anti rabbit IgG 1:800 
human integrin α3 Chemicon rabbit, polyclonal 1:500 
Alexa Fluor 488  
goat anti rabbit IgG 1:800 






mouse,   
monoclonal 1:500 
Alexa Fluor 488  
goat anti mouse IgG 1:800 
human α-tubulin Oncogene mouse,    monoclonal 1:100 
Alexa Fluor 488  
goat anti mouse IgG 1:800 
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2.2.2.5 Histological analysis  
For histological analysis of mouse and human tissues, specimens were either directly 
embedded in Tissue-Tek® or fixed for 12h in Roti®-Histofix 4% (Roth, Karlsruhe, Germany) at 
4°C and embedded in paraffin. Paraffin sections (7µm) of mouse skin from different parts of 
the body (head, back, belly, tail) were stained with H&E (Thermo Fischer Scientific, 
Schwerte, Germany). To analyze collagen organization and distribution Sirius Red staining 
(Junqueira et al., 1979) was used.  
Haematoxylin and eosin staining (H&E-staining): 
Deparaffinized skin sections (chapter 2.2.2.3) were first stained with hematoxylin for 3 to 
5min and rinsed with lukewarm tap water. Slides were shortly (2sec) destained by dipping in 
acid alcohol (1% HCl in 70% EtOH) and stained with Eosin for 5-8sec.  
Sirius Red staining: 
After deparaffinizing (chapter 2.2.2.3), sections were stained for 5min with Weigert’s iron 
haematoxylin (Waldeck GmbH, Münster, Germany) followed by several rinsing steps in 
lukewarm tap water. After destaining cell cytoplasm in 1% HCl (in 96% EtOH), rinsed 
sections were incubated in 0.5% Sirius Red in watery picrin acid for 1h at RT and rinsed 
twice with 0.5% acetic acid. 
All rinsed sections were dehydrated using ascending alcohol series, mounted with GLCTM 
Mounting Medium (Sakura, Zoeterwoude, Netherlands) and covered with a cover slip. 
2.2.2.6 Processing of basement membrane proteins by ADAM-9 
Enzymatic assay with BM proteins were performed using 0.5µg of recombinant human 
recombinant ADAM-9 and 0.5µg of proteins in a total volume of 20µl substrate buffer over 
night. The following human proteins were used: recombinant fibronectin, collagen IV and 
laminin 511, or purified laminin 332. 
For the enzymatic processing of recombinant human laminin β3-chain, 1µg of the 
recombinant human laminin β3-chain (N-terminal fragment; amino acids 4-575; kindly 
provided by Prof. M. Koch) and 1µg of human recombinant ADAM-9 were used. Protein 
preparations without recombinant ADAM-9 or with ADAM-9 and 10mM EDTA used as 
inhibitor of enzyme activity, were used as controls. Processing was carried out over night at 
37°C and proteins were subsequently separated on 1mm NuPAGE® 4-12% Bis-Tris-Gels 
(Invitrogen, Karlsruhe, Germany) under reducing conditions. Protein bands were visualized 
by silver staining using the SilverQuestTMSilver staining kit (Invitrogen, Karlsruhe, Germany) 
according to the manufactures instructions or by immunoblotting (chapter 2.2.2.2).  
For peptide mass fingerprinting, protein bands were cut out from the silver stained gel and 
processed by LC-MS/MS (liquid-chromatographie mass-spectroscopy/mass-spectroscopy) 
after pre-digestion with trypsin. The obtained fragment spectra were used for protein 
identification using Mascot searches in fragmentation libraries. The LC-MS/MS sequencing 
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including trypsin pre-digestion and protein identification was performed in the Central 
Bioanalytic Core of the Center for Molecular Medicine Cologne.     
2.2.2.7 Cytokine antibody array 
Cytokine antibody array was performed using serum from animals (see 2.2.4.3).  Raybio® 
Mouse Cytokine Antibody Array-3 (HölzelDiagnostika, Cologne, Germany) was used 
according to the manufacturer’s manual. Briefly, membranes were blocked for 30min at RT 
with blocking buffer, then incubated overnight at 4°C with 500µl blocking buffer containing 
60µl of serum pooled from three animals (20µl from each animal). After five washes, the 
membranes were incubated with biotin-conjugated anti-cytokine antibodies diluted 1:200 with 
blocking buffer overnight at 4°C. Bound antibodies were detected with HRP-conjugated 
streptavidin secondary antibodies and proteins visualized by chemiluminescence detection 
system. Specific signals were quantified using the ImageJ program. The blank was 
subtracted from all values, which were normalized to the internal positive control and 
expressed as relative expression of genetically modified versus control animals. Only 
proteins, which were more than 2-fold regulated, were considered.  
 
2.2.3 Analysis of nucleic acids 
2.2.3.1 RNA isolation 
Total RNA was isolated from subconfluent cells. After one wash in PBS, cells were directly 
lysed into RNAzol (WAK Chemie, Steinbach, Germany) for 5min at RT and collected by 
scraping. For isolation of RNA from blood, 125µl blood was taken from heart puncture and 
mixed with 875µl RNAzol. DNA was sheared by 20 passages through a 27G needle, RNA 
extracted using ⅕ volume of chloroform and precipitated by adding 1 volume of isopropanol 
for 30min on dry ice. After centrifugation for 15min at 1500g, RNA pellet was washed using 
75% EtOH, air dried for 10min and resuspended in DEPC-treated H2O. Integrity of RNA was 
analyzed by electrophoresis on a 1% agarose-TBE gel and concentration determined by 
measuring the optical density at 260nm (OD260 x 40µg/ml RNA).  
2.2.3.2 Reverse transcription and polymerase chain reaction (RT-PCR) 
1 µg of total RNA protected by adding RNase Inhibitors (20U/µl) was reverse transcribed into 
cDNA by using Oligo d(T)16 primers (50µM), MuLV reverse transcriptase (50U/µl) and 10µM 
of dNTPs. Reverse transcription was performed using the following conditions: 21°C 10min; 
42°C 20min; 99°C 5min. 
After reverse transcription, PCR fragments were generated from cDNA using 
REDtaqTMReadyMixTM PCR Reaction Mix (Sigma Aldrich, München, Germany) and 10µM of 
each forward and reverse specific primers whose sequences are shown in Table 8. PCR 
amplification was performed with initial denaturation step at 94°C for 5min, followed by cycles 
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of 1min at 94°C, 1min at annealing temperature, 1min elongation at 72°C. The cycle number 
used was within the linear amplification range. To detect transcripts of Pmel17/gp100 used 
as markers for melanoma cells (Kobayashi et al., 1994; Singh et al., 2008) a nested PCR 
was used. The cDNA was first amplified using external Pmel17 primers and the fragment 
reamplified using nested primers and 2µl of the first PCR reaction (Tsukamoto et al., 2000). 
Figure 6 shows a schematic overview about the performance of the nested PCR. Size of 




Table 8: Information about primers used in RT-PCR reactions. 





 ADAM-9 CCTCGGGGACCCTTCGTGT 52 30 424 ATCCCATAACTCGCATTCTCTAAA 
 ADAM-10 ACACCAGCGTGCCAAAAGAG 58 30 440 CCTCTACACCAGTCATCTGG 
 ADAM-12 TGCAGGCAGAGGCTTCTGAGG 58 30 514 GTTTGGCTTTGGAGGAAGCACAG 
 ADAM-15 GGCTGGCAGTGTCGTCCTACCA 65 30 421 GTGCACCCAGCTGCAGTTCAGC 
 ADAM-17 TTTCAAGGTCGTGGTGGTGG 52 30 451 TTCCCCTCTGCCCATGTATC 
 ADAM-19 GAACATCCGGATTGCTCTCG 52 30 456 TGGGTCATGCCAAAGTTGTG 
ADAM-21 CCCTCCCAGCATTTCACTTC 57 30 299 
AAGCCCCCAAAACAAGCAC 
Aquaporin-3 GAAAGTTCCAGGAGGGTGTGTAT 52 30 334 CGGATCCCTAAGACTGTAAC 
IL-1α 
CCAAGATGAAGACCAACCAG 54 33 261 TGAGATTTTTAGAGTAACAGG 
MMP-2 AAGATTCCAGAGAGTGGCTC 58 35 470 TGCACTGTCAGTGACTTCA 
MMP-9 CAGGCTCCGGTGGACGATGCC 60 30 243 GCCCTCAGAGAATCGCCAGTA 
MMP-13 CTGGCTGCCTTCCTCTTCTT 58 35 608 ATGTCAGCAATGCCATCGTG 
MMP-14 ATGTTCGAAGGAAGCGCTAC 55 35 948 TCCAGAAGAGAGCAGCATCA 
S26 CCGTGCCTCCAAGATGACAA 52 30 375 AGAACTCAGCTCCTTACA 
       
Figure 6: Schematic over-
view about the nested PCR. !
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ADAM-9 TTGCCTCTCTGCGACTAAG 48 40 130 GTAAGAGATCTGCTGTGAACTG 
β1 integrin GCAGAGCATAAAGAATGTGT 60 30 335 CAAGGCAAGGCCAATAAGAA 
β3 integrin TTACCCCGTGGACATCTACTA 50 30 456 AGTCTTCCATCCAGGGCAATA 
ICAM-1 GTGTCTCCTTCTTTGACACT 48 30 237 ATGACATGCTTGAGCCAGG 
Pmel17 
(external) 
CGGATGGTCAGGTTATCTGG 58 30 334 ATGGTGAAGGTTGAACTGGC 
Pmel17 
(nested) 
ACAGCCAGTGTATCCACAGG 58 30 202 ACTTCCATTGTGTGTGTGCC 
S26 AATGTGCAGCCCATTCGATG 56 30 324 CTTCCGTCCTTACAAAACGG 
VCAM GAGAACCCAGATAGACAGCC 50 30 238 CAAACACTTGAGCGTGACC 
VE-cadherin ACGGACAAGATCAGCTCCTC 57 30 200 TCTCTTCATCGATGTGCATT 
 
2.2.3.3 Quantitative real-time PCR 
For quantitative real-time PCR analysis 1µg of RNA was reverse transcribed according to the 
protocol described in chapter 2.2.3.2. Each PCR reaction was carried out in triplicate in a 
total volume of 20µl, containing 10µl of Power SYBR®Green PCR Master Mix (Applied 
Biosciences, Foster City, CA, USA), 0.2 µl of each, 10µM forward and reverse primers, 8.6µl 
water and 1µl cDNA. Forward and reverse primer sequences, annealing temperature, cycle 
number and product size for every primer pair used, are summarized in Table 9. The thermal 
cycling conditions were set to 95°C for 2min, followed by 40 cycles of amplification at 95°C 
for 10sec and 60°C for 2min for each cycle. The specificity of the PCR products was 
confirmed by melting curve analysis.  
The relative expression levels were determined by normalizing to the house keeping gene to 
S26 signals used as control and calculating the expression by the comparative ΔΔCt method.  
 
Table 9: Information about primers used in real-time PCR reactions. 
Human gene  Primer sequences 5´-3´ Annealing temperature [°C] 
Cylce 
number 
Product   
size [bp] 
ADAM-9 CCTCGGGGACCCTTCGTGT 60 40 424 ATCCCATAACTCGCATTCTCTAAA 
S26 CCGTGCCTCCAAGATGACAA 60 40 375 AGAACTCAGCTCCTTACA 
       
Mouse gene  Primer sequences 5´-3´ Annealing temperature [°C] 
Cylce 
number 
Product   
size [bp] 
ADAM-9 TGACCATCCCAACGTACAGA 60 40 131 TTCCAAAACTGGCATTCTCC 
S26 GTGCCATCCATAGCAAGGTT 60 40 105 GTGGAGGTCGAGGTGCAG 
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2.2.3.4 Analysis of genomic DNA 
Approximately 0.5cm of the tail of three week old mice were cut and incubated in 750µl tail 
lysis buffer supplemented with 50U/ml proteinase K (Fermentas, St. Leon-Rot, Germany) 
over night under shaking conditions (~80g) at 55°C. The next day 250µl of 6M NaCl were 
added and the solution was mixed at 100g for additional 5min at 55°C. Subsequently the 
solution was centrifuged for 10min at 1500g at RT. The supernatant was mixed with 1 
volume of isopropanol to precipitate genomic DNA and centrifuged for 10min at 1500g at RT. 
The DNA pellet was washed with 70% EtOH, air dried and suspended in H2O by incubation 
at 50°C for 1h. The genomic DNA was stored at 4°C until genotyping. 
PCR fragments were generated from genomic DNA using REDtaqTMReadyMixTM PCR 
Reaction Mix (Sigma Aldrich, München, Germany) and 10µM of each forward and reverse 
specific primers. Forward and reverse primer sequences, annealing temperature, cycle 
number and product sizes for every primer pair used, are summarized in Table 10. PCR 
amplification for ADAM-9 was initiated by incubation at 94°C for 5min and followed by cycles 
of amplification of 1min at 94°C, 45sec at annealing temperature, 1min at 72°C. For CDK4 
PCR amplification was initiated by incubation at 94°C for 5min and followed by cycles of 
30sec at 94°C, 40sec at annealing temperature, 1min at 72°C. Size of PCR products was 
analyzed on agarose gels in TBE.  
 
Table 10: Primers and amplification products for genotyping PCR  
Mouse 









54 30 121 wt 1000 ko CGTTCATAGTTCTCAGAAG 
CDK4 ACTGTGTGATCCTCTTTGTG 54 40 640 wt 740 mut ATCCATCAGCCTGAGAAG 
2.2.4 In vivo experiments 
 
2.2.4.1 Animal housing 
All animals were kept in the animal facility of the Institute of Pathology or Pharmacology of 
the University of Cologne, in cages covered with air filters under specific pathogen-free 
conditions with 12h light-dark cycle and free access to water and food. All animal 
experiments were performed in compliance with the German Law for Welfare of Laboratory 
Animals and approved by the Regierungspräsidium Köln, Germany. Reference for official 
approval: 50.203.2-K 37a, 20/05 and 87-51.04.2010 A356. 
 
2.2.4.2 Generation of Adam-9-/-//Hgf/Cdk4R24C/R24C animals 
Hgf/Cdk4R24C/R24C C57/Bl6 mice (Tormo, et al., 2006) were crossbred with Adam-9-/- 
Sv129/Bl6 mice (Weskamp et al., 2002). A summary of the crossbreading scheme for the 
generation of the animals is depicted in Table 11.  
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Table 11: Overview about the generation of Adam-9+/+//Hgf/Cdk4R24C/R24C and Adam-9-/-




used for following generation female male 
 
Adam-9-/- Hgf/Cdk4R24C/R24C ♀  Adam-9 
+/-//Cdk4R24C/wt 
♂ Adam-9 +/-//Hgf/Cdk4R24C/wt 
F1  Adam-9 +/-//Cdk4R24C/wt Adam-9 +/-//Hgf/Cdk4R24C/wt 
♀  Adam-9 -/-//Cdk4R24C/wt                 
♀  Adam-9 +/-//Cdk4R24C/R24C 
♂ Adam-9 -/-//Hgf/Cdk4R24C/wt 
♂ Adam-9 +/-//Hgf/Cdk4R24C/R24C 
F2 
 Adam-9 +/-//Cdk4R24C/R24C 
or                                                 
Adam-9 -/-//Cdk4R24C/wt 
 Adam-9 +/-//Hgf/Cdk4R24C/R24C 
or                                                
Adam-9 -/-//Hgf/Cdk4R24C/wt 
♀  Adam-9 -/-//Cdk4R24C/R24C                  
♀  Adam-9 +/+//Cdk4R24C/R24C 
♂ Adam-9 -/-//Hgf/Cdk4R24C/R24C                 
♂ Adam-9 +/+//Hgf/Cdk4R24C/R24C 
F3 
 Adam-9 -/-//Cdk4R24C/R24C                          
and                                                 
Adam-9 +/+//Cdk4R24C/R24C 
 Adam-9 -/-//Hgf/Cdk4R24C/R24C                            
and                                             
Adam-9 +/+//Hgf/Cdk4R24C/R24C 
♀ Adam-9 -/-//Cdk4R24C/R24C                  
♀  Adam-9 +/+//Cdk4R24C/R24C 
♂ Adam-9 -/-//Hgf/Cdk4R24C/R24C                 
♂ Adam-9 +/+//Hgf/Cdk4R24C/R24C 
 
Briefly, male Hgf/Cdk4R24C/R24C mice, which were heterozygous for Hgf were paired with 
Adam-9-/- female mice. The offspring was composed of approximately one-third Adam-9+/-
//Hgf/Cdk4R24C/wt animals. Animals, which were positive for Hgf, could be phenotypically 
distinguished from their Hgf negative littermates, because overexpression of Hgf leads to a 
dark skin phenotype, which was most prominent at the ears and the bottom side of the paws. 
Heterozygous Adam-9+/-//Hgf/Cdk4R24C/wt male mice were paired with Adam-9+/-/Cdk4R24C/wt 
female mice. Pairing of heterozygous male Adam-9+/-//Hgf/Cdk4R24C/wt directly with female 
Adam-9+/-//Hgf/Cdk4R24C/wt mice was not possible as female mice carrying the Hgf transgene 
are not fertile, due to presently unknown reasons. The animals used for the experiments 
were obtained from the F3 progeny and were Adam-9-/-//Hgf/Cdk4R24C/R24C mice and Adam-
9+/+//Hgf/Cdk4R24C/R24C littermates. In all following chapters the Adam-9+/+//Hgf/Cdk4R24C/R24C 
mice will be termed control and the Adam-9-/-//Hgf/Cdk4R24C/R24C mice Adam-9mutated/ko. 
2.2.4.3 Induction and analysis of melanoma formation 
At postnatal day three the back of male and female Adam-9mutated/ko and littermate control 
animals was painted with 40µg DMBA (Sigma Aldrich, München, Germany) dissolved in a 
final volume of 10µl acetone (16nmol/µl). The number of developing tumors was carefully 
recorded on a weekly basis from week four after DMBA treatment onwards. When the 
animals were killed the volume (mm³) of all developed tumors was calculated after 
measurement of the tumor size in three bisecting diameters using a digital caliper. 
Additionally tumor growth was recorded by digital photography. Most of the animals were 
killed when largest tumors exceeded a size of at least 200 mm³ at ~week 13 after DMBA 
treatment. Occasionally animals were also killed at earlier time points due to signs of illness. 
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Animals were killed by CO2 inhalation and lung, liver, spleen, kidneys, heart, brain and the 
intestinal tract were carefully inspected for macroscopically visible metastases. The number 
of black nodules on the organ surface was counted as indicator of metastatic spread of the 
primary cutaneous tumors. To determine the metastatic spread to the lymph nodes, the size 
(mm³) of axillary and groin lymph nodes was determined by measurement of lymph node 
size in three bisecting diameters. The largest tumors were excised with the surrounding 
stroma and all tissues were either processed for paraffin embedding or directly embedded in 
Tissue-Tek® (chapter 2.2.2.5). 
At the time when the animals were killed, also blood was collected for further analysis. To 
obtain serum, 400-700µl blood were taken by heart puncture using a 2ml syringe and a 22G 
needle. The blood was allowed to clot for ~2h on ice and the serum was separated from the 
cellular components by centrifugation at 4°C for 30min at 110g. The cleared serum was 
stored at -20°C until using for further analysis. For isolation of RNA from the blood see 
chapter 2.2.3.1. 
2.2.4.4 Tail vein injection of B16-F1 melanoma cells 
For tail vein injection of B16-F1 cells (chapter 2.2.1.5) six to ten weeks old female and male 
Adam-9+/+ Sv129/Bl6 mice were used. To dilate and better visualize the blood vessels, the 
tail of the mice was illuminated using a heat lamp for 1min. Afterwards the mice were 
transferred to a holding device and 100,000 B16-F1 cells in a final volume of 100µl PBS 
were injected into the tail vein. The animals were sacrificed three weeks after injection and 
the inner organs including lung, liver, kidney, heart, stomach, intestine, spleen, lymph nodes 
and brain were carefully prepared and inspected for visible metastases. The number of black 
nodules on the organ surface was counted as indicator of metastasis. Additionally formed 
metastases were recorded by digital photography.  
2.2.5 Statistical analysis 
Statistically significant differences were calculated employing the Graph Pad Prism 4.03 
software using two-tailed unpaired or paired Student´s t-test, depending if independent or 












3.1 Analysis of ADAM expression in melanoma cells 
3.1.1 ADAM expression in human melanoma cells lines 
Expression of several ADAM proteases was shown in melanoma. ADAM-9 expression was 
detected in both, tumor cells and peritumoral stromal cells (Zigrino et al., 2005) whereas 
others, e.g. ADAM-15, were primarily detected in melanoma cells of primary tumors  
(Ungerer et al., 2010). To analyze which other known ADAMs are expressed by melanoma 
cells, RT-PCR analysis for ADAM-9, -10, -15 and -17 was performed on RNA isolated from 
cell monolayers of cell lines with various invasive capacities. The melanoma cell lines 
investigated were characterized as: low invasive cell lines: Skmel23, Skmel28, WM164/4, 
IF6; high invasive cell lines: BLM, MeWo, VMM5; and WM75/6 cells whose invasive capacity 
is not known. This analysis revealed transcript expression of ADAM-9, -10, -15 and 17 in all 
assayed cell lines. The expression level of ADAM-10, -15 and 17 varied between the cell 
lines, the expression of ADAM-9 was comparable.  No correlation of the expression level and 
the invasive capacity was found for any of the analyzed ADAM (Figure 7).  
 
Figure 7: RT-PCR analysis of the expression of ADAMs in human melanoma cell lines. The 
expression of several ADAMs was analyzed in RNA isolated from human melanoma cell lines after 
growing to subconfluency in tissue culture plates. The invasive capacities of the used melanoma cell 
lines are indicated apart from the WM75/6 (*), which has not been tested. Amplification of S26 
transcripts was used as loading control. The figure shows a representative of two independent 
experiments.  
 
3.1.2 ADAM-9 transcript and protein expression 
The most ubiquitous expression detected was for ADAM-9 and -15, with a stronger intensity 
for ADAM-9. However, in vitro no correlation between ADAM-9 expression and invasive 
capacity of the cells was observed. 
To further investigate the ADAM-9 expression in melanoma cells, the transcript analysis was 
extended to three additional cell lines, A375 known to be high invasive (Kozlowski et al., 
1984) and the two cell lines Ma-Mel-119 and Ma-Mel-85, which were isolated from a 
melanoma metastasis, but have not been tested again for invasive potential. 
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However also for these lines, quite comparable levels of ADAM-9 transcripts were detected. 
As ADAM-9 is a proteolytic enzyme, protein synthesis was analyzed in an attempt to 
correlate the presence of the active form of ADAM-9 with cell invasiveness. Immunoblot 
analysis revealed the presence of the pro- and active form of ADAM-9 in all analyzed cell 
lines, except from the cell line Ma-Mel-119, which showed no detectable ADAM-9 protein. 
The low invasive cells lines Skmel23 and Skmel28 and the high invasive lines VMM5 and 
A375 displayed generally lower protein expression as compared to all other cells. Despite the 
differences in pro-form detection, e.g. higher in Ma-Mel-86a and WM 75/6, all cells exhibited 
active ADAM-9 on the cell surface (Figure 8). Thus in steady-state conditions of human 
melanoma cells, ADAM-9 potein amounts were variable, although expression was 
comparable on transcript level. However, both analyses failed to indicate any correlation with 
the invasive capacity of the cells.  
 
Figure 8: ADAM-9 expression in different melanoma cell lines.  
ADAM-9 transcript and protein expression was analyzed in melanoma cell lines of different invasive 
capacities (chapter 2.2.1.1) by RT-PCR and immunoblot. ADAM-9 expression was variable in all cell 
lines on mRNA as well as on protein level (pro- and active form). No correlation with the invasive 
behaviour was observed. S26 or β -actin were used as loading control. The figure shows a 
representative of two independent experiments.  
 
3.2 In vitro analysis of ADAM-9 function in melanoma cells 
 
3.2.1 Stable down-regulation of ADAM-9  
The results obtained so far showed that despite the fact that no correlation of ADAM-9 with 
the invasive characteristics of human melanoma cell lines exits, the active form of ADAM-9 is 
expressed in the majority of all analyzed melanoma cell lines. To explore the importance of 
ADAM-9 for tumor growth and invasion, ADAM-9 was stably down-regulated in BLM 
melanoma cells using shRNA. As control, cells were transfected with shRNA carrying a 
scrambled sequence not matching with any known sequence. The BLM cells were chosen, 
because these cells exhibited the highest active ADAM-9 expression among the analyzed 
cell lines and are characterized by their high invasive and metastatic phenotype. After 
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transfection, stable cell clones were isolated after selection pressure was applied (chapter 
2.2.1.5). ADAM-9 expression in two selected control and ADAM-9 down-regulated clones 
was determined on transcriptional and protein level. A significant down-regulation of 
transcripts of about 90% was observed after quantitative real-time PCR analysis using S26 
as internal control (shAdam-9 clone 1: 91% inhibition, p = 0.002; shAdam-9 clone 2: 88% 
inhibition, p = 0.008). The control clones were set as 100%. A similar result was also visible 
by RT-PCR analysis of ADAM-9 transcripts in those cells (Figure 9 A). Immunoblot analysis 
of cell lysates detected a reduction of ADAM-9 pro- and active form in both shADAM-9 
clones, 1 and 2 (Figure 9 B). Densitometric analysis of ADAM-9 protein in shADAM-9 clones 
as compared to control cells, which were set as 100%, revealed a  ~90% inhibition of ADAM-
9 synthesis after normalization to actin, used as loading control (Figure 9 B). These results 
indicate that silencing of ADAM-9 in melanoma cells by shRNA resulted in an efficient protein 
down-regulation. Thus, stable cell clones of BLM melanoma cells with silencing of ADAM-9 
have been generated, which can be used in further experiments. 
 
 
Figure 9: Stable down-regulation of ADAM-9 in high invasive BLM melanoma cells. High invasive 
BLM melanoma cells were stably transfected with shRNA targeted to ADAM-9. ADAM-9 transcript (A) 
and pro- and active protein (B) levels from two separately isolated clones for control and ADAM-9 
down-regulated cells were determined. ADAM-9 expression levels were determined by quantitative 
real-time PCR and densitometric analysis of western blot signals normalized to respective loading 
control. Bars represent the average ± SD of at least three independent experiments. Control cells 
were transfected with a scrambled shRNA sequence and considered to show 100% expression. The 
bars for the control cells represent the average of both control clones.  **: p<0.01; ***: p<0.001.  
 
To analyze whether depletion of ADAM-9 in BLM cells results in compensation by other 
ADAM proteases known to exert a similar function, expression of ADAM-10, -12, -15, -17, -
19 and -21 was investigated by RT-PCR. Specific signals for indicated ADAMs were 
quantified by desitometry, normalized to S26 signals and expressed as percentage of the 
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control cells set as 100% expression. No significant change in the expression of other 
ADAMs was observed (Figure 10 A). Additional proteolytic enzymes, which are important in 
the context of melanoma and are implicated in the efficient processing of the ADAM-9 
substrates gelatin, collagen and fibronectin (Schwettmann et al., 2001), are the 
collagenolysins, MMP-13 and -14 and the gelatinases, MMP-2 and -9 (Hofmann et al., 2005). 
Transcriptional analysis of MMP-2, -9, -13 and -14 did not reveal any significant altered 
expression profile upon ADAM-9 down-regulation (Figure 10 B). 
 
Figure 10: ADAM and MMP transcript expression in ADAM-9 down-regulated cells (shAdam-9). (A) 
ADAM-9 down-regulation did not alter expression of other ADAM as well as (B) MMP enzymes as 
determined by RT-PCR. Specific signals were measured and normalized to S26 control. Average 
expression ± SD of two different control or ADAM-9 down-regulated clones of three independent 
experiments are shown. ***: p<0.001.  
 
3.2.1.1 Regulation of cell size by ADAM-9 
Upon culture on plastic surfaces, the ADAM-9 down-regulated BLM cells appeared smaller in 
size than control clones (Figure 11 A). To quantify cell size, the cells were grown for 24h on 
plastic surface and cell area of 50 single grown cells for each clone was measured using the 
ImageJ program. This analysis revealed that ADAM-9 down-regulated cells showed a 2-fold 
smaller cell area in comparison to control cells (Control 1: 1531 ± 697 µm²; Control 2: 1553 ± 
472µm²; shAdam-9 clone: 841 ± 303µm²; shAdam-9 clone 2: 798 ± 405µm²; p < 0.0001) 
(Figure 11 B). Reduced cell area may result either from reduced ability of the cells to spread 
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or from reduced cellular volume. To address if cell volume was altered upon ADAM-9 
silencing, the volume of suspended cells was estimated in an automated system, which is 
able to determine contemporarily the cell number as well as the cellular volume (CASY® 
device model TT). In these experiments ADAM-9 down-regulated cells exhibited a significant 
decrease (p = 0.034) of about a 2-fold in cell volume (mean of control 1 and 2: 4336 ± 828fl; 
mean of shAdam-9 clone 1 and 2: 3193 ± 474fl)  (Figure 11 C). 
 
Figure 11: Analysis of cell area and volume in control and ADAM-9 down-regulated cells. 
(A) Representative phase contrast pictures of ADAM-9 down-regulated (shAdam-9) and control cells 
grown on plastic surface. ADAM-9 down-regulated cells appeared smaller than the control cells.  
(B) Cell area of single cells was measured in 50 different control and Adam-9 down-regulated cells by 
image analysis. The graphic shows a representative of two independent experiments. (C) Cell volume 
of suspended cells was determined in an automated cell counter revealing a significant decrease in 
cellular volume after ADAM-9 down-regulation. Bars represent the average ± SD of two control or 
ADAM-9 down-regulated clones from four independent experiments. *: p<0.05;***: p<0.001. !
To investigate whether an altered cellular spreading, which is accompanied with cytoskeleton 
rearrangements, could also contribute to the reduced cell area, actin filaments were stained 
using phalloidin (Wulf et al., 1979) and tubulin by immunocytochemistry. For these 
experiments the cells were grown for 24h on plastic surfaces in the presence of serum prior 
to the staining procedure. As observed in Figure 12 no obvious alterations in the organization 
of the actin filaments were visible in shAdam-9 down-regulated clones as compared to 
control cells, even though a more intense phalloidin signal was detected in the control. The 
tubulin cytoskeleton remained unaltered upon ADAM-9 down-regulation.  




Figure 12: Cytoskeletal arrangement in control and ADAM-9 down-regulated cells. 
ADAM-9 down-regulated (shAdam-9) and control cells were plated on cover slips and grown for 24h. 
After fixing, actin was detected using fluorescently labelled phalloidin (red) and tubulin by 
immuncytochemistry using a specific antibody. Cell nuclei were visualized with the fluorescent dye 
DAPI. 
 
Thus differences in cell size upon ADAM-9 down-regulation are most likely the result of 
altered cell volume, but not of altered cell spreading. The regulation of cell volume may occur 
through the expression and activity of aquaporin water channels, which transport fluids over 
the cell membrane (Verkman, 2005). In atopic eczema, cell shrinkage and water loss was 
shown as result of up-regulation of water channels such as aquaporin-3 (Hara-Chikuma and 
Verkman, 2008; Verkman, 2005). Alteration in this channel may also account for the altered 
cell volume upon ADAM-9 depletion. To find out whether melanoma cells express aquaporin-
3 and if alterations in the expression of this molecule occur in ADAM-9 silenced BLM cells, 
aquaporin-3 expression was analyzed in control and ADAM-9 down-regulated clones. 
Aquaporin-3 transcripts were not altered upon ADAM-9 down-regulation, however by 
immunolocalization in cells, the protein expression levels seemed increased in the ADAM-9 
silenced compared to the control cells (Figure 13 A). To investigate whether increased 
expression of aquaporin-3 also leads to altered channel function and thereby altered cell size 
in ADAM-9 down-regulated cells, channel activity was inhibited by mercuric chloride (HgCl2), 
which is a general aquaporin inhibitor (Ismail et al., 2009). For this experiment, control and 
ADAM-9 silenced cells, were suspended, treated with 0.15mM HgCl2 for 1h and cell volume 
was determined subsequently. As already shown in Figure 11 C cell volume of ADAM-9 
down-regulated cells was decreased, when no inhibitor was applied (p < 0.0001). After 
application of the inhibitor the volume of the ADAM-9 down-regulated cells (3842 ± 924 fl) 
was comparable to that of the untreated control cells (3898 ± 70 fl). However, upon treatment 
also the volume of the control cells increased (1,4-fold). Thus upon treatment of both, the 
control and the ADAM-9 silenced cells, the ADAM-9 down-regulated cells still exhibited a 
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decreased cell volume (p = 0.0001), indicating that differential activity of water channels is 
not the reason for decreased cell volume (Figure 13 B).  
Taken together these data indicate that silencing of ADAM-9 in melanoma cells results in 
altered cell volume, which is not resulting from functional water channel alterations. 
 
 
Figure 13: Expression of aquaporin-3 in control and ADAM-9 down cells. 
(A) Expression of aquaporin-3 mRNA was determined by RT-PCR. Immuncytochemistry on PFA-fixed 
cells revealed stronger staining for aquaporin-3 in ADAM-9 down-regulated BLM cells (shAdam-9) 
compared to control cells. Cell nuclei were visualized with the fluorescent dye DAPI. (B) For inhibition 
of aquaporin activity, cells were treated with the general aquaporin inhibitor HgCl2. Control and ADAM-
9 down-regulated cells were grown for 24h and afterwards treated in suspension with 0.15mM HgCl2 
for 1h. Bars represent the mean ± SD of two independent experiments performed in triplicate.              
***: p<0.001.  
 
3.2.1.2 Analysis of proliferation  
A remarkably altered cytoskeleton arrangement as well as changed aquaporin-3 activity 
turned out not to be the reason for the altered cell size upon ADAM-9 down-regulation. 
Another possible explanation for the altered cell size might be an increased proliferation rate 
of the ADAM-9 down-regulated cells, because if the cells divide faster compared to the 
control cells, the time to spread and regulate cell volume to the same extent as in the control 
cells, is reduced. It was shown that stimulation of B16 melanoma cells with TPA, which 
induces ADAM-9 mediated ectodomain shedding, decreased proliferation resulting in an 
increased cell size (Izumi et al., 1998; La Porta et al., 1998). To analyze if silencing of 
ADAM-9 effects cellular proliferation, the proliferative potential was determined by BrdU 
incorporation of cells grown in monolayer culture. After BrdU labelling the proliferation of 
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ADAM-9 down-regulated cells was increased (shAdam-9 clone 1: p = 0.04, shAdam-9 clone 
2: p = 0.17) after 48 hours, but not after 24h (Figure 14). However the difference was only 
significant for clone 1.  
 
 
As melanoma cells do also have the capability to grow in suspension, which would not be 
detected by the BrdU incorporation assay, cell proliferation was tested in a soft agar colony 
formation assay over a period of 21 days. This analysis revealed that ADAM-9 silenced cells 
formed significantly (control: 37 ± 16; shAdam-9 clone 1: 60 ± 20, p = 0.012; shAdam-9 clone 
2: 63 ± 20, p = 0.012) more colonies as compared to control cells (Figure 15). 
 
Figure 15:  Analysis of anchorage independent proliferation upon ADAM-9 down-regulation.  
ADAM-9 down-regulated (shAdam-9) and control cells were grown for three weeks in 0.2% soft agar 
and the number of formed colonies was counted. For every clone the experiment was performed in 
triplicate and for each culture dish the number of formed colonies was counted in 8 randomly chosen 
microscopic fields (100 x magnification). Bars represent the average ± SD of counted colonies of three 
independent experiments (control: average of the two control clones). *: p<0.05.  
 
3.2.1.3 In vitro cell invasion  
ADAM-9 exhibits proteolytic as well as adhesive functions (Peduto, 2009), indicating that 
ADAM-9 may participates in cell invasion. The previous experiments also detected its ability 
to modulate melanoma cell proliferation. To analyze how down-regulation of ADAM-9 and 
thereby reduced proliferation and cellular volume influences the invasive capacity of BLM 
cells, these cells were seeded on dermal equivalents (dead de-epidemized skin) and their 
!Figure 14:  Analysis of anchorage 
dependent proliferation upon ADAM-9 
down-regulation (shAdam-9).  
Proliferation was analyzed by BrdU 
incorporation after 24 and 48h. The 
graph shows percent proliferation and 
the mean of triplicate measurements of 
four independent experiments. The 
values for the control cells were set to 
100% and the bars represent the 
average ± SD of the two different control 
clones. *: p<0.05. !
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capacity to penetrate the tissue was measured over time. The de-epidermized, devitalized 
dermal equivalent was choosen as invasion assay as it represents closely the in vivo 
situation (Dennhöfer et al., 2003). In this assay cells are tested for both, their ability to invade 
the dermal compartment or to penetrate the BM before invasion of the dermis. The migrated 
distance within the tissue is then a direct measure of their invasive capacity.  
 
 
Figure 16: Invasion in DDS upon ADAM-9 down-regulation.  
BLM cells were seeded either on top of the basement membrane (BM) (A) or directly on the dermal 
side (B) of skin composits (chapter 2.2.1.9) and cultured for three weeks at the air-liquid interface.  
(A) Representative H&E stained sections of cultures using ADAM-9 down regulated (shAdam-9) and 
control cells seeded on the BM side. The presence of the BM was confirmed by staining for laminin 
α3-chain and collagen IV, in green. Cell nuclei were stained in blue with DAPI. (B) H&E stained 
sections of cultures using control and shAdam-9 cells grown on the dermal connective tissue side. 
Graphs in (A) and (B) show the quantification of the invasion depth through the BM and the dermal 
connective tissue. The bars represent the mean ± SD of three independent experiments performed in 
triplicate. Control cells, two different clones, are here averaged. *: p<0.05; **: p<0.01.  
 
When cells were seeded on the BM side, control cells penetrated into the dermal connective 
tissue. In contrast down-regulation of ADAM-9 clearly resulted in reduced invasion as seen in 
H&E stained tissue sections. The presence of the BM in cultures was tested by detection of 
the BM proteins collagen IV and laminin α3-chain. Quantification of the invasion depth 
  Results 
47 
 
revealed a significantly reduced invasion through the BM from shAdam-9 clones as 
compared to controls (control: 316µm ± 22µm; shAdam-9 clone 1: 55µm ± 26µm; p = 0.011; 
shAdam-9 clone 2: 84µm ± 27µm; p = 0.006) (Figure 16 A). Quantification of the distance 
migrated within the dermal compartment by either ADAM-9 down-regulated or control cells, 
when seeded on the dermal side showed a similar invasion depth in both (control: 636µm ± 
264µm; shAdam-9 clone 1: 597µm ± 205µm; shAdam-9 clone 2: 659µm ± 213µm) (Figure 16 
B). Thus, whereas ADAM-9 depletion in melanoma cells does not affect their migratory ability 
through the dermal compartment, it interestingly impairs penetration of the basement 
membrane and thereby invasion. 
 
3.2.1.4 Adhesion to basement membrane proteins  
Invasion through the BM follows a step-wise process, which involves firstly substrate 
recognition followed by adhesion and degradation thus allowing cell penetration (Haass et 
al., 2005; Bacac and Stamenkovic, 2008).  
 
Figure 17: Adhesion of ADAM-9 silenced (shAdam-9) and control cells to BM components. Tissue 
culture plates were coated over night with matrigel, collagen IV (10µg/ml), laminin 332 (5µg/ml), 
collagen I (10µg/ml). Cells were allowed to adhere for 1h, stained with crystal violet and the extent of 
adhesion measured at 595nm. The bars represent the mean ± SD of quadruplicate measurements 
and it is representative of four independent experiments shown. *: p<0.05; **: p<0.01.  
The photographs below show pictures of crystal violet stained cells, adhering to the different 
substrates. Col IV: collagen IV; Lam 332: laminin 332; Col I; collagen I. 
 
To test whether altered recognition and adhesion to BM components occurs when ADAM-9 
is down-regulated, adhesion of ADAM-9 silenced and control cells to matrigel, which is a 
protein mixture resembling a complex extracellular environment containing BM proteins 
extracted from EHS tumors (Benton et al., 2010; Hughes et al., 2010), collagen IV (10µg/ml) 
and laminin 332 (5µg/ml), was tested. Additionally adhesion to collagen I (10µg/ml) was 
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tested, as this is the main component of the dermal connective tissue. Analyzing adhesion 
towards BSA (1%) serverd as a control. The melanoma cells were allowed to adhere for 1h 
at 37°C to the respective substrates. Significantly decreased adhesion of ADAM-9 silenced 
compared to control cells to matrigel  (p = 0.043) and collagen IV (p = 0.007) was observed. 
In contrast adhesion to laminin 332 and to collagen I was not affected. However the 
adherence of the cells to collagen I in general was low. No adhesion to BSA was observed 
(Figure 17). 
 
3.2.1.5 Analysis of integrin expression  
Integrins are molecules mediating adhesion of cells towards extracellular matrix proteins 
(Hynes, 2002). In the adhesion assays the ADAM-9 down-regulated cells exhibited a 
significantly reduced adhesion towards collagen IV, which is the main component of the BM 
(Kalluri, 2003). Cellular receptors for collagen type IV belong to the integrin family and 
among those are the integrins α1β1, α2β1 and α3β1 (Khoshnoodi et al., 2008). To test 
whether altered adhesion of shAdam-9 clones derives from disturbed receptor expression, 
cells were either plated on plastic (steady-state expression level) or on collagen type IV 
coated dishes (induced receptor expression) and integrin expression was assayed by FACS 
analysis using antibodies directed against the extracellular domain of the integrins. This 
analysis revealed an unchanged expression of α1, α3 and antibodies directed against the 
extracellular domain of the integα2 integrin was significantly increased upon ADAM-9 down-
regulation, when cells were grown on plastic (p = 0.036). When cultured on top of collagen IV 
expression of α1 integrin was significantly lower in the ADAM-9 down-regulated cells 
compared to the control cells (p = 0.009). In parallel the α2 integrin chain was up-regulated in 
the ADAM-9 down-regulated cells upon culture on collagen IV (p = 0.017).  Compared to the 
steady-state conditions on plastic the induction of the α2 integrin was higher on collagen IV. 
The expression of α3 integrin was also induced upon culture on collagen IV compared to 
culture upon plastic, but the induction was comparable in the ADAM-9 down-regulated and 
control cells. The β1 integrin chain was slightly lower expressed in the ADAM-9 down-
regulated cells on collagen IV, resulting from a lower induction of the protein compared to the 
control cells. However this difference was not significant. Unspecific IgG antibodies, which 
were used as isotpype control, showed no staining (Figure 18).  




Figure 18: FACS analysis of integrin expression.  
(A) ADAM-9 down-regulated (shAdam-9) and control cells were plated for 2h on plastic or collagen IV 
(10µg/ml) coated culture dishes. After trypsinization the expression profile of α1, α2, α3 and β1 
integrins was analyzed by FACS. (B) The graph shows the average expression ± SD of triplicate 
stainings. Unspecific IgG were used as negative control. *: p<0.05; **: p<0.01.  
 
At points of contacts between cells and the substrate integrins form culsters, which facilitate 
intracellular signalling and adhesion. To analyze if ADAM-9 down-regulation not only leads to 
an altered integrin expression level on the cell surface, but also to an altered integrin 
clustering, the cells were plated for 2h on collagen IV (10µg/ml) and immunohistochemically 
stained using antibodies directed against α1, α2, α3 and β1 integrin. These experiments 
showed that the integrins α1, α2 and α3 were arranged in clusters and located at the cell 
membrane, in cellular protrusions, which contact the substrate (indicated by the arrows in 
Figure 19). A difference in the clustering of those integrins could not be observed. The β1 
integrin was also present in clusters on the cell surface in the control as well as in the ADAM-
9 down-regulated cells, but a lower expression of this integrin chain together with reduced 
number of clusters was observed in the ADAM-9 down-regulated cells (Figure 19). The data 
from the FACS analysis together with the immnuohistochemical stainings indicate that upon 
ADAM-9 silencing the α1 integrin chain is significantly lower expressed, while the α2 integrin 
is up-regulated on the cell surface upon culture of the cells on collagen IV. The β1 integrin 
chain is also tendentially lower expressed upon ADAM-9 down-regulation. Integrin clustering 
was not altered in both control and ADAM-9 silenced cells. In summary the adhesion 
experiments and the integrin analyses showed that reduced adhesion upon ADAM-9 down-
regualtion is reflected by an altered integrin expression pattern. 




Figure 19: Immunohistochemical analysis of integrin expression of ADAM-9 down-regulated 
(shAdam-9) and control cells on collagen type IV. shAdam-9 and control cells were plated for 2h on 
collagen IV coated dishes, fixed and immunohistochemically stained using antibodies against the 
cytoplasmic domain of α1, α2, α3 and extracellular domain of β1 integrins. Cell nuclei, in blue, were 
stained with DAPI. White arrowheads indicate clustered integrins at cell protrusions contacting the 
substrate.  
 
3.2.1.6 Analysis of cell migration 
Upon ADAM-9 down-regulation the adhesion of BLM melanoma cells towards collagen IV 
and matrigel was reduced, however not completely abolished, indicating that some cells are 
still able to adhere to the BM. Moreover in the DDS assay a clearly impaired invasion through 
the BM was observed. Since proteolytic activity of ADAM-9 can modulate cell migration (Fry 
et al., 2010; Mauch et al., 2010), which is a critical process for invasion through the 
extracelluar matrix, it was next assayed if ADAM-9 down-regulation affects migration of these 
cells over BM components. For these experiments tissue culture plates were coated with 
matrigel, collagen IV (10µg/ml) or laminin 332 (5µg/ml). Fibronectin (10µg/ml) was also 
included in this analysis, because ADAM-9 can degrade fibronectin (Schwettmann et al., 
2001). On these matrices ADAM-9 down-regulated and control cells were seeded in cloning 
rings and their migration over the matrix was followed over a period of 24h. For all used 
substrates no significant difference in migration between control and ADAM-9 down-
regulated cells was observed at any analyzed time point. However a tendency towards 
higher migration of the ADAM-9 down-regulated cells was detected at 18 and 24h of 
migration over collagen IV, fibronectin and laminin 332 (Figure 20). Taken together the 
migration experiments demonstrated that migration of BLM melanoma cells over BM 
components is not significantly altered upon down-regulation of ADAM-9. 




Figure 20: Migration of ADAM-9 down-regulated (shAdam-9) cells over BM components. shADAM-9 
and control cells were seeded on culture plates coated with matrigel (A), 10µg/ml collagen IV (B), 
10µg/ml fibronectin (C) or 5µg/ml laminin 332 (D). Cells were allowed to attach for 1h before starting to 
record cell migration over a period of 24h. The migrated area was measured at the indicated time 
points. Every line represents the average ± SD of the two control or ADAM-9 down-regulated clones of 
three independent experiments performed in triplicates.  
 
3.2.2 Processing of basement membrane proteins by ADAM-9 
The DDS assay revelaed a significantly reduced invasion of the ADAM-9 down-regulated 
BLM cells through the BM. Migration of melanoma cells through the BM involves enzymatic 
cleavage of the BM components to allow cells to invade the underlying dermis (Bacac and 
Stamenkovic, 2008). To investigate whether ADAM-9 contributes to BM breakdown, various 
human BM proteins (collagen IV, laminin 332, laminin 511; each 0.5µg) were incubated in 
the presence of proteolytically active human recombinant ADAM-9 (0.5µg). Fibronectin, 
which is a known substrate of ADAM-9 (Schwettmann et al., 2001), was used as control for 
ADAM-9 activity. The 210kDa fibronectin protein was cleaved by active ADAM-9 (~55kDa), 
releasing two fragments of ~170kDa and ~40kDa (Figure 21 A). These bands were not 
visible in the presence of EDTA, which inhibits ADAM-9 metalloprotease activity by chelating 
Zn2+ ions required for enzyme activity. This indicates that these fragments resulted from 
enzymatic processing of fibronectin by ADAM-9. In contrast recombinant collagen IV was not 
cleaved by ADAM-9. SDS-PAGE under reducing conditions resulted in several bands 
ranging from ~100-400kDa. This protein laddering of collagen IV may be due to the fact that 
it is composed of three different α-chains, which are processed by many co- and 
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posttranslational modifications, thus appearing in several molecular weight forms 
(Khoshnoodi et al., 2008). No difference in the band pattern was observed after incubation 
with ADAM-9, indicating that collagen type IV is not a substrate of ADAM-9.  
Laminins are composed of three chains, namely the α-, β-, and γ-chain (Tzu and 
Marinkovich, 2008). The α-, β- and γ-chain of laminin 511 were observed at ~404, ~196 and 
~177kDa. Some additional bands were also visible, but no differences were detected after 
incubation with ADAM-9 (Figure 15 A). Strikingly, laminin 332 was cleaved by ADAM-9 
releasing a ~80kDa fragment. For laminin 332 the α-, β- and γ-chains of the protein were 
visible at ~160, ~140, and ~105kDa under reducing conditions. After incubation of human 
laminin 332 together with ADAM-9 an additional band appeared at ~80kDa. This fragment 
was not detected after addition of EDTA and identified laminin 332 as so far not described 




To confirm that the obtained fragment is indeed a product of laminin 332 digestion, the 
fragment underwent peptide mass fingerprinting. This analysis revealed that the fragment 
originates from the laminin β3-chain. Matching sequences were located in the C-terminal 
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region of the β3-chain from amino acid 680 to 1153 (Figure 22, position 1). The molecular 
weight of the proteolytically released fragment was ~80kDa as observed by the silver stain. 
Thus it is expected that one fragment is generated and spans from about amino acid 420 to 
1170 with the cleavage site expected to be located in the EGF-like domain III or IV of the 
laminin β3-chain (Figure 22, position 2). 
 
Figure 22: Identification of Laminin 332 proteolytically released fragment by peptide mass 
fingerprinting. Human laminin 332 (Lam 332; 0.5µg) was incubated with 0.5µg human recombinant 
ADAM-9 and processed proteins resolved under reducing conditions on 4-12% SDS gels followed by 
silver staining. The originated ~80kDa fragment was identified by peptide mass fingerprinting. The 
matching peptides covered the amino acid sequence from 1153 up to 680 in the coil-coiled region of 
the β3-chain of laminin 332 (position 1). The fragment of ~80kDa which was visible on gel was 
predicted to cover this molecule up to amino acid 420 in the EGF-like domain III or IV (position 2). FG; 
proteolytic fragment. 
 
To further confirm that the laminin β3-chain is a substrate for ADAM-9 and to localize the 
cutting site of ADAM-9 in the laminin β3-chain, the enzymatic assay was conducted using a 
recombinant protein corresponding to amino acids 4-575 of the human laminin β3-chain, 
indicated by the black line in Figure 23 A. Proteins were separated by gel electrophoresis, 
immunoblotted and the membrane was incubated with a polyclonal antibody raised against 
the human laminin β3-chain. 




The recombinant laminin β3-chain was detected as a band of ~65 kDa (Figure 23 B). After 
incubation with active ADAM-9, an additional band of ~58kDa was observed. Incubation in 
the presence of EDTA completely blocked the processing and this band was no longer 
visible by immunoblotting (Figure 23 B). As the released fragment has now a reduction of 
~13kDa, corresponding to ~120 amino acids, it is possible that, as expected, the cleavage 
site would be located around amino acid 420.  
This result confirmed the previous finding that human laminin β3-chain is cleaved by ADAM-9 
in the N-terminal region.  
 
3.3 Regulation of ADAM-9 expression  
 
3.3.1 Analysis of ADAM-9 regulation by IL-1α  
  
3.3.1.1 Regulation of ADAM-9 by exogenous IL-1α   
The tumor microenvironment is enriched by cytokines including IL-1α produced at high levels 
by tumor cells, activated fibroblasts and inflammatory cells generating a highly pro-
inflammatory peritumoral environment (Apte et al., 2006). In vitro it was demonstrated that 
one function of IL-1α is to down-regulate ADAM-9 transcripts in melanoma cells (Zigrino et 
al., 2005). However, in vivo, expression of ADAM-9 is detected in tumor cells of primary 
melanoma, but not of metastases (Zigrino et al., 2005). Thus it is possible that there is a 
concentration-dependent effect of IL-1α on the regulation of ADAM-9 in vivo. To analyze if 
IL-1α expression correlates with the expression of ADAM-9 in high invasive melanoma cells, 
four human melanoma cell lines grown as monolayer cultures were studied for mRNA 
expression of these molecules. This analysis showed transcript expression of IL-1α in all 
high invasive melanoma cell lines, with the highest expression in BLM cells. No correlation 
between the expression of IL-1α and that of ADAM-9 could be detected (Figure 24).  
Figure 23: Digestion of recom-
binant laminin β3-chain.   
(A) Recombinant laminin (Lam) β3-
chain (N-terminal fragment; amino 
acid 4-575; 1µg) was incubated 
with 1µg human recombinant 
ADAM-9 with or w/o 10mM EDTA. 
(B) Proteins were separated under 
reducing conditions and visualized 
by immunoblotting using an anti-
body to the human laminin β3-
chain. FG: proteolytic fragment. 
The drawing was adapted from 
Marinkovich, Nat. Rev. Cancer, 
2007. 
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To mimic the in vivo situation, where increased extracellular IL-1α is available within the 
microenvironment, and to analyze how this effects the expression and activation of ADAM-9 
in invasive BLM melanoma cells, these cells were grown as monolayers and stimulated with 
10U/ml recombinant human IL-1α for 24h. In agreement with previous data (Zigrino et al., 
2005), this stimulation resulted in a significant (p = 0.012) down-regulation of ADAM-9 
transcript level to 56 ± 17% as compared to unstimulated control cells (Figure 25 A). In 
parallel, immunoblotting analysis of ADAM-9 in crude membrane fractions from IL-1α 
stimulated cells showed a significant (p = 0.046) reduction of 50 ± 19% in the synthesis of 
ADAM-9, as detected after densitometry and normalization to proteins stained with 
Coomassie blue, used as control (Figure 25 B).  
 
Figure 25: Stimulation of high invasive BLM melanoma cells with IL-1α.  
BLM melanoma cells grown as monolayer were stimulated with 10U/ml human recombinant IL-1α for 
24h. ADAM-9 transcripts (A) and protein levels, in crude membrane fractions (B) were quantified by 
densitometry and normalized to S26 or Coomassie as loading control from at least three independent 
experiments. The graphs on the right side show the mean ± SD of these quantifications. The values of 
unstimulated cells were set as 100%. *: p<0.05.  
Figure 24: Expression of ADAM-
9 and IL-1α in high invasive 
melanoma cell lines. Four cell 
lines with high invasive capacity 
were analyzed by RT-PCR, 
using primers for IL-1α and 
ADAM-9. S26 was used loading 
control. The figure shows a 
representative experiment out of 
two independent experiments.!




The molecular mechanisms leading to ADAM-9 down-regulation by IL-1α are undiscovered. 
It is known that the IL-1 receptor signals through the NFκB pathway, but can also activate 
MAP kinases like p38 and JNK (O´Neill et al., 1998). Therefore a pharmacological approach 
was used blocking either nuclear translocation of activated NFkB using the inhibitor SN50 
(18µM) or phosphorylation of c-Jun by the inhibitor SP600125 (10µM). BLM melanoma cells 
were incubated for 24h with 10U/ml IL-1α alone or in combination with one of the inhibitors, 
or with 0.0002% DMSO the solvent for SP600125, used as control. ADAM-9 expression was 
down-regulated in BLM cells when IL-1α was applied alone, together with DMSO or in 
combination with the NFkB inhibitor SN50. However, when IL-1α was applied together with 
the JNK inhibitor SP600125, IL-1α-induced ADAM-9 down-regulation was abolished (Figure 
26). These results indicate that exogenously supplied IL-1α regulates expression of ADAM-9 
in BLM melanoma cells through the JNK pathway. 
 
 
3.3.1.2 Analysis of melanoma cell derived IL-1α  on ADAM-9 expression in high    
  invasive melanoma cells 
 
IL-1α is very little secreted and the majority of this cytokine is stored intracellularly. However, 
also intracellular IL-1α appears to be functionally active (Apte et al., 2006). To investigate 
whether alterations in intracellular retained IL-1α may impact ADAM-9 expression in 
melanoma cells, IL-1α endogenous expression was stably down-regulated in BLM 
melanoma cells. These cells showed highest IL-1α transcript expression among all the 
analyzed high invasive melanoma cell lines (see 3.3.1.1). Clones with stable IL-1α down-
regulation, were generated within the diploma work of Birgit Seyfarth and were used for 
further experiments. These cells showed IL-1α down-regulation of  ~85% on mRNA and 
~47% on protein level, as observed by RT-PCR and immunoblot analysis of cellular lysates 
(Figure 27). Secreted IL-1α was reduced by ~29% in cellular supernatants of IL-1α silenced 
compared to scrambled transfected control cells, as assessed by ELISA measurements 
(Diploma thesis Birgit Seyfarth).  
Figure 26: Pharmacological inhibition of signall-
ing pathways upon IL-1α stimulation. 
BLM melanoma cells were stimulated for 24h 
with 10U/ml IL-1α in presence of the inhibitors of 
NFκB SN50 (10µM) or JNK SP600125 (18µM). 
DMSO (0.0002%), the solvent for the inhibitors, 
was used as control. ADAM-9 expression was 
determined by RT-PCR. S26 was used as 
loading control. The figure shows a represent-
tative of two independent experiments. !




Expression of ADAM-9 was determined at transcript and protein level in BLM shIL-1α and 
control cells after growing for 24h in monolayer culture. Analysis of ADAM-9 expression 
showed that upon stable silencing of IL-1α, increased expression of ADAM-9 transcripts was 
detected. After desitometric analysis of ADAM-9 signals and their normalization to S26, the 
ADAM-9 expression for the two analyzed clones was increased to 154% as compared to 
controls cells set as 100%. The increased expression of ADAM-9 was significant in clone 2 
(p=0.011). Analysis of ADAM-9 protein content in crude membrane preparations revealed an 
up-regulation, with a detected maximal 2-fold in clone 1, of both, the pro- and active protein 
forms (Clone 1: 214 ± 76%; Clone 2: 147 ± 86%), as observed after desitometric 
quantification of the ADAM-9 signals and normalization to Coomassie  (Figure 28).   
 
Figure 28: Analysis of ADAM-9 in IL-1α down-regulated BLM cells. 
BLM shIL-1α and control cells were grown for 24h as monolayers and RNA or proteins were extracted. 
ADAM-9 transcript (A) and protein (B) levels in IL-1α down-regulated and control cells were analyzed 
by RT-PCR and immunoblot analysis using crude membrane fractions. The graphs on the right side 
show the densitometric quantification of ADAM-9 mRNA and protein levels after normalization to S26 
or Coomassie as loading controls of three independent experiments. Bars represent the average ± 
SD. The control represents the average of two control clones set as 100%.  *: p<0.05.  
 
Figure 27: Stable down-regulation of IL-1α in 
BLM melanoma cells.  
Two clones, either transfected with a scrambled 
control shRNA sequence (Control 1 and 2) or 
sequences targeted to IL-1α (shIL-1α) were 
assayed for IL-1α expression on mRNA and 
protein level. S26 or β-actin, respectively, served 
as loading control (adopted from the Diploma 
thesis of Birgit Seyfarth). !
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To investigate whether stable silencing of IL-1α activates JNK or ERK mediated intracellular 
signalling pathways regulating ADAM-9 expression levels in cell steady-state conditions, the 
phosphorylated forms of these mediators were measured by immunoblot analysis. The 
signals for phosphorylated ERK and JNK were quantified by densitometry and normalized to 
the expression of total unphosphorylated ERK or JNK, respectively. This analysis revealed a 
significantly reduced phosphorylation of ERK upon IL-1α down-regulation compared to 
control cells (Clone 1: 46 ± 21%, p = 0.048; Clone 2: 36 ± 23%, p = 0.039), whereas 
phosphorylation levels of JNK were not remarkably altered (Clone 1: 66 ± 32%; Clone 2: 77 ± 
55%) (Figure 29). Thus, endogenous IL-1α controls constitutive expression of ADAM-9 
through the activity of ERK.   
  
 
3.3.1.3 Invasion through the basement membrane upon IL-1α  down-regulation 
In order to determine the functional relevance of IL-1α down-regulation, leading to increased 
ADAM-9 synthesis, for invasion of melanoma cells, both, IL-1α down-regulated and control 
cells, were analyzed in DDS invasion assay (described in chapter 3.2.1.3). When cells were 
sedded on the BM side the IL-1α down-regulated cells invaded slightly more the underlying 
tissue as compared to control cells (Figure 30 A). Presence of the BM was confirmed by 
staining for laminin α3-chain (Figure 30 A). Quantification of the invasion depth of the cells 
into the dermal compartment revealed that at least for clone 1, this increased invasiveness of 
BLM cells is significantly higher than for control clones (invaded depth of control cells: 106µm 
± 37µm; shIL-1α clone 1: 192µm ± 76µm; p = 0.009). The other IL-1α down-regulated clone 
(number 2) showed only a tendency to higher invasion, but due to the higher variability 
detected, no significant difference could be measured (shIL-1α clone 2: 133µm ± 93µm; p = 
0.399). 
 
Figure 29: ERK and JNK phosphory-
lation upon IL-1α down-regulation. 
Immunoblot analysis of phosphorylated 
ERK and JNK levels was performed on 
lysates from control and IL-1α silenced 
cells. The graphs show the densi-
tometric quantification of pERK or 
pJNK protein levels after normalization 
to ERK 1/2 or JNK 1/2/3 as loading 
control of three independent experi-
ments. Bars represent the average ± 
SD. The control represents the aver-
age of two control clones set as 100%.  
*: p<0.05. !





Figure 30: Invasion of DDS composites by IL-1α down-regulated BLM cells.  
Invasion of DDS composits by shIL-1α and control cells was tested either through the BM (basement 
membrane) or the dermal connective tissue. (A) Representative sections of H&E stained cultures with 
control or shIL-1α cells seeded on the BM side. The presence of a BM was visualized by staining for 
laminin α3-chain (green). Cell nuclei were stained in blue by DAPI. (B) Representative sections of 
H&E stained cultures of cells on the dermal side. Graphs in (A) and (B) show the quantification of the 
migrated distance in the tissues depth. Shown is the mean ± SD of three independent experiments 
performed in triplicate. The average of two different control clones is shown. **: p<0.01.  
 
When the cells were seeded on the dermal side, IL-1α down-regulated as well as control 
cells invaded into the tissue and no difference in the invasion depth was measured (control: 
641µm ± 146µm; shIL-1α clone 1: 654µm ± 150µm; shIL-1α clone 2: 692µm ± 232µm) 
(Figure 30 B).   
These results indicate that endogenous IL-1α regulates ADAM-9 steady-state levels of 
expression in BLM melanoma cells. Furthermore, up-regulation of ADAM-9 leads to 
increased invasion through the BM, which further confirms a direct role for ADAM-9 in 
mediating BM penetration as seen in 3.2.1.3 together with the data shown in 3.2.2.  
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3.3.2 Modulation of ADAM-9 expression by indirubins 
Indirubins were initially characterized as the active ingredient of a traditional Chinese 
medicine preparation, consisting of eleven herbal components (Eisenbrand et al., 2004). 
These molocules have already been used for anticancer treatment and they were shown to 
reduce cancer cell proliferation by inhibiting cyclin dependent kinase activity (Eisenbrand et 
al., 2004). By a cooperative project within the Melanoma Research Network we had access 
to indirubin derivates (chapter 2.2.1), which have been generated to specifically interfere with 
pathways activated in melanoma cells. In order to find potential inhibitors of tumor cell 
invasion, the effect of indirubins on ADAM-9 synthesis was analyzed. To test indirubin 
activity, the low invasive melanoma cell line Skmel28, the high invasive cell lines BLM and 
A375 and primary human dermal fibroblast monolayers were treated for 24h with 10µM of 
either an “ineffective” indirubin (SL-22), an indirubin causing a slight antiproliferative effect 
(SL-85) or a highly effective indirubin (KD-65). The efficacy of the indirubines to affect 
melanoma cell proliferation was tested in the lab of Prof. M. Kunz (University of Rostock). 
The solvent 0.001% DMSO served as control. Intensity of ADAM-9 transcript fragments 
amplified by RT-PCR was quantified by desitometry, normalized to S26 signals and 




Whereas the application of SL-22 and SL-85 did not alter ADAM-9 transcript levels in any of 
the analyzed cells, application of the effective indirubin KD-65 led to significantly decreased 
Figure 31: Stimulation of melanoma cells and fibroblasts with 
indirubins. 
The high (BLM, A375) and low (Skmel28) invasive cell lines  
and human dermal primary fibroblasts were treated for 24h 
with an ineffective (SL-22), slightly (SL-85) and a highly 
effective indirubin (KD-65). ADAM-9 expression level was 
measured by RT-PCR, the specific signals quantified by 
densitometry and normalized to the S26 control. Incubation 
with KD-65 decreased ADAM-9 expression in BLM and A375 
cells, but not in Skmel28 cells and human dermal fibroblasts. 
The bars represent the mean ± SD of five (BLM), four (human 
dermal fibroblasts) and two (A375, Skmel28) independent 
experiments. *: p<0.05.  !
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ADAM-9 transcript expression in the high invasive line BLM (p = 0.02) as compared to 
DMSO treatment control (Figure 31). The decrease of ADAM-9 transcripts caused by KD-65 
was lower in A375 cells, and no effect was detected in the low invasive Skmel28 cells and in 
fibroblasts (Figure 31). 
This data showed that the efficient indirubin, KD-65, can selectively reduce ADAM-9 
expression in the high invasive melanoma cells, but does not alter ADAM-9 expression in 
Skmel28 cells and fibroblasts.  
To test if indirubins also influence ADAM-9 protein synthesis, BLM melanoma cells, which 
showed the highest response to KD-65 and primary human dermal fibroblasts were treated 
with indirubins for 24h followed by crude membrane preparation. Immunoblot analysis of 
ADAM-9 on SDS-PAGE resolved lysates from treated cells, showed that the highly effective 
indirubin KD-65 decreased ADAM-9 production by melanoma cells, but not by fibroblasts 
(Figure 32).  
Taken together indirubins are molecules controlling ADAM-9 expression, specifically in high 





3.4 In vivo analysis of ADAM-9 function in a mouse model for spontaneous      
      melanoma development 
The so far obtained in vitro data have shown that ADAM-9, produced by melanoma cells, is 
important for tumor cell invasion through the BM. Thus one can hypothesize that ADAM-9 
also in the in vivo situation is involved in melanoma invasion and metastases formation, as 
BM penetration is one key event in those processes. In order to investigate the contribution 
of melanoma-derived ADAM-9 for tumor development, growth and metastatses formation in 
vivo, Adam-9-/- animals (Weskamp et al., 2002) were crossed with Hgf/Cdk4R24C/R24C animals 
(Tormo et al., 2006), which develop tumors spontaneously. DMBA treatment in perinatal 
stages has been also shown to accelerate tumor formation in these animals (Tormo, et al., 
2006). 
Figure 32: Stimulation of melanoma 
cells and fibroblasts with indirubins. 
The indirubins SL-22, SL-85 and KD-
65 were applied for 24h to cells prior to 
analyze ADAM-9 protein content in 
crude membrane preparations.  
The effective indirubin KD-65 decrea-
sed ADAM-9 production in BLM cells, 
but not in fibroblasts.  !
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3.4.1 Generation of Adam-9-/-//Hgf/Cdk4R24C/R24C animals 
After four generations of crossing, Adam-9+/+//Hgf/Cdk4R24C/R24C (control) and Adam-9-/-
//Hgf/Cdk4R24C/R24C animals named Adam-9mutated/ko in the following chapters were obtained. 
The crossing schema is shown in 2.2.4.2. The deletion of the Adam-9 gene was confirmed 
by PCR on genomic DNA isolated from tails of three-week old animals. This analysis 
revealed a 121bp fragment in the control animals corresponding to amplification of the wild-
type gene and a 1000bp fragment in the Adam-9mutated/ko animals, which contains the 
neomycin cassette inserted within the gene leading to an interruption of the ADAM-9 
sequence. Loss of Adam-9 gene transcription was further confirmed by RT-PCR on cDNA 
from RNA isolated from tails of three weeks old animals (Figure 33 A). The fragment 
containing the mutation of the Cdk4 gene was amplified by PCR on genomic DNA and 
revealed for all animals a 740bp fragment, resembling the mutated Cdk4 gene. The not 
mutated gene should create a fragment of 640bp, which was not detected (Figure 33 A). 
Animals, which were positive for the Hgf transgene could be phenotypically distinguished 
from their Hgf-negative littermates, because of their black skin phenotype. This was most 
obvious on the bottom side of the paws (Figure 33 B). All animals were viable after birth and 
developed normally. They had no obvious, macroscopically visible, phenotype. In Figure 33 
B representative photos of three weeks old control and Adam-9mutated/ko mice are shown.  
 
Figure 33: Generation of control and Adam-9mutated/ko animals.  
To generate animals, which spontaneously develop tumors in the absence of ADAM-9 expression, 
Adam-9-/- animals were crossed with Hgf/Cdk4R24C/R24C animals. (A) PCR amplification of the wild type 
or mutated Adam-9 allele on genomic DNA detects ablation of the Adam-9 (1000bp fragment) or the 
presence the Adam-9 wildtype gene (121bp fragment). The homozygous insertion of the mutated 
Cdk4 gene (Cdk4R24C/R24C) was proven by PCR on genomic DNA generating a fragment of 740bp in all 
animals. RT-PCR using cDNA from RNA of tails of control and Adam-9mutated/ko animals further 
confirmed Adam-9 transcript deletion. (B) Representative photographs of three weeks old control and 
Adam-9mutated/ko animals. The transgenic overexpression of Hgf (Hgf pos.) could be phenotypically 
observed by the black skin phenotype most prominent at the bottom side of the paws. 
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3.4.1.1 Analysis of skin architecture and differentiation  
To test if ablation of ADAM-9 in addition to transgene expression of Hgf/Cdk4R24C/R24C 
influenced skin homeostasis, skin samples from different parts of the body (head, back, belly, 
tail) were collected from control and Adam-9mutated/ko animals at postnatal day 1 (P1; new born 
skin) and postnatal day 21 (P21; adult skin). Skin histology in these animals was analyzed by 
common established histological staining procedures, such as H&E and Sirius red staining, 
this last allowing visualization of fibrillar collagens by polarized light. At P1 (Figure 34) as well 
as at P21 (Figure 35) no differences in skin histology between control and Adam-9mutated/ko 
were detected. In all studied parts of the body, the epidermis and dermis, including hair 
follicles, collagen and fat content was comparable among control and Adam-9mutated/ko mice. 
Visualization of Sirius red stained sections with polarized light also indicated that collagen 
fibril bundles, visible with this light, are comparable in thickness and density in both animal 
genotypes at both analyzed time points (Figures 34 and 35).  
 
Figure 34: Skin histology at postnatal day 1 (P1) in control and Adam-9mutated/ko animals. Skin sections 
obtained from head, back, belly and tail of one day old mice were stained with H&E and Sirius red. 
The Sirius Red stained sections were visualized with polarized light. No differences between control 
and Adam-9mutated/ko animals were observed in any staining or body region. The dotted line indicates 
the epidermal-dermal border. 
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In H&E stained tissue sections of P21 animals of both genotypes many heavily pigmented 
cells, which most likely represent melanocytes, could be found in the dermis and particularly 
at the epidermal-dermal junction (Figure 35). In tail sections these cells were additionally 
found accumulated around the hair follicles and in the dermis between the hair follicles, 
whereas in head and back skin these cells were more evenly distributed. The belly turned out 
to be the only region with less pigmented cells than the other analyzed body parts. Some 
pigmented cells were also found in the epidermis in all inspected body regions (Figure 35).  
 
 
Figure 35: Skin histology at postnatal day 21 (P21) in control and Adam-9mutated/ko animals. Skin 
sections from head, back, belly and tail of 21 days old mice were stained with H&E and Sirius red 
(visualized by polarized light). No alterations were detected in any staining or body region in both 
animal genotypes. In H&E stained sections of the head, back and tail many pigmented cells could be 
found in the dermis particularly located at the epidermal-dermal junction and in the tail also around the 
hair follicles (HF). The dotted line indicates the epidermal-dermal border. 
 
To investigate whether these heavily pigmented cells do actually represent melanocytes, skin 
sections obtained from back and tail at P1 and P21 were immunohistochemically stained 
against the melanocyte specific antigen tyrosinase related protein-1 (TRP-1). In back skin 
from P1 animals TRP-1 positive cells were located in the basal layer of the epidermis and in 
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the hair follicles (Figure 36 A, B). Some single positive cells could be found inside the dermis 
(arrowheads Figure 36 A, B). In tail skin from P1 animals TRP-1 positive cells were also 
present in the basal layer of the epidermis as well as in the hair follicles (Figure 36 E, F). 
However staining in the hair follicles in tail skin was not as strong as in the hair follicles in the 
back skin. In the tail some positive cells were also located inside the dermis (arrowheads 
Figure 36 E, F). In back and tail skin from P21 animals a similar staining pattern compared to 
one day old mice could be observed with positive cells in the basal layer of the epidermis and 
the hair follicles (Figure 36 C, D, G, H) and single positive cells inside the dermis 
(arrowheads Figure 36 C, D, G, H). At both analyzed time points and body regions no 
obvious differences in the distribution and number of melanocytes between control and 
Adam-9mutated/ko animals were detectable. 
 
Figure 36: Localization of melanocytes at postnatal day 1 (P1) and 21 (P21) in control and Adam-
9mutated/ko animals. Melanocytes were detected using antibodies for the melanocyte specific protein 
TRP-1 (green). Cell nuclei, in blue, were visualized with DAPI. In skin collected at P1 (A, B, E, F) as 
well as at P21 (C, D, G, H) TRP-1 positive cells were located in the basal layer of the epidermis (e) 
and in the hair follicles (HF). Some positive cells were also detected inside the dermis (arrows). The 
dotted line indicates the epidermal-dermal border. TRP-1: tyrosinase related protein- 1. 
 
Skin differentiation was investigated in Adam-9mutated/ko animals in skin sections from P1 and 
P21 animals using antibodies directed against cytokeratin 14, a marker for undifferentiated 
keratinocytes, and the late differentiation marker loricrin. The studied skin sections were 
taken from back skin and the tail, as the latter one is the only part of the mouse body with a 
multilayered epidermis in adulthood. Neither at P1 nor at P21 any difference in the 
expression of the used differentiation markers was observed (Figure 37). In back and tail skin 
of control and Adam-9mutated/ko animals, cytokeratin 14 positive cells were found in the basal 
layer of the epidermis and the outer layer of the hair follicles at P1 and P21 (Figure 37 left 
panel). In tail skin of one day old mice, some positive cells were also detected in suprabasal 
layers. Positive staining for loricrin was exclusively found at both analyzed time points and 
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body regions in the upper layers of the epidermis, located in the stratum granulosum (g, 
Figure 37 right panel).  
 
 
Figure 37: Skin differentiation at postnatal day 1 (P1) and 21 (P21) in control and Adam-9mutated/ko 
animals. Skin sections of back and tail of one and 21 day old mice were stained for cytokeratin 14 
(red; undifferentiated keratinocytes) and the late differentiation marker loricrin (red). Cell nuclei were 
visualized in blue by DAPI. Cytokeratin 14 positive staining was localized in the basal layer of the 
epidermis (epi) and in hair follicles (HF) at both time points in back and tail skin (left). Loricin was 
detected in the stratum granulosum (g) at both time points and both analyzed body regions (right). No 
difference in the expression of both markers was detected in both animal genotypes. The dotted line 
marks the epidermal-dermal border. der: dermis. 
 
3.4.2 ADAM-9 expression in melanomas developed in control mice  
It was shown that the Hgf/Cdk4R24C/R24C animals develop spontaneous melanomas and that 
treatment with DMBA or UV light induces these tumors also at earlier time points (Tormo et 
al., 2006; Landsberg et al., 2010; Gaffal et al., 2011).  
A first investigation was aimed to determine whether also in the mice used here expression 
of ADAM-9 is induced and localized at the tumor-stroma border in stromal cells as well as in 
the tumor cells as our group has shown before in human specimens and in melanomas 
developed in C57/Bl6 mice upon dermal injection of murine B16-F1 cells (Zigrino et al., 2005; 
Abety et al., 2012). Analysis of ADAM-9 transcript expression was performed by RT-PCR 
using RNA isolated from DMBA induced tumors (n=4) 13 weeks after DMBA treatment and 
from normal skin from 13 weeks old untreated animals (n=3). This analysis showed that 
ADAM-9 transcripts are induced in the tumors (Figure 38 A).  




Figure 38: Expression and localization of ADAM-9 in DMBA induced tumors in                                 
control animals. (A) ADAM-9 transcript expression was measured in normal skin from 13 week old 
untreated animals (n=3) and DMBA induced tumors (n=4) harvested 13 weeks after DMBA treatment. 
The graph shows the average ± SD of signal intensities after normalization to S26, used as control.       
*: p<0.05. (B) ADAM-9 immunodetection in tumors shows the protein localized at the tumor-stroma-
border (a), marked by the dashed line, in the stroma and in some tumor cells, indicated by the arrow. 
Higher magnification of the tumor mass (b) revealed ADAM-9 positivity in tumor cells (arrows). The 
fluorescent dye DAPI was used to visualize cell nuclei. s: stroma; t: tumor. 
 
To localize ADAM-9 protein in these tumors, sections obtained from control animals were 
immunohistochemically stained with an antibody directed against the ectodomain of ADAM-
9. ADAM-9 staining appeared to be localized at the tumor-stroma border in stromal cells and 
in some tumor cells at the periphery indicated by the arrow (Figure 34 B, a). Inside the tumor 
stained cells were also found at larger magnification (Figure 34 B, b).  
 
3.4.3 Analysis of DMBA-induced tumor growth and development  
Next, we induced tumor growth in control and Adam-9mutated/ko animals. For this back skin of 
mice was painted once with DMBA at day three after birth. The number of developing tumors 
was counted on a weekly basis over time. In both genotypes the first visible tumors were 
observed four weeks after DMBA treatment. The tumors appeared as dots, smaller than 
1mm³, on the back of the animals and tumor number was recorded from week four after 
DMBA treatment until the animals were sacrificed, around week 13. In Figure 39 A, 
representative photographs of the back of control and Adam-9mutated/ko animals at week four 
and 13 after DMBA treatment are shown. The tumors appeared primarily on the back of the 
animals, but occasionally tumors were also observed at the head, paws and the tail in both 
genotypes, likely due to scratching and mutual touching of the animals, which led to 
spreading of the DMBA to other body regions than the back. 





Figure 39: Tumor development in control and Adam-9mutated/ko animals. Tumors were induced by 
treatment of mice back skin with DMBA at postnatal day three. (A) Macroscopic pictures of the back of 
control and Adam-9mutated/ko mice bearing melanomas at week four (arrows indicate the tumors) and 
13 after DMBA application. (B) The number of tumors developed in control or Adam-9mutated/ko mice, 
counted weekly from week four to 13 after DMBA treatment. The graph shows the mean ± SEM.           
*: p<0.05; **:p<0.01; ***:p<0.001.  
 
When the tumor number was counted at week four after DMBA treatment a significantly 
increased tumor number was observed in Adam-9mutated/ko mice compared to the control 
animals (p = 0.0009). Interestingly, from week six onwards the Adam-9mutated/ko mice exhibited 
a reduced number of tumors as compared to control animals. This reduced tumor number in 
the absence of ADAM-9 was observed in all the following analyzed time points and was 
significant from week eight till week 13  (Figure 39 B). 
To find out if ADAM-9 depletion influenced not only the generation, but also the growth of the 
tumors, in one cohort of control (n=10) and Adam-9mutated/ko (n=8) animals, the size of all 
developed tumors was measured after the animals were sacrificed at week 13. The tumors 
were divided into groups according to the tumor size and the proportion of the different tumor 
groups of the total tumor number was calculated in percent (Figure 40). This analysis 
revealed that in the control animals 1,6-fold higher number of tumors of 0-10mm3 volume 
developed compared to the Adam-9mutated/ko mice. However the proportion of tumors with 
larger size was higher in the Adam-9mutated/ko animals (10-50mm3: 1,4-fold; 50-200mm3: 1,7-
fold; >200mm3: 1,9-fold). This indicates that the Adam-9mutated/ko mice developed more tumors 
with a larger size compared to the control animals. 




Figure 40: Tumor growth in control and Adam-9mutated/ko animals. Tumor formation was induced by 
treatment with DMBA on the back skin at postnatal day three. Mice were sacrificed at week 13 and 
the number of developed tumors counted. The volume of each tumor was determined by 
measurement the three tumor diameters using a caliper. The tumors were divided into different groups 
according to their size and expressed as percent of total number. 
  
3.4.3.1 Histology of DMBA-induced tumors 
To analyze the histomorphology of grown tumors, the largest tumors were isolated and 
stained with H&E. In Figure 41 photographs of H&E stained sections from tumors isolated at 
week four and week 13 (control (A, E); Adam-9mutated/ko (B, C, F, G) are shown. The tumors 
consisted of a mixed population of many heavily pigmented, epitheloid shaped cells, 
arranged among lightly pigmented cells, which were all identified as melanocytes by the 
TRP-1 immunostaining (Figure 42 D, H). After analysis of several tumor sections (n=6) no 
obvious difference neither in the density of these differentially pigmented cells nor in the 
structural appearance of the tumors could be detected in Adam-9mutated/ko as compared to 
control mice.  
 
Figure 41: Histomorpholgy of DMBA-induced tumors grown in control and Adam-9mutated/ko animals 
four and 13 weeks after DMBA application. Animals were sacrificed at the indicated time points and 
the largest tumors were fixed, sectioned and stained using H&E. Representative pictures of tumors 
are shown. In C, G higher magnification of the internal parts of tumors at week 13 is shown 
(magnifications of squares in B, F). Immunohistochemical detection of the melanocyte specific protein 
TRP-1 (D, H) in tumor sections. Cell nuclei were visualized with the fluorescent dye DAPI, blue. TRP-
1: tyrosinase related protein- 1. 
 
 
  Results 
70 
 
3.4.3.2 Analysis of vascularization and proliferation of DMBA-induced tumors 
The DMBA treatment experiments revealed an initial increase (week 4) in tumor 
development in the absence of ADAM-9, whereas at later time-points (weeks 6-13) the tumor 
number in the Adam-9mutated/ko animals was decreased compared to the control mice. A 
different vascularization of the tumors might provide, among others, an explanation for the 
difference in the tumor growth between control and Adam-9mutated/ko animals.  
 
Figure 42: Vascularization of tumors grown in control and Adam-9mutated/ko animals. Frozen tumor 
sections were double stained for the blood vessel endothelial cell specific marker CD31 (green) and 
the lymphatic endothelial cell specific marker LYVE-1 (red). Cell nuclei were visualized with the 
fluorescent dye DAPI (blue). Photographs show a representative picture of stained tumors from four 
and 13 weeks after DMBA application. The tumor (t)-stroma (s) border is indicated by the dashed line. 
The graphs in the right panel show quantification of the CD31 staining. Different parts of the tumors 
from the indicated number of animals (n) were analyzed and the average expressed ± SEM.   
 
Indeed, ADAM-9 was previously shown to be expressed by endothelial cells and moreover 
being functionally involved in pathological neovascularization of the retina (Guaiquil et al., 
2009). To determine if ablation of ADAM-9 caused an altered vascularization in the DMBA 
induced tumors, tissue sections, obtained from tumors isolated four and 13 weeks after the 
DMBA application, were double-stained against CD31 (also known as PECAM and 
expressed by vascular endothelial cells) and LYVE-1 (expressed by lymphatic endothelial 
cells). Representative pictures of these stainings are shown in Figure 42. In tumors from 
control and Adam-9mutated/ko animals vessels positive for CD31 are found in the tumor-stroma 
as well as within the tumor mass at week four as well as at week 13, whereas lymphatic 
vessels are preliminary located at the tumor-stroma border. Quantification of the CD31 
staining using the ImageJ program revealed no differences in vascularization. 
Another reason, which may account for the difference in tumor development, might be an 
altered proliferation or apoptosis of the tumor cells. In Figure 43 representative photographs 
of Ki67 (proliferating cells) and cleaved caspase-3 (apoptotic cells) double-stained tumor 
sections from week four and 13 are shown. In all tumors many proliferating cells could be 
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found within the tumor mass, whereas apoptotic cells were only barely detected, indicated by 
the white arrowheads.  
 
Figure 43: Proliferation and apoptosis of tumors grown in control and Adam-9mutated/ko animals. Frozen 
tumor sections were double stained for Ki67 (green) and cleaved caspase-3 (red). Cell nuclei were 
visualized with the fluorescent dye DAPI (blue). The photographs show representative pictures of the 
proliferation and apoptosis in tumors obtained from control (A, C) and Adam-9mutated/ko (B, D) animals 
four and 13 weeks after DMBA application. The white arrowheads point to cleaved casapase-3 
positive cells. The tumor (t)-stroma (s) border is indicated by the dashed line. In the graph, the number 
of Ki67 positive cells were counted in different parts of the tumors and expressed as percent of all 
counted cells. The bars represent the mean of different animals ± SEM. 
 
Apart from some single cells in the basal layer of the epidermis no proliferating cells were 
found in the tumor-stroma at any time-point, whereas inside the tumors many proliferating 
cells were found in control as well as in Adam-9mutated/ko animals at week four and week 13. 
To quantify the amount of proliferating cells in the tumors, the Ki67 positive cells were 
counted in different parts of the tumors and expressed as percent of the total number of 
counted cells. This analysis showed that at week four slightly more proliferating cells where 
found in the tumors of Adam-9mutated/ko animals, whereas at week 13 proliferation was 
reduced in the absence of ADAM-9. 
 
3.4.3.3 Inflammatory infiltration of DMBA-induced tumors 
The tumor microenvironment is enriched by inflammatory cells, which are a critical 
component of tumor progression by influencing proliferation, survival and migration of cancer 
cells (Coussens and Werb, 2002). The expression of ADAM-9 in inflammatory cells was 
shown for peripheral blood monocytes and macrophages, where the protein is involved in the 
formation of multinuclear giant cells (Namba et al., 2001; Mackiewicz et al., 2005; Ma et al., 
2006). To analyze if ADAM-9 depletion altered the inflammatory infiltration of DMBA induced 
tumors, tissue sections from tumors obtained at week 13 were immunohistochemically 
stained with antibodies directed against lymphocytes (CD45), macrophages (CD68) and 
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neutrophils. CD45 positive cells were mainly found in the tumor-stroma (Figure 44 A, B) and 
some cells also infiltrated the tumor tissue (arrowheads Figure 44 C, D). Macrophages were 
also located in the tumor stroma and no CD68 positive cells were detected inside the tumor 
(Figure 44 E-H). Neutrophil infiltration was not detected in the tumors. No obvious difference 
in the recruitment of macrophages or lymphocytes to the tumor of control and Adam-9mutated/ko 
animals was found. 
 
Figure 44: Inflammation of tumors grown in control and Adam-9mutated/ko animals. Frozen tumor 
sections were obtained from animals 13 weeks after DMBA application, fixed in acetone and 
immunohistochemically stained using specific antibodies against CD45 (lymphocytes) and CD68 
(macrophages). The fluorescent dye propidium iodide (PI) was used to visualize the cell nuclei (red). 
The dotted line indicates the border between tumor (t) and stroma (s) tissue. Arrows indicate CD45 
positive cells. CD68 positive cells were found in the peritumoral stroma (E, F), but not inside the tumor 
(G, H).  
  
3.4.4 Metastatic spread in control and Adam-9mutated/ko animals  
Once melanoma has invaded the tissue cells spread through lymphatic and blood vessels to 
distant organs of which, apart from skin, lung, liver, kidneys, heart and brain include the most 
frequently metastasized organs by melanomas (Leiter et al., 2004). To study metastases 
formation to the different organs, lung, liver, kidneys, heart, brain and the intestinal tract of 
control and Adam-9mutated/ko animals were inspected for visible metastases after tumor 
bearing animals were killed. Metastases were found predominantly in the lungs. Only in two 
control animals metastases were also detected in the liver and the kidney. In none of the 
other analyzed organs macroscopically visible metastases were observed. The axillary and 
groin lymph nodes were prepared and size was measured in three bisecting diameters using 
a precision caliper. The mean size of the right and the left lymph node was calculated and 
the average depicted in Figure 45. The average size of the axillary and groin lymph nodes 
measured in DMBA treated control animals (n=28) and in Adam-9mutated/ko animals (n=29) was 
comparable (Figure 45).  




Figure 45: Metastases in lymph nodes of DMBA treated control and Adam-9mutated/ko animals. 13 
weeks post DMBA tumor induction animals were killed. Axillary and groin lymph nodes were prepared 
and their volume was measured. Each dot represents the mean volume of the right and the left lymph 
node of a single animal. The red line indicates the mean value of all animals. No significant difference 
in lymph node volume between control (n=28) and Adam-9mutated/ko (n=29) animals was detected. 
Photographs show representative pictures of the macroscopic appearance of the lymph nodes of both 
genotypes. 
 
Macroscopically all lymph nodes obtained form DMBA-treated animals, from both genotypes, 
were much darker in color compared to lymph nodes from untreated animals indicating 
melanoma cell colonization (Figure 45). Representative photographs of axillary and groin 
lymph nodes of DMBA treated and untreated control and Adam-9mutated/ko animals are shown 
in the lower panel of Figure 45. 
Lymph node morphology was further explored in tissue sections stained by H&E. In sections 
of axillary lymph nodes from control as well as from Adam-9mutated/ko animals infiltrates of dark 
pigmented cells could be detected in the periphery and the inner parts of the lymph nodes 
(Figure 46 A, D). Higher magnifications of areas containing these pigmented cells show a 
mixed population of these cells and the normal lymphatic tissue (Figure 46 B, E). This was 
also visible by staining with TRP-1 and CD45, a lymphocyte specific marker (Figure 46 C, F). 
In lymph nodes form untreated animals no pigmented and TRP-1 positive cells were 
detected (Figure 46 G, H, I). Also when the groin lymph nodes were analyzed the same 
result was obtained. 




Figure 46: Histological appearance of lymph nodes of DMBA treated control and Adam-9mutated/ko 
animals. Sections of axillary nodes stained with H&E. In addition lymph nodes of an untreated animal 
were included into the analysis. In the left column overview photographs of axillary (A, D) lymph nodes 
are shown. High magnifications (B, E) show pigmented cells within the tissue. In untreated lymph 
nodes no pigmented cells were detected (G, H). Staining of lymph node tissue with the melanoma cell 
specific marker TRP-1 and the lymphocyte marker CD45 detected infiltrated melanoma cells (green) 
within axillary lymph nodes of DMBA treated animals. These cells were surrounded by normal lymph 
node tissue, which was positive for CD45 (red). In untreated animals only CD45 positive, but no TRP-
1 positive cells were observed. The fluorescent dye DAPI was used to visualize the cell nuclei (blue). 
TRP-1: tyrosinase related protein- 1. 
 
The metastatic spread to the lungs, was quantified by counting the number of visible 
metastases on the surface of the lungs. This analysis revealed a significantly reduced 
(p=0.03) number of metastases to the lungs in Adam-9mutated/ko (3 ± 1 metastases; n=29) 
compared to control (7 ± 1; n=30) animals at ~week 13 post DMBA treatment (Figure 47). 
Representative pictures of lungs, with metastatic nodules (indicated by the arrows) obtained 
from Adam-9mutated/ko and control animals are shown in Figure 47. In H&E stained lung 
sections from control animals, metastases cloud be clearly detected as pigmented nodules in 
these sections (arrows in Figure 48 A), whereas metastases in lungs of Adam-9mutated/ko 
animals were hardly detectable (Figure 48 B). 




Figure 47: Metastases formation in lungs of DMBA treated control and Adam-9mutated/ko animals. The 
back of control and Adam-9mutated/ko animals was painted once with DMBA on postnatal day three and 
at ~week 13 the animals were killed. The number of black nodules visible on the surface of the lungs 
was counted. Every dot represents the average number of visible metastases counted in a single 
animal. The red line indicates the mean value. A significantly reduced number of metastatic nodules 
on the lungs of Adam-9mutated/ko (n=30) compared to control (n=29) animals was found. *: p<0.05. The 
photographs on the right show pictures of lungs from representative animals. The arrows indicate 
visible metastases on the lung surface. 
 
Further immunohistological staining using the TRP-1 marker, confirmed the presence of 
TRP-1 positive nodules in the lungs of control animals (Figure 48 C). In lungs of Adam-
9mutated/ko animals TRP-1 reactivity could not be detected in nodules as seen in the control 
animals (Figure 48 D).  
 
Figure 48: Histological appearance of lungs of DMBA treated control and Adam-9mutated/ko animals. 
H&E stained sections of the lungs obtained from DMBA treated control and Adam-9mutated/ko animals, 
revealed the presence of metastatic nodules (arrows) in the lungs of control mice, whereas in Adam-
9mutated/ko animals metastases were only hardly detected (A, B). The metastatic nodules in control were 
positive for the melanoma cell specific marker TRP-1 (white arrow) (C, D). The fluorescent dye DAPI 
was used to visualize the cell nuclei. TRP-1: tyrosinase related protein- 1. 
 
  Results 
76 
 
According to theories on metastatic spreading, it is still matter of discussion in the scientific 
society how metastases formation occurs. From the one side it is believed that metastatic 
spread parallels tumor growth, with larger tumors having higher probability to metastasize 
(Klein, 2009). A second more recent and likely realistic theory, indicates that the two 
processes are independent from each other and thus, when tumor is not yet diagnosed it 
may have already spread to distant organs (Klein, 2009). To investigate whether in our 
animal model, the reduced number of metastases is the result of reduced tumor growth, thus 
agreing with the older theory of metastasis, we compared control and Adam-9mutated/ko 
animals bearing tumors larger than 200 mm3 or having more than 20 tumors.  
In every group the number of lung metastases was significantly reduced in Adam-9mutated/ko 
animals independently of the size of primary tumor, which was comparable in both animals 
and of number of tumors. This would indicate that metastatic spread in these animals is not 
dependent on the tumor size and number. In Table 12 the size of the tumors, age of mice, 
tumor and metastases number and the statistical significance for the different groups is 
summarized.  
 
Table 12: DMBA treated animals were subdivided into different groups, matching the animals either 
for the tumor size, the number or the age. Values show the mean ± SEM, except for the age where the 
SD is shown. Significance was tested with Student´s t-test, with p < 0.05 considered to be statistically 
significant. 
 
Taken together these analyses interestingly indicated that in the absence of ADAM-9 
metastatic spreading of melanoma cells to the lung indeed is reduced. 
 
3.4.5 Characterization of mechanisms responsible for reduced lung metastases 
         formation in Adam-9mutated/ko animals    
 
3.4.5.1 Melanoma cell chemoattraction  
Melanoma cells were shown to be attracted to organs of metastases by the activity of 
chemokines and cytokines (Kakinuma and Hwang, 2006). Thus, reduced lung colonization in 
Adam-9mutated/ko animals may result from altered release of chemotactic factors. To 
investigate whether ADAM-9 depletion leads to alterations in the amount of circulating 
cytokines released in tumor bearing animals, the amount of different cytokines present in the 












control 20 98 ± 19 560 ± 78 35 ± 13 8 ± 2 
0.04 Adam-9 
mutated/ko 17 95 ± 16 599 ± 106 23 ± 10 3 ± 1 
                
>20 tumors 
control 24 97 ± 17 390 ± 77 37 ± 10 8 ± 2 
0.04 Adam-9 
mutated/ko 19 91 ± 17 454 ± 110 34 ± 10 3 ± 1 
  Results 
77 
 
serum of DMBA treated control and Adam-9mutated/ko mice was determined using RayBio® 
mouse cytokine array (Figure 49). These membranes, which allow simultaneous analysis of 
62 different factors, were incubated with serum pooled from three different animals per 
genotype, obtained at week 13 after DMBA treatment. The expression of the cytokines was 
quantified by densitometry. Only those proteins, which were more than 2-fold regulated, were 
considered as valid. Among the 62 cytokines increased amounts of 12 proteins were 
detected in the serum of Adam-9mutated/ko compared to control animals (Table in Figure 49). 
The highest difference was detected for interleukin-17 (IL-17) and Lymphotactin with 3,93- or 
3,97-fold, higher amounts in the serum of Adam-9mutated/ko as compared to control animals. 
Surprisingly, none of the analyzed proteins was found to be reduced more than 2-fold in the 
Adam-9mutated/ko serum compared to control animals. Interestingly SDF-1α also known as 
CXCL12 was up-regulated 3,17-fold in the serum from Adam-9mutated/ko compared to control 
animals. This cytokine has previously been reported to be important for recruting melanoma 
cells to the lung. CXCL12 is released in lung tissue and reacts with the receptor CXCR4 
expressed on melanoma cells, thereby attracting them to the lung (Kakinuma and Hwang, 
2006). 
 
Figure 49: RayBio® mouse cytokine antibody array. 
RayBio® mouse cytokine antibody array detecting 62 different murine cytokines was used to analyze  
serum from control and Adam-9mutated/ko animals 13 weeks after treatment with DMBA. Membranes 
were incubated with serum pooled from three different animals for each genotype. Specific signals 
were quantified by densitometry, normalized to the positive control and expressed as ratio of Adam-
9mutated/ko versus control. The table summarizes factors, which were at least 2-fold regulated after 5sec 
exposure time. To detect all proteins present in the serum of the animals, even if in reduced amounts, 
films were also exposed for a longer time, which is not in the linear amplification range (30 sec).  




This increased amount of CXCL12 would not agree with reduced attraction of the melanoma 
cells to the lung in the absence of ADAM-9. As CXCL12 needs to interact with the relative 
receptor on melanoma cells, CXCR4, it is yet possible that despite the increased levels, 
melanoma cells do not express the receptor.  
To analyze expression of the CXCR4 receptor, sections of tumors from control and Adam-
9mutated/ko animals obtained 13 weeks after DMBA application were immunostained using an 
antibody directed against CXCR4. Despite the positive staining seen in the spleen, which 
served as control (Figure 50 C), in the tumor very low and diffuse staining was observed 
(Figure 50 A, B), suggesting that those tumors do not express high amounts of CXCR4. 
 
Figure 50: CXCR4 expression in DMBA induced tumors from control and Adam-9mutated/ko animals. 
Tumor sections from animals at 13 weeks after DMBA application were immunohistochemically 
stained using an antibody against CXCR4 (green). DAPI was used to visualize the cell nuclei, in blue. 
Only very faint staining was present in the tumor cells (A, B). Spleen sections from control animals 
were used as positive control (C). 
 
 
Once the metastatic cell seeds into the organ, it needs to generate a favorable 
microenvironment and to counteract the host-immunity, which is activated (Bacac and 
Stamenkovic, 2008). Thus higher infiltration of the lung by inflammatory cells may counteract 
metastases formation in lungs of Adam-9mutated/ko animals. However, inflammatory reaction 
around the lung metastases in control and Adam-9mutated/ko animals as analyzed by 
immunodetection of the lymphocytes markers CD45, CD3, CD3 and CD8 was not altered 
(data not shown). These data indicate that host-immunity does not play a role in the 
observed reduced metastatic load to the lung in Adam-9mutated/ko animals. 
 
3.4.5.2 Basement membranes in DMBA-induced tumors 
One characteristic of malignant tumors is the presence of a discontinuous BM. Degradation 
of this barrier by the tumor cells enables them to invade the surrounding connective tissue 
(Baluk et al., 2005; Bacac and Stamenkovic, 2008). The in vitro studies using ADAM-9 down-
regulated cells in the DDS invasion system revealed a reduced invasion through the BM 
upon ADAM-9 silencing (chapter 3.2.1.3). Morevover the BM protein laminin β3-chain could 
be identified as a substrate for ADAM-9 (chapter 3.2.2). To analyze if the absence of ADAM-
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9 in DMBA induced tumors results in reduced BM degradation in the tumors, 
immunostainings for laminin β3-chain were performed on tumor tissues.   
Tissue sections of tumors obtained from control and Adam-9mutated/ko animals four and 13 
weeks after DMBA application were immunhistochemically stained with an antibody against 
the laminin β3-chain, which is a subunit of laminin 332, present in the BMs of the skin (Tzu 
and Marinkovich, 2008).  
 
Figure 51: BMs in tumors grown in control and Adam-9mutated/ko animals. To visualize BMs, acetone-
fixed frozen tumor sections were immunohistochemically stained with an antibody directed against the 
laminin 3-chain. The fluorescent DAPI was used to visualize the cell nuclei. The appearance of the 
BM between the epidermis (e) and the tumor (t) at week four (A, B) and week 13 (E, F) after DMBA 
treatment is shown. Additionally high power magnifications of BMs surrounding tumoral vessels at 
week four (C, D) and week 13 (G, H) are depicted.  
 
At week four and 13 after DMBA treatment the BM separating the epidermis and tumor was 
clearly destructed and appeared discontinuous with clear interruptions in the BM zone 
indicated by the white arrows in Figure 51 in control animals (Figure 51 A, E). Additionally at 
week 13 laminin β3-positive areas were also found in these animals below the BM (Figure 51 
E). In constrast in tumors of Adam-9mutated/ko animals a mostly regular and continuous staining 
pattern was observed with only little interruptions (Figure 51 B, F). The BM around the tumor 
blood vessels did not show destruction in both genotypes at week four (Figure 51 C, D). At 
week 13 the BM surrounding tumor blood vessels was also discontinuous and partially 
destructed in control animals, whereas in tumors obtained from Adam-9mutated/ko mice the BM 
appeared more continuous, however also destructed parts were observed (Figure 51 G, H). 
These data indicated that also in the in vivo situation cleavage of the laminin β3-chain occurs 
leading to destruction of the BM, which is reduced in the Adam-9mutated/ko animals.  
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3.4.5.3 Intra- and extravasation of melanoma cells 
The data of previous chapter showed that in absence of ADAM-9 the destruction of the BM 
around tumor vessels is reduced, which leads to the hypothesis that in the Adam-9mutated/ko 
animals the intravasation of melanoma cells might be decreased. If melanoma cells are able 
to intravasate in the absence of ADAM-9, they should be dectacable as circulating cells in 
the blood. To address this question we have collected blood from 13 weeks old tumor 
bearing animals and used the prepared RNA/cDNA for amplification of the melanoma marker 
Pmel17 also known in human as gp100 (Kobayashi et al., 1994; Singh et al., 2008). For 
improved amplification a nested PCR was employed (chapter 2.2.3.2). Pmel17 transcripts 
could be amplified in control as well as in Adam-9mutated/ko animals, indicating that in both 
genotypes melanoma cells are present in circulation suggesting that melanoma cells are able 
to cross the vessel wall and intravasate independent of the presence of ADAM-9. As a 
control, PCR was also performed using blood from a control animal, which was not treated 
with DMBA and therefore showed not tumor formation. No signal for Pmel17 was detected, 
thus excluding the presence of any circulating melanocytes (Figure 52). 
 
Figure 52: Analysis of circulating melanoma cells. 
Circulating tumor cells were detected by nested PCR on RNA isolated from the blood of control and 
Adam-9mutated/ko tumor bearing animals at week 13 post DMBA application. Isolated RNA was reverse 
transcribed into cDNA and subsequently used to amplify Pmel17, a melanocyte specific glycoprotein 
(chapter 2.2.3.2). Pmel17 transcripts were detected in the control as well as Adam-9mutated/ko animals. 
No fragment was generated from blood of untreated control animals, which did not develop 
melanoma. S26 served as loading control. 
 
A prerequisite of metastases formation is that melanoma cells are able to leave the 
circulation. Melanoma cells require first attaching to endothelial cells and thereafter 
penetrating the vessel wall to enter the tissue of a distinct organ. A role for ADAM-9 in 
mediating these cell-cell interactions has been demonstrated for adhesion of human lung 
cancer cells to endothelial cells (Monagret et al., 2010). As culture of melanoma cells 
isloated from the control and in Adam-9mutated/ko animals was not successful in our hands, we 
used B16-F1 melanoma cells, in which ADAM-9 was stably down-regulated via shRNA to 
study if silencing of ADAM-9 reduces adhesion of melanoma cells to endothelial cells. 
ADAM-9 silencing in B16-F1 cells resulted in a ~80% inhibition of transcripts expression (p = 
0.02) as compared to scrambled transfected control cells shown by quantitative real-time 
PCR (Figure 53 A). Immunoblotting confirmed efficient down-regulation of ADAM-9 pro- and 
active form (Figure 53 A right). To mimic the adhesion of melanoma cells to an activated 
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endothelium, as it occurs in vivo, endothelial cell monolayers were treated with TNF-α before 
melanoma cells were added to measure adhesion. 
 
Figure 53: Analysis of adhesion of melanoma cells to endothelial cells. 
(A) B16-F1 mouse melanoma cells were stably transfected with shRNA targeted to ADAM-9 or a 
scrambled control sequence. ADAM-9 expression was measured by quantitative real-time PCR and 
shown in the graph as mean ± SD of three independent experiments. ADAM-9 expression was also 
analyzed by immunoblotting using antibodies against ADAM-9. β-actin was used as control. (B) 
Control or shAdam-9 B16-F1 melanoma cells, were seeded for 1h on top of TNF-α activated sEND-1 
mouse endothelial cell monolayers. Adhesion was measured by quantifying the B16-F1-fluorescence 
and expressed as mean ± SD of control, set as 100%. The data represent the mean of four 
independent experiments performed in sextuplicate. *: p<0.05. The pictures on the right show 
representative photographs of fixed melanoma cells (green) adhering to the endothelial cell monolayer 
visualized by phase contrast (lower panel). 
 
B16-F1 melanoma cells with stable down-regulation of ADAM-9 or carrying unspecific 
shRNA sequences, used as controls, were labeled with a fluorescent substance, which is 
retained from the cells upon entry, were seeded on TNF-α activated endothelial cell 
monolayers and allowed to adhere for 1h. In this assay the ADAM-9 down-regulated 
melanoma cells exhibited a significantly reduced (p = 0.01) adhesion towards the endothelial 
cells as compared to scrambled transfected control cells (Figure 53 B). This finding for the 
first time indicates that ADAM-9 expressed by melanoma cells is important for melanoma cell 
adhesion to endothelial cells. 
Activation of endothelial cells with TNF-α up-regulates several adhesion molecules, which 
are involved in the interaction of melanoma cells with endothelial cells (Sikorski et al., 1993; 
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McAteer et al., 2008). In an attempt to identify a ligand for ADAM-9 on the surface of TNF-α 
activated endothelial cells, after 18h stimulation of sEND-1 endothelial cells, the expression 
of adhesion molecules, such as β1 and β3 integrin, ICAM-1, VCAM and VE-cadherin, was 
investigated by RT-PCR. Transcripts of all assayed molecules were up-regulated by TNF-α 
stimulation. The highest induction was observed for β1 integrin and VCAM. ICAM-1, β3 
integrin and VE- cadherin were also clearly induced, but to lower extent (Figure 54). These 
data indicate that these analyzed adhesion molecules can provide potential binding 
candidates for ADAM-9, which need to be further investigated in future studies. 
                          
 
To analyze the direct contribution of melanoma cell-derived ADAM-9 to tumor cell 
extravasation in vivo, B16-F1 control and B16-F1 ADAM-9 down-regulated cells were 
injected into the tail vein of wild-type mice. The mice were killed three weeks after cell 
injection and the inner organs were prepared and carefully inspected for macroscopically 
visible metastases. Injection of B16-F1 control cells resulted in metastases formation in 
various organs in 100% of the injected animals (n=5/5), whereas only in 43% (n=3/7) of the 
animals, which were injected with ADAM-9 silenced cells, metastases were observed (Figure 
55). Metastases were found in the lungs (Figure 55 A, E), the liver (Figure 55 B, F) and the 
heart (Figure 55 C, G). Control cells also metastasized into the kidney in one animal (Figure 
55 D), whereas ADAM-9 silenced did not (Figure 55 H). In summary this experiment revealed 
that ADAM-9 down-regulation in B16-F1 cells, present in the circulation, reduced the general 
metastatic potential of the cells. No organ could be identified, which was preferentially 




Figure 54: Analysis of adhesion molecule 
regulation after TNF-α stimulation of 
endothelial cells.  
Monolayer cultures of sEND-1 mouse 
endothelial cells were stimulated with 
50ng/ml recombinant TNF-α for 18h in 
serum-free medium and the expression of 
different adhesion molecules was deter-
mined by RT-PCR. S26 was used as 
control.  !
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Figure 55: Tail vein injection of ADAM-9 silenced B16-F1 melanoma cells 
100,000 B16-F1 control or B16-F1 shAdam-9 cells were injected in the tail vein of six-to-ten week old 
male and female Adam-9+/+ mice. The animals were killed three weeks after injection and the inner 
organs were inspected for macroscopically visible metastases. In the table the number and 
percentage of metastases bearing mice is summarized for control and shAdam-9 silenced cells. The 
photographs show pictures of metastatic nodules in the liver (A, E), the lung (B, F), the heart (C, G) 
and the kidney (D, H). 
 
3.5 Role of ADAM-15 in growth and invasion of melanoma 
Another member of the ADAM family, which is implicated in tumor growth and invasion, is 
ADAM-15 (Chen et al., 2008; Najy et al., 2008; Ungerer et al., 2010). ADAM-15 is highly 
expressed by endothelial cells and, as well as in ADAM-9-/- animals, in ADAM-15-/- mice 
pathological neovascularization of the retina and growth of B16-F0 melanomas is reduced 
(Horiuchi et al., 2003; Guaiquil et al., 2009). These data suggest that ADAM-9 and ADAM-15 
might exhibit overlapping functions in vascularization and melanoma growth.  
One further aim of the laboratory was the investigation of the expression of ADAM-15 in skin 
and its role in skin repair and melanoma development. 
In particular I have investigated the functional role for ADAM-15 in melanoma development 
and performed in vivo experiments using grafts of B16-F1 melanoma cells in the skin of 
control and Adam-15-/- mice. I have further proceeded into the microscopical analysis of 
vascularization, inflammatory infiltration around the tumors and metastatic spread in those 
animals. These data have been recently published and the publication can be found at the 
end of this thesis (Schönefuß et al., 2012). The published data will be summarized in the 
following.  
Expression of ADAM-15 in skin was detected in epidermal keratinocytes and by dermal 
vascular structures as well as by fibroblast-like cells. Analysis of ADAM-15 transcripts by RT-
PCR performed on dissociated epidermis and dermis, as well as on entire human skin 
detected ADAM-15 in comparable levels in both skin compartments. In cultured primary 
human skin cells, ADAM-15 transcripts were detected in keratinocytes, endothelial cells, 
fibroblasts and melanocytes. A similar expression pattern was detected in murine cells. 
Despite this broad expression pattern in skin, ablation of ADAM-15 did not affect skin 
homeostasis and morphology. Intradermal injection of B16-F1 melanoma cells in ADAM-15+/+ 
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and ADAM-15-/- animals resulted in comparable melanoma growth kinetics in both mice, but, 
in agreement with previously published data (Horiuchi et al., 2003) at day 21 post injection, 
tumors grown in the in Adam-15 -/- animals were smaller as compared to control. Analysis of 
vascularization in tumor specimens from day 12 and 21 post injection, by staining for CD31 
(blood vessel endothelial cells) and LVYE-1 (lymphatic vessel endothelial cells), failed to 
detect any significant alterations in blood vessel density in peritumoral or intratumoral areas 
in Adam-15 -/- as compared to ADAM-15+/+ animals at both analyzed time points. Similarly, no 
significant alterations in the infiltration of tumors by neutrophils, macrophages (F4/80), 
cytotoxic T-cells (CD8) and lymphocytes (CD45) were detected.  
Finally, analysis of the metastatic dissemination of the injected B16-F1 cells to the lungs and 
the lymph nodes revealed that lung metastases formation 16 days post B16-F1 injection was 
consistently reduced. The number of lungs positive for melanoma cells in Adam-15 -/- was 
only 13% of the total as compared to 54% detected in ADAM-15+/+ animals. A similar, though 
less prominent difference was detected in lymph nodes, where 13% of examined organs 
were positive in Adam-15 -/- as compared to 23% in ADAM-15+/+ animals.  
In conclusion, while stromal expression of ADAM-15 is not important for melanoma growth in 
vivo, this study highlights ADAM-15 as a pro-metastatic molecule.  
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4. Discussion  
 
Proteases, like MMPs and ADAMs, are implicated in the biology of melanoma. Expression of 
these enzymes is localized in stromal cells including fibroblasts and inflammatory cells, but 
also in tumor cells. In both compartments these enzymes exhibit distinct functions, e.g. 
shedding of surface molecules and degradation of the extracellular matrix, which support or 
counteract tumor growth, depending on the particular proteases and their expression sites. 
For example expression of MMP-2 in melanoma cells facilitates tumor invasion, and stromal 
expression of ADAM-15 contributes to melanoma metastases formation (Hofmann et al., 
2005; Schönefuß et al., 2012). On the contrary stromal expression of ADAM-8 decreased 
melanoma growth (Guaiquil et al., 2010). Interestingly a similar effect was shown to be 
associated with stromal expression of ADAM-9 (Abety et al., 2012). However, in another 
study stromal expression of ADAM-9 was supporting growth of other melanoma cells 
(Guaiquil et al., 2009).  Despite these discrepancies, the function of ADAM-9 expression in 
the melanoma cells, where the protease is up-regulated during tumor development (Zigrino 
et al., 2005), is unknown. The present work was intended to unravel the cell-specific function 
of ADAM-9 produced by tumor cells for development, growth and metastases formation of 
melanoma in vivo and in vitro. An additional aim of this work was to investigate the molecular 
mechanisms by which ADAM-9 expression is regulated in melanoma cells by IL-1α as well 
as by anti-cancer drugs, the indirubins, and their potential use as therapeutic. 
 
4.1 Expression of ADAM-9 in melanoma cells 
Several proteases have been implicated in the invasive process of cancer cells and these 
include also the ADAMs. The versatile functions of ADAMs and the documented evidence of 
their over-expression in a variety of tumors suggest that these proteins are potential targets 
for tumor therapy. Although several ADAMs e.g. ADAM-10 and -12 have been detected in 
melanoma cells we identified ADAM-9 as being induced in melanoma cells at the periphery 
of the tumor and by adjacent peritumoral stromal cells. This observation suggests that 
ADAM-9 plays a role in mediating tumor-stroma communication (Zigrino et al., 2005; Zigrino 
et al., 2011). In a high-throughput analysis of human melanomas Alonso et al. demonstrated 
a correlation of ADAM-9 expression and tumor progression (Alonso et al., 2007). In mouse 
models for prostate, breast and intestinal cancer high ADAM-9 expression correlated with 
poor differentiation of the tumors (Peduto et al., 2005). Furthermore, in human renal cell 
cancer ADAM-9 protein expression was associated with higher tumor grade (Fitzsche et al., 
2008) and in human hepatocellular carcinoma ADAM-9 positive tumors were less 
differentiated compared to negative tissues (Tao et al., 2010). Although we described 
induction of ADAM-9 protein in melanoma cells and in stromal cells at the invasive part of the 
tumors (Zigrino et al., 2005), in vitro analysis of ADAM-9 transcripts in melanoma cell lines 
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did not show any correlation between ADAM-9 expression and the invasive potential of the 
tumor cells (Zigrino et al., 2005). In line with these data is the study showing that ADAM-9 
gene amplifications in human breast cancer tissues, were not related to tumor grade 
(Moelans et al., 2010).  
The studies presented herein confirm the findings relative to melanoma cells not only at the 
transcriptional level but also at the protein level, showing that expression of active protease 
on the cell surface of melanoma cells does not correlate to their invasive potential. On one 
side one can consider that the used monolayer cultures are simplified in vitro systems, thus 
the complexity of the in vivo system may be important to address the functional relevance for 
expression data. Several studies detected reactive oxygen species as modulators of ADAM-
9 expression in different cancer cell lines (Fischer et al., 2004; Sung et al., 2006; Monagret et 
al., 2010). It might be possible that different levels of oxidative stress at the periphery of the 
tumor and the inner tumor mass result in distinct induction of ADAM-9 in different parts of the 
tumor in vivo, which is not mimicked by the in vitro situation. On the other hand it is also 
possible that additional molecular events contribute to define protease functional relevance in 
this pathological condition. For instance, ADAM-9 proteolytic activity is not inhibited by TIMPs 
(Amour et al., 2002), but it is possible that additional factors may be necessary to modulate  
its function. Thus, ADAM-9 expression and “co-factor” levels may be important to define its 
function in melanoma. A similar concept was described for MMP-14, whose expression was 
comparable in melanoma cells of high and low invasive potential, but levels of the TIMP-2, 
higher in the low invasive cells, which was necessary not only for enzyme inhibition but also 
activity, determined the net activity of the enzyme (Kurschat et al., 1999).  
 
4.2 Role of ADAM-9 for melanoma growth and invasion in vitro 
4.2.1 Involvement of ADAM-9 in melanoma cell proliferation 
To investigate the function of ADAM-9 for melanoma growth and invasion in vitro, we 
decided to stably down-regulate the expression of ADAM-9 using shRNA. A stable approach 
was necessary, as functional assessment of melanoma cell invasion in vitro and in vivo 
requires long-term experiments. BLM melanoma cells were chosen because they exhibited 
very high ADAM-9 transcript and protein expression levels as compared to other analyzed 
melanoma cell lines. The down-regulation was efficient at both, transcriptional and protein 
levels and despite the known redundancy in protease activities, no additional ADAM 
members were found up-regulated.  
Interestingly, ADAM-9 down-regulation in BLM melanoma cells led to increased growth in 
presence and absence of anchorage. Even though no direct link between ADAM-9 and 
melanoma cell proliferation has been published, lines of evidence suggest a direct or indirect 
connection between ADAM-9 and cell proliferation or cycle control. A distinct protein, which 
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may provide a possible link between ADAM-9 and cell proliferation, is the mitotic arrest 
deficient 2β (MAD2β) molecule. Nelson et al. (1999) have shown that the intracellular tail of 
ADAM-9 interacts with MAD2β. MAD2β is a variant of MAD2, which is involved in the control 
of spindle assembly during mitosis, however the function of this further variant is largely 
unknown. It has been suggested that also MAD2β may exert similar functions, but this 
hypothesis has not been proven yet. As described above, this protein binds the cytoplasmic 
tail of ADAM-9, thus one could speculate that ablation of ADAM-9 leads to an altered 
localization of MAD2β, which in turn induces cellular events leading to increased cell 
proliferation. It was shown that the proline rich domain of the ADAM-9 intracellular tail binds 
to endophilin and paxin 3, which are involved in receptor recycling (Howard et al., 1999), but 
it also binds PKC-δ, which leads upon phosphorylation of the intracellular domain to 
modulation of HB-EGF shedding (Izumi et al., 1998). HB-EGF as many other EGF-like 
molecules have a potent effect in modulating cellular proliferation (Hashimoto, 2000), thus 
altered proteolysis of growth factors can also result from reduced ADAM-9 expression and 
lead to modification of proliferation. However it is possible that other mechanisms are 
responsible for increased cell proliferation upon ADAM-9 down-regulation mediated by other 
proteolytic enzymes, which compensate the lack or reduced expression. Other ADAMs like 
ADAM-10 or ADAM-17 were shown to contribute to proliferation of various tumor cell types 
by shedding and activating growth factors or receptors (Mochizuki and Okada, 2007; Rocks 
et al., 2008). Indeed an up-regulation of ADAM-10 and -17 was observed in lysates obtained 
from wounds created in ADAM-9-/- animals (Mauch et al., 2010) or in fibroblasts from ADAM-
9-/- mice (Abety et al., 2012). However within this work no significant alteration of these 
proteins was found in ADAM-9 silenced melanoma cells.  
In contrast to the increased proliferation upon ADAM-9 down-regulation in BLM cells are the 
data obtained using indirubins. These substances are known to inhibit with different 
efficiency several CDKs, which are important molecules in cell cycle control and lead to 
inhibition of cell proliferation (Eisenbrand et al., 2004). Treatment of BLM cells, most 
prominently down-regulates expression of ADAM-9. However, as silencing of ADAM-9 in the 
same cells leads to increased proliferation, it is possible that the effect detected on ADAM-9 
expression by indirubins is indirect, mediated by a yet unknown molecule. One candidate 
could be c-jun, because it was shown that application of indirubin derivates to melanoma 
cells caused beside CDK inhibition also inhibition of c-jun (Kunz et al., 2010). Furthermore c-
jun responsive elements have been identified in the ADAM-9 promotor (Cong and Jia, 2009). 
However, contrasting results were also shown using other tumor cell species, thus 
application of siRNA targeted to ADAM-9 led to reduced cell proliferation in adenoid cystic 
carcinoma cells (Xu et al., 2010). An additional study conducted using gastric caner cell lines 
revealed that treatment of cells with anti-ADAM-9 antibodies led to decreased cell 
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proliferation of one cell line, but not of all tested cell lines (Carl McGrath et al., 2005). When 
breast or gastric cancer cells were treated with anti-ADAM-15 or anti ADAM-17 antibodies 
proliferation was also reduced, but when anti ADAM-12 antibodies were applied cell growth 
of some cell lines was stimulated (Lendeckel et al., 2005). Alltogether, these data may 
indicate that specific ADAM proteases may exert different effects on cancer cell proliferation 
depending on the cell type expressing them. 
 
4.2.2 Regulation of cell size by ADAM-9 
Besides increasing the proliferation rate, down-regulation of ADAM-9 showed a major impact 
on the cellular shape of melanoma cells. Analysis of actin distribution in these cells revealed 
reduced polymerization of intracellular actin. It is unclear whether this is a direct effect of 
ADAM-9 silencing or an indirect effect due to reduced cellular volume followed by adjustment 
of cell cytoskeleton. This aspect is important for tumor cell invasion as changes in cell 
volume and the actin cytoskeleton may indeed alter tumor cell ability to cross three-
dimensional structural molecules in a protease independent fashion (Wyckoff et al., 2006). A 
recent study using prostate cancer cells treated with siRNA targeted to ADAM-9 also 
detected phenotypical changes in these cells after several passages, changing from an 
epithelial into a cobblestone morphology, accompanied with increased E-cadherin and 
altered integrin expression (Josson et al., 2011). The cellular volume might be regulated from 
activity of water channels like aquaporins and among the different members aquaporin-3 is 
expressed in human and murine skin (Verkman, 2005). We also found expression of 
aquaporin-3 in melanoma cells and we could detect increased aquaporin-3 protein synthesis 
in ADAM-9 silenced cells by immunolocalization. 
Interestingly, aquaporin-3 overexpression has been shown in human squamous cell 
carcinomas and aquaporin-3 knockout mice were resistant to the development of skin tumors 
after carcinogen treatment (Hara-Chikuma and Verkman, 2008). Aquaporin-3 was found to 
facilitate glycerol transport, suggesting that up-regulation of this protein could result in 
increased proliferation by providing a substrate for increased ATP generation (Hara-Chikuma 
and Verkman, 2008). However when we inhibited aquaporins function with mercuric chloride 
(Ismail et al., 2009) we could not rescue the cell volume phenotype upon ADAM-9 silencing, 
although a higher protein expression level of aquaporin-3 was observed. This might be due 
to the performace of this experiment as inhibition of aquaporins was only conducted for one 
hour prior to cell volume determination to avoid toxicity. This time might not be long enough 
for synthesis of new membrane or cytoskeletal proteins leading to restoration of the cell 
volume. In TGF-β stimulated breast cancer cells it was shown that actin transcripts peaked 
not until 4-8h after TGF-β addition (Leof et al., 1896) and in mitogen activated bovine 
lymphocytes actin mRNA synthesis increased within 3h (Degen et al., 1983). On the other 
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side, as mercuric chloride is a general aquaporin inhibitor (Ismail et al., 2009), other 
substances like copper ions might be necessary to more specifically inhibit aquaporin-3 
activity (Zelenina et al., 2004). Another putative explanation for the observed effect is that the 
reduced cell size upon ADAM-9 silencing might also result from increased proliferation of 
these cells. Due to the higher proliferation rate the time to synthesize new proteins and gain 
cell volume in the G1-phase of the cell cycle might be reduced, leading to a decreased cell 
size. Interestingly stimulation of B16 melanoma cells with TPA, which was shown to activate 
ADAM-9, caused a block in the G1 phase of the cell cycle resulting in an increased cell size 
(Izumi et al., 1998; La Porta et al., 1998). Thus one could envision that active ADAM-9 in 
control cells might delay cell cycle progression, giving the cells enough time to restore cell 
volume after mitosis, whereas in the ADAM-9 down-regulated cells, cell cycle progression is 
enhanced resulting in a decreased cell size. 
 
4.2.3 Basement membrane penetration mediated by ADAM-9 
Upon silencing of ADAM-9 in BLM melanoma cells, these cells displayed a significant 
reduced penetration of the basement membrane (BM) in an in vivo like system, while 
invasion of the dermal compartment was not altered. The finding that ADAM-9 up-regulation 
upon IL-1α silencing led to a modest increase in BM penetration partly supports the 
suggested pro-invasive role of ADAM-9 in melanoma cells. The reduced effectiveness is 
likely due to the fact that down-regulation of IL-1α is not sufficient to up-regulate ADAM-9 to 
an extent, which is high enough to lead to increased invasion. Furthermore while application 
of shRNA targeted to ADAM-9 is specific to down-regulate ADAM-9, down-regulation of IL-1α 
via shRNA also might lead to regulation of other proteins apart from ADAM-9, which are 
involved in melanoma cell invasion.  
Involvement of ADAM-9 in BM invasion was also provided by the studies from Xu et al. 
(2010). These authors used siRNA against ADAM-9 in adenoid cystic carcinoma cells, which 
led to reduced cell invasion through matrigel. In addition, treatment of lung carcinoma cells 
with H2O2, which induces ADAM-9 expression increased invasion through matrigel, whereas 
shRNA targeted to ADAM-9 reduced H2O2-induced invasion (Monagret et al., 2010). In 
prostate cancer cells ADAM-9 down-regulation led to decreased invasion in transwell assays 
(Josson et al., 2011). However all these in vitro invasion systems employed matrigel, which 
is a mixture of several BM components produced by EHS tumor cells (Benton et al., 2010; 
Hughes et al., 2010) and only represent an “equivalent” in vitro system for the BM. Although 
the epidermal celllayers have been removed in the DDS skin equivalent system used in the 
studies here, this system likely resembles more closely a normal BM containing all proteins 
present in the in vivo situation in a ratio and distribution comparable to human skin. This was 
the case for laminin α3-chain and collagen IV, which appeared to localize normally within the 
BM in the composites. As in the DDS system the epidermis was stripped off and the 
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fibroblasts killed before seeding the melanoma cells on top of the BM, with this system an 
evaluation of the invasive capacity of melanoma cells, which might also depend on 
interactions with keratinocytes or factors produced by either epidermal cells or fibroblasts is 
not possible. For this purpose additional experiments using organotypic culture systems 
(Stark et al., 1999; Meier et al., 2007) may help to address whether ADAM-9 silencing in 
melanoma cells results in altered melanoma-stroma cross talk and also results in reduced 
invasion.  
Altered invasion through the BM may be due to an altered recognition of and adhesion to BM 
components or degradation products to allow penetration. Analysis of the adhesive abilities 
of ADAM-9 down-regulated cells, indicated reduced adhesion to matrigel and collagen IV, the 
latter being the most abundant BM protein (Kalluri, 2003). This provides an explanation for 
the observed effect. Decreased adhesion towards BM proteins would point to an altered 
expression of integrin receptors upon ADAM-9 silencing. Integrins are the main cellular 
receptors mediating cell-matrix interactions (Hynes, 2002). Several studies showed a parallel 
regulation of ADAM-9 and integrins. Thus transfection of lung cancer cells with ADAM-9 
resulted in increased expression of α3β1 integrin resulting in increased adhesion to brain 
tissue (Shintani et al., 2004). In smooth muscle cells stimulated by PDGF, increased ADAM-
9 expression was paralleled by expression of integrins αvβ5 and α5β1 (Al-Fakhri et al., 
2003). In prostate cancer cells ADAM-9 silencing resulted in increased expression of α1, α2, 
α5, and β1 integrin and decreased expression of αv integrin (Josson et al., 2011). In BLM 
melanoma cells plated on collagen type IV-coated surfaces, down- regulation of ADAM-9 led 
to significantly decreased expression of α1 integrin chain and an up-regulation of the α2 
integrin compared to control cells, as detected by FACS analysis. The α3 integrin remained 
unchanged. The fact that α1 integrin was down-regulated, whereas the expression of the α2 
integrin was increased indicated that loss of α1 integrin might be compensated be an up-
regulation of the α2 integrin. The integrins α1β1 and α2β1 were shown to interact with 
collagen IV with different affinities. The affinity of α1β1 integrin for collagen IV is very high, 
whereas the α2β1 exhibits a lower affinity towards this collagen (Khoshnoodi et al., 2008). 
Therefore down-regulation of the α1 integrin may be responsible for decreased adhesion 
towards collagen IV, although the α2 integrin was up-regulated. As matrigel is a protein 
mixture of several proteins secreted by EHS tumos cells, which contains collagen IV (Benton 
et al., 2010; Hughes et al., 2010), the reduced adhesion towards this matrix can also be 
explained with decreased integrin expression. Despite the fact that adhesion to collagen type 
IV was reduced, few cells still retained their ability to penetrate the BM and migrate in the 
tissue underneath. One explanation for this event may be the reduced cell size of BLM cells 
with ADAM-9 down-regulation. These cell size alterations may facilitate the tumor cells to 
cross the three-dimensional structure. 
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Besides the role in cell adhesion, we could also demonstrate that ADAM-9 exhibits 
proteolytic activity towards the β3-chain of laminin 332 in vitro. ADAM-9 has already been 
reported to cleave different extracellular matrix proteins, among them fibronectin, gelatin or 
laminin 111 (Schlöndorff and Blobel, 1999; Mazzocca et al., 2005). However no BM protein 
was identified as ADAM-9 substrate so far. Laminin 332 is a component of the dermal-
epidermal BM and is located in the hemidesmosome complex, connecting the basal 
keratinocytes to the BM via interaction of the C-terminal part of the α3-chain with α6β4 and 
α3β1 integrins (Aumailley et al., 2003). Furthermore the N-terminal regions of the laminin α3, 
β3- and the γ2-chains interact with collagen VII, establishing a connection of the BM to the 
underlying dermis (Aumailley et al., 2003). For the laminin β3-chain additional binding to 
laminin 321 and laminin 311 was shown. Hence laminin 332 promotes mechanical stability of 
the BM, which is underlined by the fact that mutations in any of the three chains lead to 
blistering diseases (Tzu and Marinkovich, 2008). Thus proteolytic cleavage of laminin β3-
chain by ADAM-9, expressed on melanoma cells, might destabilize the laminin 332 structure 
and in turn disturb BM integrity and consequently facilitate invasion. Processing of the 
laminin 332 molecule is a physiological process and truncations are common in the α3-chain 
as well as in the γ2-chain (Aumailley et al., 2003; Tzu and Marinkovich, 2008), which are 
present only in their processed forms in the epidermal-dermal BM (Tunggal et al., 2002). 
Data on the physiological processing of the β3-chain are rare and only one study identified 
proteolytic cleavage of the N-terminal region of the β3-chain by endogenous proteases in 
keratinocytes (Nakashima et al., 2005). In prostate and colon carcinoma cells processing of 
the laminin β3-chain via the activity of MMP-14 or MMP-7, respectively was shown 
(Udayakumar et al., 2003; Remy et al., 2006). Both proteases created a C-terminal fragment 
of the laminin β3-chain of around 80-90kDa, similar to the fragment we have detected by the 
cleavage of laminin β3-chain by ADAM-9, indicating that this region of the laminin β3 
molecule is prone to proteolytic cleavage. The exact cleavage site was only identified for 
MMP-7 and located between Ala515 and Ile516 (Remy et al., 2006). Processing by ADAM-9 
occurs upstream of this site as proteolysis of the recombinant N-terminal fragment of laminin-
β3 around aspartic acid420 generated a proteolytic fragment localizing the cleavage site ~100 
amino acids upstream of the Ala515 and Ile516sequence. The exact ADAM-9 cleavage site 
within this molecule remains to be determined. Interestingly both fragments generated by 
MMP-14 and MMP-7, exhibited pro-migratory activity towards cancer cells in vitro 
(Udayakumar et al., 2003; Remy et al., 2006). Thus one can speculate that processing of 
laminin β3-chain by ADAM-9 can destabilize the laminin structure and release a fragment 
that promotes cell migration through the BM. However, when migration assays were 
performed, no differences in migration between control and ADAM-9 silenced cells were 
detected when cells were seeded on laminin 332-coated plates. We cannot exclude that the 
  Discussion 
92 
 
small amount of ADAM-9 still expressed in silenced cells is sufficient to generate the 
fragment or that the pro-migratory effect might only be visible in a more complex system, e.g. 
on collagen gels or DDS. If the cleavage of the laminin β3-chain by ADAM-9 results in a pro-
migratory signal for melanoma cells, this should at least partially rescue the observed 
reduced invasion through the BM upon ADAM-9 down-regulation. 
Taken together the obtained in vitro data strongly suggest a role of melanoma-derived 
ADAM-9 for tumor cell proliferation and invasion. The effects observed upon ADAM-9 down-
regulation are summarized in the working model for the reduced BM invasion in Figure 56.  
 
 
Figure 56: Effects of ADAM-9 down-regulation and working model for reduced BM penetration. Upon 
ADAM-9 silencing BLM melanoma cells exhibited higher proliferation and reduced cell size as well as 
decreased invasion through the BM and reduced adhesion towards BM proteins, which might be 
attributed to a reduced expression of integrins. The reduced penetration through the BM might also 
result from a decreased cleavage of laminin 332 (lam 332) in the β3-chain by ADAM-9 and 
subsequent hindered migration through the BM zone.  
 
 
4.3 Regulation of ADAM-9 expression in melanoma cells by IL-1α  
In vivo host-derived IL-1α was shown to be required for melanoma invasiveness and 
angiogenesis (Voronov et al., 2003) and systemic treatment with IL-1 receptor antagonist 
inhibited melanoma xenograft growth of IL-1-producing tumor cells (Elaraj et al., 2006). 
However, the clear molecular mechanism by which IL-1α modulates melanoma growth is not 
fully understood. It was previously shown that this cytokine may is responsible for induction 
of MMP-1 in stromal fibroblasts, which degrades the collagenous extracellular environment 
favouring tumor progression (Löffek et al., 2005). It was also shown that ADAM-9 is an 
additional target for IL-1α in melanoma cells (Zigrino et al., 2005). The data presented herein 
confirmed and extended these data indicating not only down-regulation at the transcriptional, 
but also on the protein level. Two intracellular singalling molecules were identified, namely 
JNK and ERK, being involved in ADAM-9 regulation by IL-1α in melanoma cells. Although 
NFκB is the main mediator conveying signals of the IL-1 receptor, also ERK and JNK have 
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been shown to be downstream targets in the IL-1 signalling pathway (O´Neill et al., 1998). A 
recent study has identified transcription factor binding sites in the promoter of ADAM-9 and 
those include that for AP-1 (Cong and Jia, 2009), which is a transcription factor composed 
either of a c-jun-c-fos heterodimer or of a c-jun-c-jun monomer (Ashida et al., 2005). Thus 
regulation of the expression of ADAM-9 by exogenously supplied IL-1α, which was shown to 
depend on the phosphorylation of c-jun is likely to occur via binding of the AP-1 factor to the 
ADAM-9 promoter. However, we have also shown that ERK may represent an additional 
molecular regulator of ADAM-9 endogenous expression. This kinase was also shown to 
influence the activation of the AP-1 complex (Whitmarsch and Davis, 1996; Ashida et al., 
2005), thus the final molecular target that regulates ADAM-9 at the transcriptional level may 
be the same, even though two singalling molecules can be envisioned. Taken together these 
data for the first time provide evidence for involvement of JNK and ERK in the intracellular 
signalling pathways leading to transcriptional regulation of ADAM-9 by IL-1α.  
 
Figure 57: Working model for regulation of ADAM-9 by IL-1α in BLM melanoma cells. High 
extracellular IL-1α concentrations lead to decreased ADAM-9 expression via a JNK mediated 
mechanism. Down-regulation of IL-1α production in BLM melanoma cells induces up-regulation of 
ADAM-9 by decreasing ERK phosphorylation. 
 
4.4 Role of ADAM-9 for melanoma growth and invasion in vivo 
4.4.1 Role of ADAM-9 for melanoma development and growth 
To investigate the role of ADAM-9 for melanomagenesis in vivo the Hgf/Cdk4R24C/R24C mice 
were crossed with Adam-9-/- mice (Weskamp et al., 2002). In the Hgf/Cdk4R24C/R24C mice 
melanomas arise spontaneously because of the HGF overexpression and the mutation in the 
cyclin (CDK4), a situation that resembles human melanomas (Sotillo et al., 2001; Tormo et 
al., 2006), mice. The generated control (Adam-9+/+//Hgf/Cdk4R24C/R24C) and Adam-9mutated/ko 
(Adam-9-/-//Hgf/Cdk4R24C/R24C) mice developed normally and exhibited no differences in skin 
architecture and differentiation. Thus no developmental or skin phenotype was visible in 
these animals by combining three genetic alterations (ADAM-9 knock out, CDK4 mutation, 
HGF overexpression). In all Hgf positive animals, melanocytes were located at the 
epidermal-dermal junction in the dermis as well as in the epidermis, independent if the 
animals were control or Adam-9mutated/ko. Upon treatment with DMBA control as well as Adam-
9mutated/ko animals developed tumors at about four weeks after the carcinogen application. 
This in agreement with the data published for the Hgf/Cdk4R24C/R24C mice, although in this 
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study the classical two-step carcinogen model, including initial treatment with DMBA and 
subsequent consecutive application of TPA, was used (Tormo et al., 2006). In the present 
study DMBA applied once at postnatal day three, evoked melanoma development similar to 
that observed in the DMBA/TPA treated animals, indicating that mutations generated by the 
DMBA alone are sufficient to induce melanoma formation.  
Upon tumor formation starting at week four post DMBA treatment, surprisingly an increased 
tumor number was found in Adam-9mutated/ko animals compared to control animals. This 
situation was inverted at later stages (weeks 6-13) where reduced numbers of tumors were 
detected in Adam-9mutated/ko animals. Comparison of the tumor numbers in the same animal 
over time, did not show any decrease in tumor number, thus implicating that no regression, 
e.g. by immunological defense, is ongoing in Adam-9mutated/ko animals. This was further 
supported by the observation, that comparable numbers of infiltrated inflammatory cells, 
including T-lymphocytes, were detected in tumors from both animal genotypes. The Adam-
9mutated/ko animals at week four exhibited a higher tumor number compared to control animals. 
At later stages (after week six) the number of developed tumors in ADAM-9 deficient mice 
was reduced and remained steady as compared to control for the remining time. At the 
endpoint the total number of tumors developed in the absence of ADAM-9 is lower than in 
control mice. As the Adam-9mutated/ko animals carry a full ADAM-9 deletion in all tissues, thus 
not only in the melanoma cells, at early stages (week four and five) the influence of ablation 
of ADAM-9 expression in stromal cells might be important for determining tumor 
development. Interestingly, in support of this hypothesis are the recent data of Abety et al. 
(2012) showing that as early as day six from murine melanoma cell grafting in ADAM-9-/- 
animals, a significant increase in tumor growth was detected as compared to wild type 
littermates and proceeded exponentially over time. This increased tumor growth resulted 
from decreased apoptosis and higher proliferation rate of melanoma cells. The molecules 
mediating these effect were shown to be TIMP-1 and soluble TNFR1, increasingly released 
by stromal fibroblasts (Abety et al., 2012). In agreement with these data, in the present study 
we also found increased tumor cell proliferation at week four in the absence of ADAM-9. The 
initially increased proliferation of the tumor cells in the absence of ADAM-9 might provide an 
explanation for the appearance of a higher proportion of tumors with a larger tumor volume in 
the Adam-9mutated/ko animals. In later time points this effect is not observed owing to either 
compensation by additional proteases or by a more important function of tumor-derived 
ADAM-9 in tumor progression. Several biological processes, beside proliferation, like 
apoptosis and vascularization, are key events in cancer progression (Hanahan and 
Weinberg, 2011) and might also account for the difference in tumor number observed 
overtime in control and Adam-9mutated/ko animals. However, no differences in apoptosis and 
vascularization were detected between control and Adam-9mutated/ko animals. Vascularization 
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was unaffected, confirming data from Guaiquil et al., 2009, who did not detect an altered size 
or number of blood vessels in ADAM-9-/- compared to Adam-9+/+ mice in tumors arising from 
injected B16-F0 cells (Guaiquil et al., 2009). In vitro ADAM-9 mediates shedding of 
molecules, like Tie-2, VCAM, Flk-1 or FGFR2iiib, which are implicated in influencing the 
angiogenic response (Peduto et al., 2005; Guaiquil et al., 2009), however none of these 
substrates have been shown to be relevant for the in vivo situation.  
As only week four and week 13 were investigated so far, the analysis of an additional time-
point between week five and six might provide more insight the mechanism responsible for 
differential tumor development in control and Adam-9mutated/ko mice.  
 
4.4.2 Role of ADAM-9 for metastases formation 
The most striking in vivo finding was the reduced lung metastases formation in Adam-
9mutated/ko animals, which was independent of tumor size as well as of the tumor number. This 
indicates that the reduced metastases formation is indeed attributed to the ablation of ADAM-
9. To further prove that reduced expression of ADAM-9 in the melanoma cells has an effect 
on metastases formation in vivo, ADAM-9 silenced B16-F1 melanoma cells were injected 
intravenously into the tail vein of Adam-9+/+ animals. Three weeks after injection a generally 
reduced formation of metastases was observed. Together these data strongly suggest that 
ADAM-9 produced by melanoma cells is a pro-metastatic protein in vivo. Similar findings 
were obtained when ADAM-9 down-regulated adenoid cystic carcinoma cells were injected 
into the tail vein of nude mice resulting in reduced metastases formation in the lung (Xu et 
al., 2010). Furthermore, intravenous injection of ADAM-9 overexpressing lung cancer cells 
resulted in metastases in the brain and lung whereas mock-transfected cells only colonized 
the lungs (Shintani et al., 2004). Several studies on different human cancer types also 
suggested a connection between ADAM-9 expression, metastases formation and patient 
survival. Thus patients with ADAM-9 positive hepatocellular carcinoma had poorer outcome 
and more frequently intrahepatic metastases (Tao et al., 2010). In renal cell cancer ADAM-9 
protein expression was associated with distant metastases and shortened patient survival 
(Fritzsche et al., 2008). In pancreatic carcinoma ADAM-9 mRNA expression was related to 
lymph node metastases and prognosis (Yamada et al., 2007).  
The molecular mechanisms leading to reduced metastases in the lung in the absence of 
ADAM-9 may be various. The data from the in vitro studies performed within this work using 
the ADAM-9 down-regulated BLM cells indicate that ADAM-9 is important for BM penetration 
and apart from cleaving the laminin β3-chain, ADAM-9 also modulates integrin expression. 
One could envision that in vivo all these events may play a distinct role in the metastatic 
process. Immunohistochemical stainings of the tumors with an antibody directed against the 
laminin β3-chain showed that in the control animals the BMs at the epidermal-dermal junction 
  Discussion 
96 
 
above the tumor as well as around the intratumoral vessels is clearly destructed and 
discontinuous, whereas in the Adam-9mutated/ko animals these BMs appeared more intact. 
Thus in the control animals melanoma cell invasion through the destructed BM might be 
facilitated whereas in the absence of ADAM-9 crossing of the BM is impaired and melanoma 
cell intravasation might be reduced. This would also explain why reduced metastases 
formation only occurred in the lungs, but not in the lymph nodes, because in contrast to blood 
vessels a discontinuous BM containing intraendothelial gaps frequently surrounds the 
lymphatic vessels, which facilitates cancer cell invasion (Karkkainen et al., 2002).  However 
the nested PCR for Pmel17 performed on blood from tumor bearing control and Adam-
9mutated/ko animals showed that melanoma cells are present in the circulation of the both 
animal genotypes. Being this type of PCR not quantitative, we cannot prove that in the 
absence of ADAM-9 reduced number of cells can enter the circulation from the primary 
tumor. 
The cell-cell adhesion assays performed with TNF-α activated endothelial cells and ADAM-9 
regulated B16-F1 melanoma cells showed that upon ADAM-9 silencing in melanoma cells 
adhesion to endothelial cells is reduced. This indicates that in melanoma cells, ADAM-9 can 
mediate adhesion of melanoma cells to endothelial cells. These results imply that ADAM-9 is 
involved in the initial cell-cell adhesion step leading to extravasation of melanoma cells into 
an organ in vivo. It was shown that ADAM-9 present on the surface of melanoma cells can 
interact with β1 integrin receptors. Application of β1 integrin blocking antibodies reduced 
ADAM-9 mediated adhesion of human lung cancer cells towards human umbilical vein 
endothelial cells (Monagret et al., 2010; Zigrino et al., 2011). Considering that TNF-α 
stimulation of endothelial cells up-regulated β1 integrin transcripts, it is possible that also 
adhesion of melanoma cells to endothelial cells is mediated via ADAM-9 β1 integrin 
interactions. This would explain the reduced melanoma cell adhesion to endothelial cell 
monolayers, when ADAM-9 is down-regulated. As both endothelial cells and melanoma cells 
express ADAM-9, it is possible that this interaction occurs in both directions. ADAM-9 
present on melanoma cell surface may interact with β1 integrin and the other way around is 
true when it is expressed on endothelial cells. This assumption could be proven by the 
application of β1 integrin blocking antibodies in further experiments.  
Reduced, but not abolished adhesion to endothelial cells can partly explain the lung 
metastatic phenotype in the absence of ADAM-9. For those cells that are still able to 
penetrate, once reached the organ, they have to counteract the immunological activity of the 
organs to be able to survive and to form metastases. It is known that T-cells can mediate 
anti-tumor immunity against melanoma cells, leading to growth restriction or tumor 
regression (Nagorsen et al., 2003; Ramirez-Montagut et al., 2003). Furthermore it was 
shown that ADAM-9 mediates shedding of MICA molecules from the surface of tumor cells 
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(Kogha et al., 2010a; Kogha et al., 2010b). These proteins are ligands for NKG2D receptors, 
which are expressed on natural killer cells and mediate recognition of tumors cells by natural 
killer cells. Thus it might be possible that in the absence of ADAM-9 shedding of MICA from 
the surface of metastatic tumor cells is reduced, leading to elevated recognition of tumor 
cells by natural killer cells and subsequent increased antitumor immunity. By staining lung 
sections with antibodies against the T-cell markers CD3, CD4, CD8 and CD45 no altered 
inflammatory reaction around the lung metastases in control and Adam-9mutated/ko animals was 
observed, indicating that an inflammatory reaction targeting the metastatic cells is not 
responsible for the reduced metastases formation in the lungs of Adam-9mutated/ko animals.  
 
Figure 58: Mechanisms responsible for reduced lung metastases formation in Adam-9mutated/ko 
animals. First, at the site of the primary tumor ADAM-9 expressing melanoma cells are able to adhere 
to and invade through the basement membrane (BM) in order to intravasate. In contrast adhesion and 
invasion of ADAM-9 deficient melanoma cells might be impaired. Second, after the cells have been 
transported to the lung via the circulation ADAM-9 expressing cells can adhere to the vascular 
endothelium, subsequently extravasate and form lung metastases, whereas adhesion of ADAM-9 
deficient cells to the endothelial cells is reduced. Other possible mechanisms like altered chemotaxis 
of the melanoma cells to the lung or an increased immune reaction in the lung counteracting 
metastases formation were not detected.  
 
Taken together the obtained data indicated that in the presence of ADAM-9, melanoma cell 
derived ADAM-9 promotes lung metastases formation by two main molecular pathways. 
First, intravasation of melanoma cells at the site of the primary tumor might be driven by 
ADAM-9, which mediates adhesion to the BM and leads to destruction of it via initial 
cleavage of the laminin β3-chain. This last also generates pro-migratory signals for 
melanoma cells. Second, ADAM-9 mediates adhesion of melanoma cells to endothelial cells, 
possibly through the interaction with β1 integrins, and leads to extravasation, which involves 
passage through endothelial cells and degradation of the underlying BM.  
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In the absence of ADAM-9, the additive effects of both, impaired intravasation and reduced 




The in vitro experiments using ADAM-9 down-regulated melanoma cells showed that ADAM-
9 participates in penetration of the epidermal-dermal BM. The studies using animals with 
spontaneous melanoma formation indicate that also in vivo ADAM-9 might contribute to this 
process. Additionally ADAM-9 is involved in the interaction of melanoma cells with 
endothelial cells. By these two processes, facilitating BM penetration and melanoma-
endothelial cell interaction, ADAM-9 contributes to lung metastases formation.  
Importantly, in this study we identified the laminin β3-chain as the first BM substrate for 
ADAM-9. Further investigations addressing the exact cleavage site in the molecule and the 
functional role for the cleavage and the generation of the laminin β3 fragment will help to 
better understand the importance of this event for melanoma function.  
In further studies it will be of importance to create strategies to cell-specifically inhibit ADAM-
9 expression in melanoma cells in vivo. Cell-specificty will be necessary as ablation of 
ADAM-9 in stromal cells leads to increased melanoma growth in animal experiments (Abety 
et al., 2012). The results with the indirubins presented in this work indicate that these 
molecules can be used to specifically inhibit ADAM-9 expression in high invasive melanoma 
cells, but not in dermal fibroblasts. Meanwhile, within the melanoma consortium, modified 
indirubins with putatively higher efficiency have been developed and could be further tested 
for their ADAM-9 “silencing” activity in melanoma cells but also in fibroblasts, keratinocytes or 
endothelial cells. These experiments might reveal potent inhibitory molecules for 
therapeutical applications.  
A completely different approach to target ADAM-9 expression in melanoma cells would 
comprise the application of siRNA to the melanoma cells. To target the siRNA specifically to 
melanoma cells, the siRNA can be packed in viral envelopes, which carry short peptides 
containing RGD sequences. These peptides are recognized by RGD dependent integrins 
highly expressed on the melanoma cells (Nahde et al., 2001). 
Finally such molecules could be tested in the in vivo situation for their ability to reduce 
melanoma metastases formation and thereby prolonging patient outcome. 
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µg  microgram 
µl  microliter 
µm  micrometer 
µM  micromolar 
7-AAD  7-Amino-Actinomycin 
ADAM  A Disintegrin And Metalloprotease 
Adam-9mutated/ko Adam-9-/-//Hgf/Cdk4R24C/R24C 
AKT  protein kinase B 
AP-1  activator protein-1 
APP   amyloid-precursor-protein 
ATP  adenosine triphosphate 
BCA  bicinchoninic acid 
BM  basement membrane 
BODIPY 8-choromethyl-4-4difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-s- indacene   
bp  basepair 
BRAF  v-rat fibrosarcoma murine sarcoma viral oncogene homolog B1 
BrdU  5-bromo-2-deoxyuridine 
BSA  bovine serum albumine 
Casp-3  caspase-3 
CCL  C-C chemokine ligand 
CCR  C-C chemokine receptor 
CDK  cyclin dependent kinase  
CDKN2A cyclin dependent kinase inhibitor 2A 
cm  centimeter 
Col I  collagen type I 
Col IV  collagen type IV 
CXCL  chemokine (C-X-C motif) ligand 
CXCR  C-X-C chemokine receptor 
Cy3  cyanid 3 
DAPI  4, 6-diamidino-2-phenylindol 
DDS  dead deepidermized skin 
DEPC  diethylpyrocarbonate 
DMBA  7,12-Dimethylbenzanthracene 
DMEM  Dulbecco’s Modified Eagle Medium 
DMSO  dimethyl sulfoxide 
DNA  deoxyribonucleic acid 
dNTP  desoxy nucleoside triphosphate 
EDTA  ethylendiamintetraacetat  
EGF  epidermal growth factor 
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EGFR  epidermal growth factor receptor     
EHS  Engelbreth-Holm-Swarm  
ELISA  enzyme linked immunoabsorbent assay 
EphB4  ephrin type-B receptor 
ERK  extracellular related kinase 
EtOH  ethanol 
FACS  fluorescence activated cell sorting 
FCS  fetal calf serum 
FGFR2  fibroblast growth factor receptor 2 
Flk-1  fetal liver kinase-1 
FN  fibronectin  
gDNA  genomic  deoxyribonucleic acid 
GPCR  G-protein-coupled-receptor 
HB-EGF heparin binding-epidermal growth factor 
HGF  hepatocyte growth factor 
HGF/SF hepatocyte growth factor/scatter factor 
HRAS  transforming protein p21 
HRP  horseradish peroxidase 
ICAM-1  intercellular adhesion molecule-1 
IgG  immunoglobulin G 
IL-1α  interleukin-1 alpha 
IL-1β  interleukin-1 beta 
ITS  insulin-transferrin-sodium selenite    
JNK  c-Jun N-terminal kinase 
kDa  kilodalton 
Lam 332 laminin 332 
Lam 511 laminin 511 
LYVE-1  lymphatic vessel endothelial hyaluronan receptor-1 
MAD2β  mitotic arrest deficient 2 beta 
MAPK  mitogen-activated protein kinase kinase 
MCAM  melanoma cell adhesion molecule 
MCP-1  monocyte chemoattractant protein-1 (=CCL2) 
MCP-5  monocyte chemoattractant protein-5 (=CCL12) 
MDM2  murine double minute oncogene 2 
mg  milligram 
MHC  major Histocompatibility Complex 
MICA/B  major histocompatibility complex related chain 1 A/B 
MITF  microphthalmia transcription factor 
ml  milliliter 
mm  millimetre 
mM  millimolar 
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MMP  matrix metalloprotease 
mRNA  messenger ribonucleic acid 
MuLV  moloney murine leukemia virus 
NFκB  nuclear factor kappa B 
ng  nanogram 
NGS  normal goat serum 
NKG2D  activating natural killer cell receptor 
nm  nanometer 
NRAS  neuroblastoma Ras viral oncogene homolog  
OD  optical density 
PAGE  polyacrylamid gel electrophoresis 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PDGF  platelet derived growth factor 
PECAM platelet endothelial cell adhesion molecule 
pERK  phosphorylated extracellular related kinase 
PFA  para formaldehyde 
PI  propidium iodide 
PI3K  phosphatidylinositol 3-kinase 
pJNK  phosphorylated c-Jun N-terminal kinase 
PKC-δ  protein kinase C delta 
Pmel17  melanocyte lineage-specific antigen GP100 
PTEN  phosphatase and tensin homolog 
RAS  rat sarcoma proto-oncogene 
RIP  regulated intramembrane proteolysis 
RIPA  radioimmunoprecipitation assay  
RGP  radial growth phase 
RNA  ribonucleic acid 
RPMI  Roswell Park Memorial Institute 
RT-PCR reverse transcription polymerase chain reaction 
SD  standard deviation 
SDF-1α stromal derived factor -1α (=CXCL12) 
SDS  sodiumdodecylsulfate 
SEM  standard error of the mean 
SH-3  sarcoma-homolgy-3 
shRNA  small hairpin ribonucleic acid 
SnoN  ski-related novel protein N 
Sp1  specificity protein 1 
TARC  thymus and activation-regulated chemokine (=CCL17) 
TBE  Tris/borate/EDTA 
TCA-3  T-cell activation-3 (=CCL1) 
   Abbreviations 
110 
 
TGF-β  transforming growth factor beta 
Tie-2  tyrosine kinase with immunoglobulin-like and EGF-like domains 2 
TIMP  tissue inhibitor of metalloproteases 
TNF-α  tumor necrosis factor alpha 
TNFR1  tumor necrosis factor receptor 1 
TPA  12-O-tetradecanoylphorbol-13-acetate 
TRP-1  tyrosinase related protein-1 
U   unit 
UV  ultraviolet 
VCAM  vascular cell adhesion molecule 
VE-cadherin vascular endothelial cadherin 
VEGF  vascular endothelial growth factor 
VGP  vertical growth phase  
(v/v)  volume/volume 
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